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ABSTRACT
Macrophages have a central role in immune responses. They are important effector
cells, binding and phagocytosing invading microorganisms, and producing reactive
oxygen species and proteases involved in tissue remodelling. In addition, they exert
immunoregulatory activity via presentation of antigen to T cells and through
production of cytokines. Macrophage phagocytic clearance of apoptotic neutrophils
is a process that is central to tissue homeostasis and for the resolution of
inflammation. Failure to remove apoptotic cells results in necrotic cell death and the
release of histotoxic intracellular contents, with the potential for exacerbating
inflammation thus contributing to the pathogenesis of inflammatory and autoimmune
diseases.
In this thesis, I have examined the effects of glucocorticoid-treatment of peripheral
blood monocytes which has previously been demonstrated to markedly augment
phagocytic capacity for apoptotic cells, an effect which may contribute to anti¬
inflammatory actions of glucocorticoids. Within the inflammatory site, the cytokine
environment governs the differentiation and function of infdtrating leukocytes. I
have investigated the effects of combinatorial treatment of monocytes with the
principal Thl and Th2 cytokines, IFN-y and IL-4 respectively. I have demonstrated
that whilst glucocorticoids exert a dominant effect over those of IFN- y in terms of
cell morphology and cell surface receptor expression, glucocorticoid-augmented
phagocytosis of apoptotic neutrophils is inhibited by IFN-y. These findings suggest
that the effectiveness of glucocorticoids in promoting a highly phagocytic
macrophage phenotype is crucially dependent on the cytokine milieu at inflammatory
sites.
Cellular migration is an important determinant for the initiation of inflammatory
responses and for the resolution phase, where macrophages migrate to draining
lymph nodes. My results provide evidence for an alteration in the adhesion and
migration of macrophages following glucocorticoid treatment. I have demonstrated
changes in cytoskeletal organisation and assembly/engagement of Rho family
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GTPase signalling pathways. These changes may influence macrophage migration
patterns that are important for the progression of inflammatory responses.
Finally, I present novel studies which separate binding and the subsequent
internalisation of apoptotic cells for the first time. Critically, I have demonstrated
that glucocorticoid-treated macrophages have an enhanced ability to bind apoptotic
neutrophils in a divalent cation independent manner, when compared to untreated
macrophages. In terms of phagocytic mechanism, I also show that internalisation
requires the presence of divalent cations and can be attenuated by blocking
phosphatidylserine-mediated uptake.
Together, the studies presented in this thesis suggest that glucocorticoids exert
profound effects upon macrophage cytoskeletal organisation that influences both
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ss Side Scatter
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Inflammation is the response mounted by the innate immune system in reaction to
infection, tissue injury or toxins. This normally self-resolving process, results in the
destruction of the invading micro-organism and healing of the damaged tissue.
Within tissues, bacteria are recognised by tissue resident phagocytes via pattern
recognition receptors such as the mannose receptor and CD 14, which bind to
conserved motifs of bacterial products (pathogen-associated molecular patterns or
PAMPs) (Janeway, 1989) or following opsonisation by immunoglobulin (Anderson
et al., 1990; Ravetch and Bolland, 2001) or complement components (Ehlers, 2000;
Plow and Zhang, 1997). The subsequent secretion of chemokines and cytokines by
leukocytes and tissue resident cells such as fibroblasts and smooth muscle cells
(Garcia-Ramallo et ah, 2002), instigates the inflammatory response. The adherence
of the inflammatory cells to the blood vessel endothelial cells and ensuing migration
into the tissues is prompted by exposure to the secreted cytokines (Garcia-Ramallo et
ah, 2002).
Neutrophils are the first cells recruited in large numbers into inflamed tissue
(Doherty et ah, 1988; Tsai et ah, 2000), where they identify, bind and phagocytose
the bacteria either via pattern recognition receptors, or following the triggering of the
complement cascade and deposition of C3b or C3dg on the pathogen surface
(Underhill and Ozinsky, 2002). Neutrophil synthesis of a range of cytotoxic
compounds products occurs via the enzyme NADPH oxidase and includes the
reactive oxygen species hydrogen peroxide (H2O2), superoxide anions (O2"), and
nitric oxide (NO), which are released into pathogen-containing phagocytic
vacuoles(Karlsson and Dahlgren, 2002; Lofgren et ah, 1999; Roos et ah, 2003).
NAPDH oxidase-induced Ca2^ release results in the opening of BK K+ channels and
the generation of a hypertonic, alkaline and K+ rich phagosome environment within
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the neutrophil, activating proteases necessary for the killing of enclosed bacteria
(Ahluwalia et ah, 2004). Phagocytosis of bacteria by neutrophils then accelerates the
onset of apoptosis (Kobayashi et ah, 2003) which is accompanied by a down-
regulation in pro-inflammatory cytokine production by the neutrophil and the up-
regulation of pathways that synthesise antioxidant products in favour of toxic
metabolites (Kobayashi et ah, 2003).
A second wave of leukocyte recruitment follows with the infiltration of monocytes
from the blood vessels. Under the influence of the tissue cytokine environment,
monocytes differentiate into macrophages and can perform key roles in the
progression and ultimately in the resolution of inflammatory responses. In the
presence of pro-inflammatory cytokines and bacterial products such as IFN-y and
LPS, monocytes differentiate into 'classically activated' macrophages, equipped for
the phagocytosis and killing of pathogen. Like neutrophils, macrophages are capable
of engulfing and subsequently killing pathogen and can therefore aid the clearance of
pathogen. Alternatively, differentiation of monocytes in the presence of anti¬
inflammatory cytokines and mediators such as IL-4 and glucocorticoids results in an
'alternatively activated macrophage' with reduced capacity for pathogen uptake but
increased capability for wound healing and inflammatory resolution (Goerdt and
Orfanos, 1999).
The Resolution of Inflammation
The induction of apoptosis in the large numbers of recruited neutrophils must be
followed by their efficient removal for the successful resolution of inflammation (See
Figure 1.1). A second important function of monocyte-derived macrophages is
therefore the recognition and phagocytosis of the apoptotic cells via receptors
binding 'eat me' signals displayed by the apoptotic cell. Phagocytosis of the
apoptotic cell not only down-regulates the secretion of pro-inflammatory cytokines
by the macrophage, but also increases the release of anti-inflammatory cytokines
(Fadok et ah, 1998a; Meagher et al., 1992). Because cytokines define the behaviour
of the infiltrating cells such as macrophages, changes in the cytokine profile can act
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as a switch in the transition from the pro-inflammatory responses required for
elimination of the pathogen, to the anti-inflammatory responses required for the
resolution phase. The interaction between monocytes and apoptotic neutrophils in the
presence of the gram negative bacterial product LPS, has been shown to deactivate
the monocytes, turning off secretion of the pivotal pro-inflammatory cytokine TNF-a
in favour of the anti-inflammatory cytokine IL-10 (Byrne and Reen, 2002).
A failure in either the induction of apoptosis, or the clearance of the apoptotic
neutrophils, will result in neutrophil necrosis accompanied by the release of
intracellular components that have the potential to generate autoantibody production
and potentially toxic contents into the surrounding tissue, exacerbating the
inflammatory process (Haslett, 1997). Accordingly, failure in the clearance of
apoptotic cells would be predicted to be associated with inflammatory disease and
autoimmunity (Beutler, 2001; Haslett, 1997; Haslett, 1999; Savill et ah, 1989b). The
pro-inflammatory consequences of disrupting induction of apoptosis have been
exploited by the disease causing pathogens Ananplasmaphagocytophi/um and
Staphylococcus aureus, which delay apoptosis or induce neutrophil necrosis
((Kobayashi et ah, 2003) and references therein). Whilst the issue of whether
phagocytosis of necrotic cells by macrophages does in fact cause the release of pro¬
inflammatory cytokines is contentious (Brouckaert et ah, 2004; Fadok et ah, 2001),
lysis of the neutrophil and release of pro-inflammatory contents, coupled with the
lengthened time required for the phagocytosis of a necrotic cell could be responsible
for an increase in the inflammatory response (Brouckaert et ah, 2004). In addition,
uptake of apoptotic cells fails to stimulate antigen presentation by macrophages,
whilst uptake of necrotic cells is associated with up-regulation of CD40 and co-
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Apoptosis
Apoptosis is a highly conserved form of programmed cell death, which results in the
safe packaging of the cell for disposal by phagocytic cells. By contrast to necrotic
cell death, apoptotic cells retain an intact plasma membrane with the result of the
containment of potentially damaging cytosolic enzymes (Searle et ah, 1982).
Apoptosis induces a co-ordinated sequence of biochemical events which serves to
destroy the nuclear and cytoplasmic mechanisms which control cellular responses,
resulting in an unresponsive cell.
Caspases are a highly conserved family of proteinases, which play a significant role
in the majority of cell apoptosis. They are retained in the cytoplasm in a non-active
form (pro-caspases), and are activated by cleavage of the pro-domain from the
protein, which is achieved by two main pathways. The first involves the formation of
a death-inducing signalling complex (DISC) at the intracellular tail of TNF family
receptors. The recruitment of pro-caspases to the DISC triggers caspase activation.
The second mechanism follows the initiation of mitochondrial membrane
permeabilisation (MMP), which triggers a surge of pro-apoptotic effects, including
the release of stores of caspases, caspase activators and proteins including
cytochrome-c and apoptosis-inducing factor (Apaf-1). Cytochrome-c release triggers
the assembly of caspase-3 and caspase-9 into an Apaf-1 containing activation
complex, termed an 'apoptosome', which activates caspase-9 (Kroemer and Reed,
2000; Reed, 2001).
Activated 'initiator' caspases, such as caspase 8 and 9, then cleave target proteins at
aspartate (Asp) residues. These target proteins include other members of the caspase
family, which are in turn activated following cleavage of their pro-domain, initiating
an amplifying cascade of caspase activation. 'Effector' caspases cleave structural
proteins such as lamins and focal adhesion kinase (FAK) that disband the
cytoskeleton of the cell and cause loss of cell adhesions. Further they breakdown
homeostatic proteins required for protein and nucleic acid synthesis and signalling
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and cell repair, irreversibly committing the cell to the apoptotic pathway (Wolf and
Green, 1999).
Regardless of the initiating stimulus, apoptosis results in a characteristic morphology
(Ellis and Horvitz, 1986; Kerr et al., 1972; Martin et al., 1994), which is
distinguishable from that of necrosis. Cytoplasmic shrinkage and membrane blebbing
are accompanied by nuclear shrinkage, chromatin condensation and DNA
fragmentation (Hebert et al., 1996). Characterised changes associated with apoptosis
in neutrophils includes the loss of functions including phagocytosis, respiratory
burst, degranulation and following down-regulation of FMLP receptor on the cell
surface, ability to migrate and shape change (Whyte et al., 1993). Loss of surface
receptors such as FcyRIII (Dransfield et al., 1994) and adhesion associated molecules
such as L-selectin (Dransfield et al., 1995) have also been reported, and together may
'functionally isolate' the neutrophil prior to phagocytosis (Hart et al., 2000; Haslett,
1997).
Failure of cells to undergo apoptosis may contribute to oncogenesis, whilst
inappropriate levels of apoptosis can lead to a range of inflammatory or degenerative
diseases such as Alzheimers, and thus agents which allow manipulation of apoptosis
have been an area of active research (Reed, 2001; Ward et al., 1999). A number of
agents have been described which alter granulocyte apoptosis, including Fas-Fas
ligand (Matsumoto et al., 1995), glucocorticoids (Meagher et al., 1996), TNF- a
(Murray et al., 1997), NF-kB inhibitors and cytosolic calcium concentration (Rossi et
al., 1995) (for review see (Ward et al., 1999)), although many have been shown to
have disparate effects on eosinophil and neutrophil granulocytes.
19
Macrophage Phagocytosis of Apoptotic Cells
Receptor mediated phagocytosis of apoptotic neutrophils
It has been proposed that the expression of ligands, so called 'eat me' signals, on the
surface of the apoptotic cells, signals for their recognition and phagocytosis by
macrophages, and to date many phagocytic receptors have been described for ligands
on the apoptotic cell (see Figure 1.2). The list includes the
avP3/CD36/thrombospondin complex (Savill et al., 1990), the phosphatidylserine
receptor (Fadok et ah, 2000), scavenger receptors such as SRA-1 (Piatt et ah, 1996)
receptors for OxLDL (Chang et ah, 1999), pattern recognition receptors such as
CD14 (Devitt et ah, 1998) and lectin receptors (Duvall et ah, 1985). Many of the
receptors involved in the recognition of apoptotic cells also have a dual role in the
binding by antigen-presenting cells of conserved regions of pathogens (pattern
recognition motifs). For example, CD 14 is involved in LPS binding and also has a
role as an apoptotic cell receptor. Studies examining the involvement of CD 14 in
apoptotic cell recognition demonstrated that, despite the fact that LPS and the
apoptotic cell ligand bind to the same receptor, LPS binding resulted in the release of
pro-inflammatory cytokines, whilst they were not detected following binding of
apoptotic cells to macrophages via CD 14. This implies that the ligand determines the
response which follows from the macrophage (Devitt et ah, 1998).
Despite the description of a large list of phagocytic receptors, very few partner
ligands on the surface of the apoptotic cell have been discovered. Profding the
surface of different apoptotic cell types (Flart et ah, 2000) (Morris et ah, 1984) has
identified very few surface changes by which the apoptotic cell can be distinguished
from the viable cell. ICAM-3 (Moffatt et ah, 1999) and phosphatidylserine (PS)
(Fadok et ah, 1992a) have been explicitly identified, although more subtle changes
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Figure 1.2 Phagocytic recognition of apoptotic cells
Adapted from Gregory et al. (2004)
Putative receptors, bridging molecules and ligands implicated in the recognition
and phagocytosis of apoptotic cells (grey target cell in centre of figure).
Clockwise the abbreviated molecules are: MFG-E8, milk fat globule epidermal
growth factor-8; MER, myeloid epithelial reproductive tyrosine kinase; Gas-6,
growth arrest specific gene-6; TSP, thrombospondin-1; Lox-1, oxidised low
density lipoprotein receptor 1; SR-A, Scavenger receptor A; PS, phosphatidylser-
ine; PSR, phosphatidylserine receptor; ABC, ATP-binding cassette transporter Al;
SHPS-1, Src homology 2 domain-bearing protein tyrosine phosphatase substrate-1;
Clq, complement component.
such as alterations in surface carbohydrates have also been implicated (Duvall et al.,
1985). In fact, many of the surface molecules profded are down-regulated on the
surface of the apoptotic cell, concurrent with the loss of plasma membrane surface
area (Morris et ah, 1984) and, coupled with macrophage engulfment of inert
particles, this argues for a loss of signal model for phagocytosis of apoptotic cells.
Changes in surface charge density on the apoptotic cell following cleavage of surface
proteins and desialylation have also been described (Morris et ah, 1984) and provide
an attractive explanation for the increased interaction between phagocyte and
apoptotic cell, whereby repulsive encounters between identically charged cells may
be overcome. Indeed, studies showing the inhibition of macrophage recognition of
apoptotic neutrophils by cationic monosaccharides and amino acids occurred in a
charge and pH dependent fashion (Savill et ah, 1989a) suggesting recognition
requires an anionic charge on the apoptotic neutrophil surface.
Exposure of PS on the outer cell surface is a feature common to all apoptotic cells
(Fadok et ah, 1992c; Martin et ah, 1995). Healthy cells maintain the asymmetrical
distribution of PS on the inner surface of the plasma membrane by active transport
via the enzyme aminophospholipid translocase (Verhoven et ah, 1995). PS surface
expression is a characteristic of early apoptosis (Martin et ah, 1995), and requires
both the loss of aminophospholipid translocase activity and activation of the calcium
dependent flip flop of phospholipids in the plasma membrane, (Bratton et ah, 1997),
aided by scrambalases, flippases (Zhou et ah, 1997) and polyamines (Bratton et ah,
1999). In addition, the ATP-binding cassette transporter 1 (ABC1), previously
implicated in phagocytic uptake of apoptotic cells, (Luciani and Chimini, 1996) has
been demonstrated to be involved in the transport of PS to the outer leaflet of the
plasma membrane (Hamon et ah, 2000).Specific recognition of PS by the recently
cloned PS receptor (PSR) (Fadok et ah, 2000) causes subsequent engulfment of the
apoptotic cell (Fadok et ah, 1992a), although recently published evidence
demonstrating nuclear localisation signals in the 'PSR' contradict its suggested role
as a phagocytic receptor (Cikala et ah, 2004; Cui et ah, 2004). The generation of a
PSR mice by Bose and colleagues has further challenged the hypothesis that the
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cloned PSR is an apoptotic cell receptor. The PSR " mice showed severe defects in
embryonic developmental and organ differentiation, with no observed defect in the
clearance of apoptotic cells during embryonic development (Bose et al., 2004).
Bridging molecules act to link the receptor on the phagocyte to ligands on the
apoptotic cell, increasing the efficiency of phagocytosis. Many of these bridging
molecules bind to PS, including MFG-E8 (Hanayama et ah, 2002), p2-glycoprotein I
(Balasubramanian and Schroit, 1998), Protein S (Anderson et ah, 2003), and Gas-6
(Ishimoto et ah, 2000)(see Figure 1.2). MFG-E8 binds to avP3 on the phagocytic
cell (Hanayama et ah, 2002), whilst Gas-6 bridges PS to the receptor tyrosine kinase,
Mer (Scott et ah, 2001). Annexin I is expressed on the surface of apoptotic Jurkat
cells following caspase activation, and co-localises with PS, potentially increasing
phagocytic uptake by the PSR (Arur et ah, 2003).
One of the major receptor mechanisms in human monocyte-derived macrophage
(MDMO) recognition of apoptotic neutrophils is the divalent cation-dependent avP3
integrin 'vitronectin receptor'/CD36/thrombospondin complex which binds an as yet
undiscovered ligand on apoptotic cells (Savill et ah, 1990). The requirement of the
vitronectin receptor and CD36 has been demonstrated using both blocking antibodies
and the RGDS peptide. Subsequently, thrombospondin has been shown to bind to
both the vitronectin receptor and CD36, acting as a bridging molecule between the
macrophage and the apoptotic neutrophil (Savill et ah, 1990).
Scavenger receptors have also been implicated in uptake of phagocytic cells. The
class A macrophage scavenger receptor (SR-A) is a trimeric membrane glycoprotein,
capable of binding a range of ligands including acetylated LDL and polyionic
molecules. The phagocytosis of apoptotic thymocytes by mouse peritoneal
macrophages was partially inhibited by blocking SR-A. This was demonstrated using
an antibody against SR-A, using competitive ligands such as fucoidan, or using
macrophages from SR-A" " mice (Piatt et ah, 1996). A second scavenger receptor, the
OxLDL receptor, is also important in mouse peritoneal macrophage phagocytosis of
apoptotic cells. Studies showing that OxLDL inhibited the binding of PS liposomes
to mouse peritoneal macrophages, suggest that OxLDL and PS compete to bind this
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receptor (Sambrano and Steinberg, 1995). In fact, many of the macrophage receptors
which recognise OxLDL e.g. CD36, CD68 and LOX-1 also bind PS liposomes or
apoptotic cells (discussed in (Chang et al., 1999)).
Inhibition studies using CD 14 specific blocking antibodies 61D3 and MEM-18
demonstrated the involvement of the glycoprotein receptor CD 14 in the interaction
between human MDMO and apoptotic lymphocytes (Devitt et al., 1998). The ligand
on the apoptotic cells which CD 14 binds to is unknown. Following the demonstration
that CD 14 bound to phospholipids including PS, and that 61D3 inhibited the
interaction between PS and macrophages (Pradhan et al., 1997), CD14 was
investigated as a putative PS receptor. Results showed that PS binding to
macrophages did not demonstrate specificity for CD 14 and that PS-liposomes did not
inhibit CD14-mediated phagocytosis (Devitt et al., 2003), suggesting that CD 14 is
not a PS receptor in human MDMO. In addition, ICAM-3 present on the apoptotic
lymphocyte has been demonstrated to mediate an interaction with the phagocyte in
an as yet undefined CD14-dependent manner (Moffatt et al., 1999).
The reported inhibition of mouse peritoneal macrophage binding of apoptotic
thymocytes by N-acetyl glucosamine supports the presence of a lectin-like receptor
on the macrophage, which recognises modified carbohydrates on the surface of the
apoptotic cell (Duvall et al., 1985). Early experiments described an increased binding
of apoptotic thymocytes compared with viable thymocytes at 4°C, to monolayers of
peritoneal macrophages (Morris et al., 1984). Later work by Brown and colleagues
demonstrated, under low shear at 37°C, a mechanism for the detachment of viable
but not apoptotic leukocytes following binding to macrophages via a CD31
homophilic interaction, providing the first evidence for a 'detachment' signal from
non-apoptotic cells (Brown et al., 2002).
Despite PS being universally displayed by apoptotic cells, different combinations of
mechanisms are responsible for uptake of apoptotic cells by different macrophage
populations. Unstimulated macrophages, such as human MDMO and murine bone
marrow-derived macrophages (BMDMO) have been suggested to rely mainly on the
'vitronectin receptor'/CD36/thrombospondin mechanism, with minor roles for the
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scavenger and lectin receptor mechanisms. However, activated macrophages, such as
elicited peritoneal macrophages or (3-glucan stimulated-BMDM® and -human
MDMd>, have been reported to utilise the PS-PSR mechanism in favour of the av(33/
CD36/ thrombospondin receptor complex (Fadok et al., 1992b) (Fadok et ah, 1998b).
Pradhan and colleagues further showed that inhibition by sugars also fell into two
groups; with glucosamine, galactosamine and arginine inhibiting non-activated
macrophages whilst N-acetylglucosamine inhibited activated macrophages. Pradhan
and colleagues propose from their data that two recognition complexes exist; PSR
and avP3/CD36/thrombospondin on unactivated macrophages and a lectin-like
receptor and PSR complex on activated macrophages (Pradhan et ah, 1997).
As research progresses, commonalities are being found between receptors initially
thought of as disparate, e.g. CD36 is associated with phagocytosis via the vitronectin
receptor, PS recognition and OxLDL receptor. There are also data supporting the
possibility of multiple receptors for single ligand, for example, PS binding to the
OxLDL receptor, CD36 and the recently described PS receptor. Finally, most
inhibition studies have failed to fully account for all macrophage phagocytosis,
implying that further recognition systems remain to be discovered.
Opsonin-mediated uptake of apoptotic cells
Opsonins are serum constituents or locally secreted proteins that are able to bind
pathogens, enhancing uptake by phagocytic cells. Complement systems are activated
by one of three pathways; the classical pathway, the alternative pathway and the
lectin pathway, which converge with the cleavage of C3 into C3a and C3b and
deposition of C3bi on the surface of the pathogen. Phagocytes such as macrophages
and neutrophils have receptors such as CR1, CR3 (CD1 lb/CD 18) and CR4
(CD1 lc/CD18) for C3bi, allowing uptake of complement opsonised pathogen.
Phagocytes also express receptors for immunoglobulin subclasses e.g. macrophages
express three receptors for the Fc portion of IgG: FcyRI, II and III. Thus, the
generation and binding of antibodies specific for bacterial antigens allow recognition
of the bacteria via the Fc portion of the antibody. There is accumulating evidence
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demonstrating a role for antibodies and complement in the uptake of apoptotic cells,
illustrating a dual role for classical receptors of pathogens.
Complement
As discussed above, inhibition of the macrophage receptors for apoptotic cell 'eat
me' signals, have failed to completely inhibit and therefore fully account for the
recognition of apoptotic cells. It is notable that many studies have been carried out in
serum-free conditions and a role for opsonisation by serum proteins was proposed
following a three fold induction in binding and phagocytosis upon the addition of
serum (Mevorach et al., 1998). Complement components Factor B, Clq and C3
present in the serum were shown to mediate the induction of phagocytosis
(Mevorach et al., 1998). The well characterised PS exposure on the surface of the
apoptotic cells permits C3bi binding and subsequent recognition by macrophage CR3
and CR4 (Mevorach et al., 1998).
Further evidence of the involvement of complement has been provided by the
identification of Clq as a major genetic risk factor for the autoimmune disease
systemic lupus erythematosus (SLE), characterised by the formation of auto¬
antibodies and immune complexes (Petry, 1998). Clq initiates the classical
complement pathway by binding to IgG- or IgM-antigen complexes on the cell
surface, and was shown to bind to keratinocyte and endothelial apoptotic cell blebs
(Korb and Ahearn, 1997) (Navratil et al., 2001). In addition, Clq knockout mice
present with a defect in clearance of apoptotic cells and develop an SLE-like
phenotype (Botto et al., 1998), with further validation of a role for Clq in apoptotic
cell uptake from in vitro studies. Calreticulin was identified as the receptor for Clq
and mannan-binding lectin and Clq/MBL bound to the surface of apoptotic cells, are
recognised by calreticulin in combination with CD91 (Ogden et al., 2001).
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Antibodies
Recently, a novel role for antibodies has been proposed to mediate recognition of
apoptotic cells bearing FcyRII. Hart and colleagues using an in vitro model have
recently suggested that immune complexes bind to apoptotic neutrophils. Further
studies revealed that immune complex opsonised cells could be recognised via an Fc-
mediated mechanism (Hart et al., 2003).
Anti-phospholipid syndrome is characterised by deep vein thrombosis and the
presence of autoantibodies, raised against apoptotic cell phospholipid-associated
proteins such as P2 glycoprotein I (P2-GPI) (Balasubramanian et ah, 1997). In vitro
studies have shown that antibodies derived from patients with anti-phospholipid
syndrome recognised (32-GPI only when bound to apoptosis associated-
phospholipids (Pittoni et ah, 2000). Further studies have shown that P2-GPI antibody
opsonisation of apoptotic cells and PS vesicles increased engulfment by immature
dendritic cells and macrophages respectively (Rovere et ah, 1998) (Balasubramanian
et ah, 1997).
The uptake of apoptotic cells by Fc-mediated phagocytosis may be expected to be
pro-inflammatory. However, in situations where large numbers of apoptotic cells
require clearance, perhaps owing to an over-whelming infection, the fast and
efficient process of Fc-mediated phagocytosis as an apoptotic clearance mechanism
may outweigh the prospective pro-inflammatory cytokine release by preventing
induction of necrosis in the apoptotic cells.
Many of the opsonins, such as Protein S (Anderson et ah, 2003), p2-glycoprotein I
(Balasubramanian et ah, 1997) and MFG-E8, which are secreted by activated
macrophages and mediate apoptotic cell uptake via avp3 integrins (Hanayama et ah,
2002), recognise and bind to PS, as discussed earlier. PS exposure is an early
characteristic of apoptosis, suggesting opsonisation may stimulate uptake of early
apoptotic cells. In contradiction to this, it has been suggested that complement
binding to necrotic lymphocytes provides a mechanism for the removal of cells
which have failed to be cleared by other means (Gaipl et ah, 2001).
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Intracellular Mechanisms Required for Cellular Engulfment
Following binding of an apoptotic cell to specific phagocyte surface receptors, a
series of signalling events are initiated which result in the formation of an F-actin
rich phagocytic cup (Aderem and Underhill, 1999). Continued membrane extension
around the apoptotic cell, followed by generation of contractile forces allows
internalisation of the cell (Chavrier, 2002). Multiple intracellular signalling pathways
may become engaged during phagocytosis. For example, an apoptotic cell expresses
multiple ligands on its surface, some or all of which may interact with their
receptors. Furthermore, there may be heterogeneity in the expression of apoptotic
'eat me' signals or in the degree of opsonisation of apoptotic cells that are bound to a
single phagocyte, and interpretation of the inputs from the different cells is required
to generate the appropriate response. For example, it is not clear whether
concomitant binding of an opsonised cell and an unopsonised apoptotic cell results in
the secretion of pro- or anti-inflammatory cytokines. The points where different
signalling pathways intersect are described as nodal points according to Prehoda and
Lim (Prehoda and Lim, 2002). Multiple signals are processed together and specific
outputs made, allowing for a single combined response to complex multiple inputs
(Prehoda and Lim, 2002). One of the future challenges in the unfurling of phagocytic
signalling pathways will be the understanding of the outputs at nodal points in
signalling pathways following multiple receptor binding.
Signalling associated with Fc-mediated phagocytosis
The signalling events involved in phagocytosis have best been studied in Fc-
mediated phagocytosis which, like apoptotic cell uptake, requires actin
polymerisation (May and Machesky, 2001). A number of distinct Fc receptors are
involved in phagocytosis (Indik et al., 1994; Park et al., 1993; Tuijnman et al., 1992),
and receptor ligation triggers phosphorylation of tyrosine residues within
immunoreceptor tyrosine-based activation motifs (ITAMS) of the cytoplasmic tail of
FcyRII or the associated y-subunit of FcyRI and IIIA(Isakov, 1997) by Src family
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kinases (Ghazizadeh et al., 1994). The phosphorylation events allow docking and
activation of the tyrosine kinase Syk (Greenberg et al., 1994), which is followed by
phosphorylation of a large number of substrates, including ERK1/2 (Crowley et al.,
1997) and paxillin (Greenberg et al., 1994). Informatively, Syk macrophages are
still capable of binding to IgG-opsonised particles and form phagocytic cups, but fail
to internalise the particles (Crowley et al., 1997). The PI3Kinase inhibitor,
wortmannin, also halts phagocytosis at the same stage, suggesting that Syk may
instigate PDKinase signalling, which is required for internalisation.
Signalling associated with complement-mediated phagocytosis
The process of complement-mediated phagocytosis is morphologically distinct from
that of Fc-mediated phagocytosis, with the target 'sinking' into the phagocyte with
the minimum of membrane disruption and little or no inflammatory response
(Aderem and Underhill, 1999). CR3 is the most widely studied complement receptor
and can bind a variety of different ligands such as C3bi (Ehlers, 2000), adhesion
molecules such as ICAM-1 (Diamond et al., 1990) and matrix molecules such as
fibrinogen (Trezzini et al., 1988). Binding of different ligands induces different
cellular responses ranging from phagocytosis to cellular spreading and chemotaxis.
Phagocytosis requires prior activation of the phagocyte e.g. by cytokines or ECM
attachment (Brown, 1991). Ligand binding to CR3 induces 'outside in' signals that
act to regulate cytoskeletal organisation and other cellular responses (Giancotti and
Ruoslahti, 1999).
C.EIegans Provides a Model Phagocytic System
The nematode C. elegans provides a genetically simplified model for identifying new
receptors and interpreting the complex and bewildering array of receptors identified
in the mammalian system. During the development of C. elegans 131 of an original
1090 cells are known to become apoptotic, upon which they are rapidly
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phagocytosed by neighbouring cells (Sulston and Horvitz, 1977). Genetic screens
have revealed seven genes which, when mutated, result in cell corpse persistence,
implicating them in the process of apoptotic cell engulfment. None of the genes are
essential for phagocytosis, suggesting a redundancy in the system, which is
conserved through to mammalian cells. Elegant mutant studies, using combinations
of different gene mutations led to the proposal that the genes fall into two, partially
redundant signalling pathways (Ellis et al., 1991); Ced-2, Ced-5, Ced-10 and Ced-12
forming one such group and Ced-1, Ced-6 and Ced-7 the other (Figure 1.3). Cloning
and structural studies of these genes and the subsequent discovery of mammalian
homologues to all but one of the genes have provided a clearer insight into the
mechanisms of apoptotic cell phagocytosis.
Within the first pathway, the mammalian homologues of Ced-2 and Ced-5 are the
adaptor proteins Crkll (Reddien and Horvitz, 2000) and Dockl80 (Wu and Horvitz,
1998b) respectively, Ced-10 is the Rho-GTPase Rac-1 (Reddien and Horvitz, 2000)
and the recently cloned Ced-12 has three homologues, ELMOl, 2 and 3 (Gumienny
et ah, 2001). Together these proteins form a signalling pathway, initiated by
apoptotic cell binding to an as yet undescribed receptor and terminating with Rac-1
activation, which has been shown to be important for apoptotic cell engulfment and
cellular migration during development (Zhou et ah, 2001a). Studies using crosses of
different Ced gene mutants have shown that Ced-2, -5 and -12 form a trimeric
complex, localised at the plasma membrane, which is required for the activation of
Ced-10 (Gumienny et ah, 2001; Wu et ah, 2001; Zhou et ah, 2001a). The pathway is
conserved in mammals where over-expression of either Crkll or Rac-1 in the
phagocytic cell line, LR73, enhanced engulfment. Transfections of cells with
combinations of Crkll and Rac-1 mutants demonstrated that Crkll functions
upstream of Rac-1 (Tosello-Trampont et ah, 2001). The trimeric complex of Crkll,
Dock 180 and ELMO-1 are thought to recruit a speculative GEF (Rho guanine-
nucleotide exchange factor), which confers Rac-1 activation by the transfer of GDP
for GTP (Gumienny et ah, 2001). The role of Rac-1 in mammalian phagocytosis is
well documented, with Rac-1 known to orchestrate actin polymerisation, needed for




Figure 1.3 C. elegans engulfment genes
Genes involved in apoptotic cell engulfment in C. elegans, fall into 2 partially redun¬
dant signalling pathways: Ced-1, Ced-6 and Ced-7 in one and Ced-2, Ced-5, Ced-10
and Ced-12 in the other. C. elegans genes are shown in bold, with the mammalian
homologues labelled underneath the respective nematode gene.
In the second pathway Ced-7 encodes a protein similar to the ABC transporters (Wu
and Horvitz, 1998a). Ced-7 is a plasma membrane protein required in both the dying
cell and the phagocytic cell, where it may function to export lipids through the
plasma membrane (Wu and Horvitz, 1998a). The mammalian homologue of Ced-1 is
a transmembrane scavenger-like receptor, the only receptor so far cloned in C.
elegans (Zhou et al., 2001b). Ced-1 protein is expressed on the cell surfaces of many
cells and was observed at high levels on membrane facing the apoptotic cell (Zhou et
al., 2001b). This may reflect clustering following receptor ligation or in a model
proposed by Hengartner, Ced-1 could be distributed into lipid rafts, which require
Ced-7 for their formation (Hengartner, 2001). SH2 (Src homology 2) and PTB
(phosphotyrosine binding) domains in the cytoplasmic tail of Ced-1 are required for
engulfment and may bind an adaptor protein, which confers signalling from the
ligand for engulfment. Ced-6 encodes a candidate adaptor protein with PTB binding
potential (Liu and Hengartner, 1998) which interestingly has been shown to act
downstream of Ced-1 and Ced-7 (Liu and Hengartner, 1998). It was therefore
thought to be a likely candidate for interpreting the Ced-1 signal. However,
experiments to test this hypothesis failed to demonstrate any interaction between
Ced-1 and Ced-6 (Zhou et al., 2001b). Thus, at the present time Ced-6 remains
isolated, down-stream from Ced-1 in this signalling pathway.
The same set of Ced genes that have been shown to mediate the engulfment of
apoptotic cells, are required for the engulfment of low numbers of necrotic-like cells
(Chung et al., 2000). This intriguingly suggests a conservation of mechanism
between the uptake of these two cell types, each of which is thought to regulate
responses with different consequences in terms of inflammation in the mammalian
system (Fadok et al., 2001). Studies in C. elegans have also demonstrated an
extended role for the engulfment genes Ced-1, -2, -5, -6, -7,-10 and -12 in the
execution of apoptosis in dying cells (Hoeppner et al., 2001; Reddien et al., 2001), a
function that also appears to hold true for macrophages in some mammalian systems
(Diez-Roux and Lang, 1997).
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Signalling associated with apoptotic cell phagocytosis
Phagocytosis of apoptotic cells by receptors which bind 'eat me' signals are actin
dependent, and share many signalling intermediates with Fc- and complement-
mediated uptake (Aderem and Underhill, 1999; Allen and Aderem, 1996; Leverrier
et al., 2003). However, the events immediately following receptor ligation are largely
unknown, although a role for receptor phosphorylation has been demonstrated
(Leverrier and Ridley, 2001). Interestingly, as reported for the Fc-receptors, the C.
elegans Ced-1 protein receptor has a YXXL motif in the cytoplasmic tail (Zhou et
al., 2001b), which could allow coupling to adaptor molecules via Src homology (SH)
domains following tyrosine phosphorylation.
Downstream pathways: PI -3Kinases
Distinct roles have been attributed to different classes of the PI-3kinases during
phagocytosis (Gillooly et al., 2001); Class 1 PI-3kinases, and PtdIns(3,4,5)P3
products are involved in stages of membrane extension and closure but not the initial
formation of the phagocytic cup, whereas Class III PI-3 kinases and PI(3)P products
are necessary for fusion of the phagosome with late endosomes and lysosomes
during phagosome maturation (Vieira et al., 2001).
pi 10(3 is the major PI-3kinase class I isoform involved in phagocytosis and has been
shown to be necessary for uptake of apoptotic cells and Fc-opsonised cells by
macrophages (Leverrier et al., 2003). In fact, the major role for the class I PI-
3kinases appears to be phagosome closure (Araki et al., 1996). PI-3 kinases become
asymmetrically distributed in response to asymmetrical activation of chemoattractant
receptors (Vanhaesebroeck et al., 1999; Wang et al., 2002) and results in actin
polymerisation and migration in the direction of the chemoattractant signal. The
signalling role of PI-3kinases in directing membrane extension is thus conserved in
phagocytosis. The contractile forces required for the closure of the phagosome
during Fc-mediated phagocytosis are dependent on both PI-3kinases and myosin
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motor proteins (Swanson et al., 1999). The proposed mechanism has Myosin X
linking the extending pseudopodia (which is enclosing the cell being engulfed) with
the cytoskeleton. Myosin X binds to both the PI-3 kinase products in the
pseudopodia membrane via pleckstrin homology (PH) domains and to actin filaments
via the motor head. Movement of Myosin X towards the barbed ends of the actin
filaments drags membrane towards the growing ends of the pseudopodia, closing the
phagosome (Chavrier, 2002; Cox et al., 2002). Class II PI-3kinase products collect
transiently in the phagosomal membrane following closure of the phagosome and
associate with a serine/threonine kinase which regulates membrane association with
late endosomes and lysosomes (Fratti et al., 2001; Vieira et al., 2001).
Downstream pathways: Rho family GTPases
The small Rho GTPases, Rho, Rac and Cdc42 regulate actin assembly and
organisation during processes such as adhesion, phagocytosis and migration. Rho
GTPase proteins cycle between an inactive (GDP-bound), and active (GTP-bound)
state. Regulation is controlled by GEFs (guanine-nucleotide exchange factors), which
activate Rho GTPases by driving exchange of GDP for GTP and GAPs (GTPase-
activating proteins), in turn enhancing intrinsic GTPase activity, inactivating the
proteins. Rho GTPase proteins direct down-stream signalling via the binding and
activation of a range of effector proteins to drive actin polymerisation (Allen et al.,
1997). In the Bacl macrophage cell line, Rac-1 was shown to induce the formation
of migration-associated lamellipodia and membrane ruffles, whilst Cdc42 regulated
fdopodia formation (Allen et al., 1997). Inhibition of the Rho GTPases with
Clostridium difficle toxin inhibited apoptotic cell-, Fc- and complement- mediated
phagocytosis. Further definition of the roles of different Rho GTPases in
phagocytosis was established by microinjection of inhibitory or dominant negative
Rho, Rac-1 and Cdc42. The inhibition of Rho, Rac-1 and Cdc42 had no effect on
apoptotic cell binding, but inhibition of Rho via a down regulation in Rho-kinase
signalling led to an increase in phagocytosis (Leverrier and Ridley, 2001; Tosello-
Trampont et al., 2003), whilst inhibition of both Rac-1 and Cdc42 inhibited apoptotic
cell phagocytosis (Leverrier and Ridley, 2001). Furthermore, activation of Rac-1 has
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been demonstrated during dendritic cell phagocytosis of apoptotic cells, following
signalling initiated by the ligation of the integrin adhesion receptor av(35 (Albert et
al., 2000). Differential involvement of Rho GTPases was observed following
triggering of Fc or complement receptors. Actin polymerisation necessary for
phagocytosis was directed by Cdc42 and Rac-1 during Fc-mediated phagocytosis but
Rho during complement-mediated phagocytosis (Caron and Flail, 1998). Flowever,
despite differential Rho GTPase activation in the different receptor-mediated
phagocytosis, the down-stream mechanism implementing Rho family GTPase
directed actin polymerisation was demonstrated to require the Arp2/3 complex in
both Fc- and complement-mediated phagocytosis (May et ah, 2000).
Downstream Pathways: Protein Kinase C
Protein Kinase C (PKC) family kinases are activated by calcium, diacylglyerol
(DAG) and phorbol esters, and are involved in both the signalling pathways for Fc-
and complement mediated phagocytosis and in the ingestion of apoptotic cells (May
and Machesky, 2001). Apoptotic thymocyte binding to mouse peritoneal
macrophages via receptor tyrosine kinase Mer (Scott et ah, 2001), was associated
with tyrosine phosphorylation of the phagocytic receptor, in common with Fc-
receptor activation. This was followed by the association and phosphorylation of the
PKC activator PLC-y2, demonstrating activation of PKC during apoptotic cell
phagocytosis (Todt et ah, 2004). Studies examining Fc-mediated phagocytosis by
human monocytes showed that following the binding, but preceding the ingestion of
IgG opsonised erythrocytes, PKC translocates from the cytosol to the plasma
membrane where it is activated. Following internalisation, PKC then localises to the
phagosome (Zheleznyak and Brown, 1992). PKC has also been shown to regulate the
early process of apoptotic cell binding. The predominant binding receptor for non¬
inflammatory macrophages is the integrin avP3, but upon PKC stimulation avP5
mediated binding is also activated, accompanied by an up-regulation in total binding
(Finnemann and Rodriguez-Boulan, 1999). Dissection of the roles of the different
PKC isoforms has demonstrated that PS-mediated phagocytosis of apoptotic cells by
mouse peritoneal macrophages requires the PKC pil isoform. This is in contrast to
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isoforms utilised in other forms of phagocytosis (Todt et al., 2002). Down stream
targets of the PKC kinases include plekstrin, MARCKS (myristoylated alanine-rich
C kinase substrate) and MacMARCKS (macrophage enriched MARCKS). The latter
two are actin-fdament crosslinking proteins, linking PKC activation to the
cytoskeletal membrane (May and Machesky, 2001).
Phagosome Maturation
'Pinching off portions of the membrane, which partially surrounds the apoptotic cell
or bacteria bound to the phagocyte surface, forms the nascent phagosome (Swanson
et al., 1999). Maturation of the phagosome follows its interaction with the endocytic
pathway, during which it undergoes dramatic membrane and vacuolar changes which
confer ability to kill micro-organisms or breakdown apoptotic cells. The nascent
phagosome sequentially associates with, and takes on characteristics of early
endosomes, late endosomes and lysosomes, by a 'kiss and run' interaction permitting
transfer of contents between the phagosome and endocytic vesicles without fusion of
membranes. This complex maturation process is governed by microtubules and
kinesin motor proteins, allowing the movement of the nascent phagosome from
regions adjacent to the plasma membrane through the cytoplasm. Further, Annexins
I, II and VI together with actin, localise to the surface of the maturing phagosome,
perhaps mediating interaction with the cytoskeleton, and aiding movement and
association with the endosomes and lysosomes (Vieira et al., 2002).
Mediators of Macrophage Phagocytosis
For therapeutic strategies for treatment of inflammatory disease via induction of
apoptosis by external mediators to be successful, there is a requirement for strategies
which increase the phagocytosis of such generated apoptotic cells. The regulation of
phagocytic ability, like the induction of apoptosis, is amenable to exogenous
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stimulation. This has been demonstrated by the short term exposure of macrophages
to pro-inflammatory cytokines such as GM-CSF, which increases both the
percentage of macrophages that phagocytose and the number of apoptotic cells
phagocytosed by an individual macrophage. Stimulation with pro-inflammatory
cytokines is independent of changes to surface receptors, suggesting alteration
instead of signal ling'pathways required for actin polymerisation (Ren and Savill,
1995). However, the involvement of immuno-modulatory cytokines in defining
macrophage phenotype and functions, such as phagocytosis of apoptotic cells, has
not been fully investigated.
Rapid modulation of phagocytic ability was also observed by ligation of extracellular
matrix receptors such as CD44 (Hart et ah, 1997) or prostaglandin receptors (Rossi et
ah, 1998), or by macrophage adhesion to fibronectin (McCutcheon et ah, 1998).
Elevation of cAMP by exogenous mediators or by the binding of PGE2, specifically
inhibited the phagocytosis of apoptotic cells whilst disrupting cytoskeletal
arrangements, resulting in loss of adhesion structures and rounding up of the
macrophages in a PKA-dependent manner (Rossi et ah, 1998). In contrast, cross-
linking of the CD44 receptors rapidly and specifically up-regulated macrophage
phagocytosis of apoptotic neutrophils (Hart et ah, 1997) and, like lipoxin-mediated
apoptotic cell phagocytosis, may also be associated with cytoskeletal alteration
(Maderna et ah, 2002). Cumulatively, these data suggest a connection between the
processes of adhesion and phagocytosis. Phagocytosis and adhesion have
cytoskeletal components in common, e.g. the adaptor protein paxillin, present in
podosome adhesion structures and in the extending phagocytic cup during
complement-mediated phagocytosis (Allen and Aderem, 1996) and the cytoskeletal
regulators, Rho-GTPases which are critical to both processes (Allen et ah, 1997;
Leverrier and Ridley, 2001). The unfolding phagocytic signalling pathways, defined
by studies in C.elegans, also demonstrate a link between adhesion, migraton and
phagocytosis. Ced-5, Ced-2, Ced-12 and Ced-10 and their mammalian homologues
DOCK180, Crkll, ELMO and Rac-1 form a signalling pathway during phagocytosis
(Gumienny et ah, 2001), initiated by the ligation of the integrin adhesion receptor,
avp5, in dendritic cells (Albert et ah, 2000). In fact, many of the receptors implicated
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in phagocytosis of apoptotic cells are also adhesion receptors e.g. CD36 and avP3.
One possibility is that ligation of these receptors may modulate adhesion, releasing
or sequestering cytoskeletal proteins necessary for phagocytosis.
Effects of Glucocorticoids on inflammation
Glucocorticoids (GCs) are the most effective and widely used compounds for the
treatment of diseases such as rheumatoid arthritis, autoimmune diseases and asthma,
owing to their associated anti-inflammatory properties (see Figure 1.4). Synthetic
GCs such as dexamethasone (Dex) and prednisolone, work by mimicking natural
glucocorticoids. GCs may mediate their anti-inflammatory effects by increasing the
transcription of anti-inflammatory genes e.g. IL-1 receptor antagonist, whilst
decreasing transcription of pro-inflammatory genes such as TNF-a (Barnes, 1998). In
addition, GCs affect the survival of inflammatory cells, for example by inducing
apoptosis in T-cells and eosinophils via down-regulation of the secretion of survival
factors. Interestingly, GCs have opposing effects on granulocyte apoptosis; inhibiting
neutrophil apoptosis, but accelerating it in eosinophils (Meagher et ah, 1996). The
mechanisms by which GCs mediate their anti-inflammatory effects are discussed in
detail in Chapter 3.
GCs also modulate the ability of macrophages to phagocytose apoptotic neutrophils.
Short term exposure of 4 day monocyte-derived macrophages to GCs increased
phagocytosis of apoptotic cells but not Fc-mediated uptake of opsonised
erythrocytes. Importantly, this augmented uptake did not induce the release of pro¬
inflammatory cytokines (Liu et ah, 1999). Recent studies have shown that exposure
of monocytes to GCs for the first 24 hours of 5 day culture resulted in a highly
phagocytic macrophage population, without any increase in the expression of any of
the putative apoptotic cell receptors. GC-treatment resulted in a homogeneous
population of small, rounded and weakly adherent macrophages with profound
alterations to the cytoskeleton. Loss of podosomes-like adhesion structures was
accompanied by a down-regulation in phosphorylation and recruitment of paxillin
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and Pyk2 to adhesions. A down-regulation in the adaptor protein pl30Cas, but a
marked up-regulation in levels of active Rac-1 were also observed (Giles et al.,
2001). Based upon these findings, it was suggested that the observed decrease in the
adhesion associated protein pi 30Cas, normally found in a complex with DOCK 180,
Crkll and ELMO, may release the other complex proteins to sites of phagocytosis.
Certainly, activity in the downstream effector Rac-1 is up-regulated in these cells and
may drive the membrane extension facilitating the high levels of phagocytosis.
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The primary aims of this study were to investigate the mechanism by which long
term glucocorticoid treatment of peripheral monocyte-derived macrophages causes in
vitro augmentation of phagocytosis of apoptotic cells. Previous studies have
demonstrated an altered macrophage cytoskeletal morphology following Dex
treatment. Considering the central role that cytoskeletal regulation plays in
macrophage function, I also sought to examine changes to macrophage adhesion and
migration caused by Dex treatment. Specifically, I wished to examine the following
hypothesis:
1. Glucocorticoid treatment of MDMO alters the utilisation of receptors required in
the binding and/or internalisation of apoptotic cells.
2. Glucocorticoid treatment of MDMO induces altered cytoskeletal regulation that
changes adhesion and migration responses in macrophages.
3. The cytokine environment of MDMO would directly modulate glucocorticoid-
mediated differentiation of macrophages.
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CHAPTER 2: MATERIALS AND METHODS
Antibodies and other reagents
Reagents were obtained from Sigma (Poole, UK) unless otherwise stated. Percoll and
Dextran were from Amersham Pharmacia Biotech (Birmingham, UK) Iscove's
DMEM was obtained from Invitrogen (Paisley, UK) and Dexamethasone (Dex) from
Organon Laboratories Ltd (Cambridge, UK).
Antibodies, murine monoclonal, unless otherwise stated, were used at saturating
concentrations as determined by titration in indirect immunoassays and flow
cytometry as follows: HLA-DR (clone WR18 IgG2a, used at 1/100, Serotec, Oxford,
UK), CD1 la (clone 38 IgG2a, used at 1/100, Serotec) (clone WAC70 IgG2a, used at
1/100) CD1 lb (clone 44 IgGl, used at 1/100, Serotec) (clone LM2 IgGl, used at
1/50), CD 14 (clone UCHM1 IgG2a, provided by Dr. Peter Beverley, Edward Jenner
Institute for Vaccine Research, Compton, UK), CD 14 (clones 61D3 and 63D3,
provided by Professor Gregory, Centre for Inflammation Research, University of
Edinburgh), CD 16 (clone 3G8 IgGl, used at 1/500, provided by Dr Unkeless, Mount
Sinai Medical School, New York), CD18/(32 (clone TS1/18 IgGl, used at 1/5),
CD29/pi (clone 12G10 IgGl, used at 1/50, Serotec) CD31 (clone Hec7.2 IgG2a,
used at 5pg/ml, Endogen, Woburn, USA), CD32 (clone IV3 IgG2b, cell culture
supernatant used neat), CD45 (clone 2D1 IgGl, used neat), CD54/ICAM-1 (clone
15.2 IgGl, used at 1/100, provided by Dr. Hogg, Cancer Research London, UK),
CD49d (clone 44H6 IgGl, Serotec), CD49e (clone JBS5 IgGl, Serotec), CD62L
(clone SK11 IgG2a, used at 1/50), CD64 (clone 10.1 IgGl, used at 1/100, provided
by Dr. Hogg), CD66 (clone KAT4C IgGl, used neat), CD86 (clone BU63 IgGl,
used at 1/50, Caltag, UK), CD51/alphaV (clone 13C2 IgGl, used at 1/500, provided
by Dr Horton, UCL, London), CD51CD61/alphavbeta3 (clone 23C6 IgGl, used at
1/100, provided by Dr Horton), CD163 (clone Bermac IgGl, used at 1/35, Dako,
Oxford, UK), mouse SRA-1 (clone 2F8 rat IgG2b, Serotec) IgGl control (MOPC
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IgGl, plasmacytoma, obtained from ECACC, UK), IgG2a (clone 0X34, Serotec),
Phosphor-c-Jun (ser63)II (rabbit polyclonal, Cell Signalling, Beverly, USA) PAK-1
(rabbit polyclonal, used at 1/500, Cell Signalling), ROCK-1 (clone 46 IgGl used at
1/250, BD Transduction Laboratories, UK), Rac-1 (clone 102 mouse IgG2b, used at
1/1000, BD Transduction Laboratories), IkB-oc (rabbit polyclonal, Cell Signalling),
Paxillin (clone 177, used at 1/400, BD Transduction Laboratories), Phospho-p44/42
MAPK (mouse IgG, used at 1/1000, Cell Signalling), Rhodamine phalloidin (used at
1/800, Molecular Probes, Leiden, Netherlands).
Secondary antibodies and directly conjugated antibodies were as follows: Goat anti-
mouse IgG 430, 488 and 568 (used at 1/400, Molecular Probes), P(ab')2 goat-anti
mouse IgG FITC (used at 1/50, DAKO, High Wycombe, UK) and rat anti-mouse
F4/80 FITC (clone CI:A3-1 IgG2b, Serotec).
Mononuclear and polymorphonuclear leukocyte isolation
Human peripheral blood was drawn from healthy volunteers and collected into tubes
containing 4ml sodium citrate (Phoenix Pharmaceuticals Ltd., Gloucester, UK) to a
final volume of 40ml and then centrifuged at 350 x g for 20 minutes. All steps
following venepuncture were carried out at room temperature unless stated
otherwise. The resulting upper platlet-rich plasma (PRP) layer was removed and
autologous serum (AS) was prepared by adding 10ml of PRP to 220pl of 1M CaCL
and incubating for 30 minutes at 37°C in glass tubes. Erythrocytes were sedimented
out of the lower cell suspension layer by the addition of 2.5ml of dextran T500
(500,000 Mwt.) per 10ml of cells and reconstituted to 50ml with 0.9% saline and
then left for 30 minutes at room temperature. The resulting leukocyte-rich upper
layer was then collected and spun at 350 x g for 6 minutes to pellet the leukocytes.
Percoll was made isotonic by preparing a 90% solution using lOx PBS. The isotonic
Percoll was then used to make 72.9%, 61.2% and 49.5% layers using lx PBS without
CaCL or MgCL. Gradients were prepared by layering 3ml of 61.2% onto 3ml of
72.9% Percoll. The cells pellets were then mixed with the 49.5% layer (pellet from
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80ml blood /3ml of 49.5% Percoll) and layered onto the gradient, before centrifuging
at 720 x g for 20 minutes. Mononuclear leukocytes were removed from the
49.5/61.2% interface whilst the polymorphonuclear leukocytes were removed from
the 61.2/72.9% interface. Leukocytes were then washed twice in PBS without CaCh
or MgCb before cell culture.
Quality control
Cells collected from each layer of the gradient were subject to flow cytometry
analysis by forward (FS) and side scatter (SS). The PMN's used were >95% pure,
with the mononuclear cells typically comprising 15-20% monocytes and 80-85%
lymphocytes (Figure 2.1).
Cell culture
Neutrophils, resuspended at 20xl06/ml in Iscove's DMEM were labelled with
2pg/ml (final concentration) CellTracker green 5-chloromethylfluorescein diacetate
(Molecular Probes, Leiden, Netherlands) for 20 minutes at 37°C. Following
labelling, the cells were pelleted by centrifugation at 220 x g for 5 minutes and the
pellet was then resuspended at 4xl06/ml in Iscove's DMEM + 10% autologous
serum and incubated for 20 hours at 37°C to induce apoptosis. The resultant
population typically consisted of 45-65% apoptotic cells with 15-20% necrosis, as
determined by morphological or flow cytometry examination. Alternatively,
neutrophils were cultured without labelling, in which case they were incubated at
4xl06/ml in Iscove's DMEM + 10% AS for 20 hours. Cultured neutrophil

















Figure 2.1 Flow Cytometry profiles for PMN- and monocyte-rich layers
following percoll gradient isolation
Mononucelar and polymorphonucelar (PMN) cells were isolated from periph¬
eral blood and separated by Percoll gradients. Representative flow cytometry
FS and SS profiles are shown for (A) the PMN fraction and (B) the mono¬
nuclear cell fraction.
Neutrophil apoptosis was also induced by treatment with TNF-a and gliotoxin for 2
hours. Following isolation, the neutrophils were centrifuged at 220 x g for 5 minutes
to pellet the cells and then re-suspended at 4xl06/ml in Iscove's DMEM + 10% AS +
O.lpg/ml (final concentration) TNF-a + lpg/ml (final concentration) of gliotoxin,
and incubated at 37°C, 5% CCE for 2 hours, following which the levels of apoptosis
(typically 85-100% apoptosis and no necrosis) were assessed as described below.
Monocytes (typically 15-20% of the mononuclear cells) were cultured by re-
suspending the mononuclear cells at 4xl06/ml in Iscove's DMEM and culturing in
tissue culture dishes for 1 hour. Monocytes were enriched by selective adherence to
tissue culture plastic followed by 4 x washes in Hanks Balanced Salt Solution to
remove the non-adherent lymphocytes. The monocytes were then cultured for 5-7
days in the presence of Iscove's DMEM + 10% AS, during which time they
differentiated into monocyte-derived macrophages (MDMO).
Dex (final concentration of 125nM or lpM) and/or cytokines (final concentration of
lOng/ml) were added to the culture media following washing, unless otherwise stated
in individual experiments. Working concentrations were established by examining
MDMO phagocytosis of apoptotic neutrophils at different concentrations (see Figure
2.2).
Characterisation of neutrophil apoptosis by morphology
220pl of unlabelled apoptotic neutrophils at 4xl06/ml were placed into a cytospin
chamber and centrifuged onto glass slides at 300 x g for 3 minutes. Following air
drying, the cells were fixed for 1 minute in 100% methanol, stained for 1 minute
each with haematoxylin and eosin (Diffquik, Baxter Healthcare, Glasgow, UK) and a
coverslip added before examination by light microscopy under oil using a 63x
objective lens.500 cells were counted per slide and apoptosis was defined as a cell
containing a condensed nucleus, distinct from the multi-lobed nucleus of a non-
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Figure 2.2 Concentration curves for Dex and IFN-y
(A) The effect of diluting concentrations of Dex on MDMO phagocytosis of
apoptotic neutrophils was determined. Concentrations between 2pM and
l25nM augmented phagocytosis equally. ***, p<0.00l vs. control MDMO,
Tukey Kramer repeated ANOVA with post-test performed on transformed data
(n=3).
(B) The concentration of IFN-y which inhibited Dex-augmented MDMO phago¬
cytosis was investigated. I Ong/ml IFN-y was chosen as the concentration to use.
* p<0.05; ** p<0.01; *** p<0.00l vs. Dex-treated MDMO, Tukey Kramer
repeated ANOVA with post-test performed on transformed data (n=2).
Characterisation of neutrophil apoptosis by flow cytometry
Following treatment, neutrophils were duel labelled for annexin V and propidium
iodide (PI). Phosphatidylserine (PS) is asymmetrically expressed on the inner
membrane of viable cells, but following apoptosis the asymmetry is lost and PS
becomes exposed on the outer leaflet where it can be detected by the specific binding
of annexin V. Because PS is also expressed on the outer leaflet of necrotic cell
membranes, PI, which specifically labels necrotic cells, was used to distinguish
between apoptotic and necrotic cells. 2pl of fluorescein isothiocyanate (FITC)-
conjugated annexin V (Roche, East Sussex, UK) (final concentration 5pM) was
added to 1ml of annexin V binding buffer (HBBS, 5mM CaCh). 280pl of annexin V
+ buffer was then added to a tube containing 20pl of neutrophils at 4xl06/ml and
incubated on ice for 10 minutes. Immediately prior to analysing the sample, 1 pi of
1 mg/ml PI was added to the cells. Annexin V and PI were measured using FL1 and
FL2 detectors respectively (see Figure 2.3B).
Assessment of macrophage phagocytosis by flow cytometry
5 day MDMO, differentiated in 48 well plates, were washed once in HBSS and the
media removed. 500pl of overnight 'aged', CellTracker green 5-
chloromethylfluorescein-labelled neutrophils (labelling as described in Cell Culture
section), at 4xlO/Aml in Iscove's DMEM were added to each well and the plate
returned to the 37°C incubator for 1 hour. Following incubation the media was
removed and replaced with 250pl of pre-warmed trypsin/EDTA, and incubated at
37°C for 15 minutes and then on ice for 15 minutes. The cells were then vigorously
pipetted to remove them from the plastic, transferred to flow cytometry tubes and
then analysed on a FACS Calibur flow cytometer (Becton Dickinson). The
macrophages were gated using FS and SS, and non-phagocytic, low FL1
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Figure 2.3 Assessment of neutrophil apoptosis
Following 20 hours culture in Iscove's DMEM + 10% AS, viability was deter¬
mined by morphological assessment and by flow cytometric analysis of annexin V
binding and PI exclusion.
(A) Overnight 'aged' neutrophils: apoptotic nuclei appear condensed whilst viable
cells have multi-lobed nuclei.
(B) Representative flow cytometry profiles. Both the apoptotic and necrotic
neutrophils are annexin V positive, whilst only the necrotic neutrophils are PI
positive. In this example approximately 14% of the neutrophils are viable (annexin
V and PI negative), 58% apoptotic (annexin v positive) and 27% necrotic (annexin
V and PI positive).
macrophages (Jersmann et al., 2003). 6000 events were collected for each sample
and the percentage of phagocytic macrophages in each population calculated (see
Figure 2.4).
Assessment of macrophage phagocytosis by plate assay
5 day MDMO, differentiated in 24 well plates, were gently washed once in HBSS
and the media then replaced with 1ml of unlabelled overnight 'aged' neutrophils. The
plate was then incubated at 37°C for 1 hour. Following incubation, the cells were
washed 3 times with PBS without CaCb or MgCb to remove all bound, non-
internalised neutrophils. The cells were then fixed in 2.5% glutaraldehyde for 20
minutes at RT. Following 3 washes in PBS without CaCB or MgCF to remove the
fixative, the neutrophils were stained for myeloperoxidase activity with O.lmg/ml
dimethoxybenzidine and 0.03% (v/v) hydrogen peroxidase for 20 minutes. The
percentage of macrophage phagocytosis was quantified microscopically by counting
a minimum of 500 cells per well, and an average between the duplicate wells
calculated. Phagocytic index was calculated as (average number of neutrophils
phagocytosed per macrophage) x (% of macrophages that had phagocytosed one or
more neutrophil).
Phagocytosis inhibitor/activator studies
MDMO were incubated with: neuraminidase (Sigma) diluted to O.lU/ml in PBS for
20 minutes at 37°C, or phorbol-12-myristate-13-acetate (PMA) diluted in Iscove's
DMEM to 30nM, or RO 31 -8220 diluted to 1 pM or 4-a-PMA diluted to 80nM
(optimal concentrations determined in previous studies in the laboratory) for 1 hour
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Figure 2.4 Flow Cytometic analysis of MDMO phagocytosis of apoptotic neutro¬
phils
(A) and (C) show representative flow cytometry dot plots (FS vs FL-1) following a
phagocytosis assay. The FL-1 labelled, unphagocytosed neutrophils are labelled in
(A) The MDMO were gated in the Control and Dex-treated MDMO plots (R3 and
R5 respectively)
(B) and (D) show FL-1 spread for the gated MDMO population, allowing the
MDMO which have phagocytosed to be identified (gate Ml) and the percentage of
phagocytic cells calculated.
1/100 in Iscove's DMEM for 30 minutes at 37 °C. The inhibitor/activator was then
replaced by apoptotic neutrophils and the flow cytometry phagocytosis assay carried
out as described.
Overnight 'aged' neutrophils were resuspended at 4xl06/ml in HBSS + 5mM CaCE
+ 1/50 annexin V-biotin (Roche) and incubated on ice for 20 minutes. The cells were
then pelleted and resuspended in Iscove's DMEM at 4xl06/ml and used in a flow
cytometry phagocytosis assay as previously described.
Assessment of macrophage binding of apoptotic neutrophils
In order to assess the binding ability of apoptotic neutrophils by different populations
of macrophages, MDMO in 24 well plates were gently washed once in HBSS and the
media then replaced with 1 ml of unlabelled 'aged' neutrophils at 4xl06/ml and the
plate incubated on ice for 1 hour. Following incubation, the plate was placed onto a
plate shaker (Eppendorf) rotating at 300rpm for 5 seconds. The media was then
replaced with PBS without cations and again placed on the mixer for a further 5
seconds. This was repeated again to give a total of 3 washes. The cells were then
fixed in 2.5% glutaraldehyde on ice for 20 minutes. Following three washes in PBS
without CaCE or MgCE the neutrophils were stained with O.lmg/ml
dimethoxybenzidine and 0.03% (v/v) hydrogen peroxidase for 20 minutes. 500
macrophages were counted per well, with duplicate wells for each treatment, and the
percentage of macrophages with 1+ neutrophils bound recorded, as well as the
number of neutrophils bound to each macrophage. Binding index was calculated as
(average number of neutrophils bound per macrophage) x (% of macrophages that
had bound one or more neutrophil).
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Binding inhibition studies
5 day MDM® were incubated with 61D3 or 63D3 (anti-CD 14) diluted to 20pg/ml in
Iscove's DMEM for 30 minutes at 37° C or Hec7.2 (anti-CD31) or IgG2a control
antibody diluted to 5pg/ml in Iscove's DMEM for 10 minutes at room temperature.
The media was then replaced with 'aged' or TNF/gliotoxin-treated neutrophils and
the binding assay carried out as described above.
Flow cytometry for profiling
MDMO, cultured for 5-7 days, were removed from the tissue culture plastic by
replacing the culture media with sufficient dissociation buffer (PBS without cations,
5mM EDTA and 0.2% serum) to cover the bottom of the well. The plate was
incubated on ice for 15 minutes followed by removal of the macrophages using a
rubber cell scraper. 50pl of cells were then added to each well of a 96 well plate and
the plate centrifuged at 200 x g for 5 minutes to pellet the cells. The buffer was then
removed by flicking the plate and the cells re-suspended by gentle vortexing. 1 OOpl
of flow buffer (PBS without cations, 0.2% BSA, 0.1% sodium azide) was then added
to each well and the plate centrifuged at 200 x g for 2 minutes at 4°C, followed by
removal of the buffer and re-suspension of the cells. To block Fc receptors, 5 pi of
rabbit Ig antibody (1/50) was added to each well and the plate incubated for 10
minutes on ice. 50pl of primary antibody was then added to each well and the plate
incubated on ice for 20 minutes, followed by 2 washes in flow buffer. 50pl of FITC
goat anti-mouse IgG (1/50) was then added to each well and the plate incubated for
20 minutes. Following two washes, the cells in each well were re-suspended in 120pl




Following 5 day's culture, MDMO culture supernatant was removed and centrifuged
at 10,000 x g for 10 minutes to pellet any cellular debris. The supernatants were then
stored at 80°C until analysis.
The method for cytokine measurement was as described by the manufacturer (BD
Biosciences). The cytometric bead array system allows single supernatant samples to
be simultaneously analysed for the presence of IL-2, IL-4, IL-6, IL-10, TNF-a and
IFN-y. The kit contains 6 bead populations, each with a distinct FL-3 intensity, that
have been coated with capture antibodies for the 6 proteins named above. The
capture beads are then incubated with the supernatant samples whilst the
vial of inflammatory cytokine standards (Becton Dickinson) were reconstituted with
0.2ml of assay diluent to make a lOx bulk standard and left to equilibrate for 15
minutes at room temperature. 12 standards were then made by diluting the bulk
standard; 900pl of assay diluent was added to the first tube and 300pl to the
remaining 11 tubes. lOOpl of lOx bulk standard was then added to the first tube and
mixed. A serial dilution was then performed.
lOpl of each capture bead (x number of assay tubes) was added to a single 'mixed
capture beads' tube and the beads mixed by vortexing. 50pl of mixed beads were
then transferred to each of the assay tubes, followed by the addition of 50pl of PE
detection reagent. 50pl of standard dilutions and test samples were then added to the
correct tubes and incubated for 3 hours at RT. 1ml of wash buffer was then added to
each tube and centrifuged at 200 x g for 5 minutes. The buffer was then carefully
aspirated off and 300pl of wash buffer added to each tube to resuspend the pellet.
Analysis was performed on a BD FACS Calibur flow cytometer with a 488nm laser
that can detect and distinguish emissions at 576 and 670nm. Each sample was
vortexed for 3-5 seconds prior to analysis.
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Electron microscopy
Monocytes seeded onto glass cover slips in 12 well plates were differentiated in the
Iscove's DMEM + 10% AS ± 125nM Dex. After 5 days the cells were washed once
in HBSS and then fixed for 3 hours in 3% glutaraldehyde in 0.1M sodium cacodylate
buffer pH7.4, on a rocking platform. The subsequent preparatory work was carried
out by Steven Mitchell, College of Medicine and Veterinary Medicine Electron
Microscopy Services. Following three, 20 minute washes in 0.1M sodium cacodylate
buffer pH7.4 the cells were placed in 1% osmium tetroxide in 0.1M sodium
cacodylate buffer pH7.4 for 2 hours. The cells were dehydrated by washing through
graded acetones for 10 minutes each wash; 50%, 70%, 90%, 100%, 100%, 100%
acetone. The cells were then critical-point dried with carbon dioxide in a poloron
E3000 SII CPD and a conductive coating of 20nM gold/palladium (60/40) added
using an Emscope SC500 sputter coater.
Cells were viewed and imaged using a Philips 505 scanning electron microscope.
Immunofluorescence
Mononuclear cells were plated at 4xl06/ml in Iscove's DMEM onto sterile cover
slips placed in the wells of 12 well plates. After one hour incubation at 37°C the cells
were washed and cultured as described in the cell culture methods section.
Alternatively, neutrophils were cultured and cytospun onto glass slides as described
previously.
The cells were fixed in 3% PFA at room temperature for 20 minutes, and then
washed 3 times in PBS. The MDMO were then permeabilised in 0.1% Triton X 100
for 4 minutes at RT, followed by a further 3 washes. To block non-specific antibody
binding, cells were then incubated in heat-inactivated human serum diluted 1/10 in
PBS for 10 minutes at RT, followed by three washes as before. The primary antibody
was diluted in PBS and the cells stained for 30 minutes on ice, followed by 3 washes
in PBS. The secondary antibody was then diluted in PBS and added into the wells of
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the plate containing the cover slips for 30 minutes on ice. The cells were then washed
a further 3 times and the coverslips were placed onto slides containing the mounting
medium mowiol and left to dry overnight in the dark. Slides were examined by using
a Zeiss Axiovert 5100 fluorescent microscope, with images captured using
AppleMac OpenLab image capture system.
Time lapse microscopy
MDMO were cultured for 5-7 days in slide flasks (Nunc). The cells were washed
once in HBSS to remove non-adherent cells and the media replaced with Iscove's
DMEM + 10 % AS. For experiments where macrophages were treated with the MAP
kinase inhibitor, PD98059, the culture media was replaced with Iscove's DMEM
containing the inhibitor diluted to 20pM and the MDMO returned to the 37°C
incubator for 1 hour before continuing as described. The monolayer of macrophages
was then wounded using a rubber cell scraper which enabled a consistent width of
cells to be removed without damaging any underlying ECM. Non adherent cells were
removed by replacing the Iscove's DMEM + 10% AS. The migration of cells back
into the wound was then examined by phase contrast microscopy with an image
captured every 5 minutes for 20 hours. Data was analysed by opening the initial
image taken at time 0 and placing an acetate sheet over the computer screen and
defining the area of the wound. Subsequent images were then opened and the number
of cells in the 'wounded area' recorded. From this information the migration of the
cells can be presented graphically and the rate of migration for different stages
recorded.
Western blotting
MDMO were cultured for 5 days in 6 well plates, and washed once in HBSS without
cations before replacing media with 200pl of lysis buffer (25mM Tris pH7.4, 1%
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NP40, 150mM NaCl and 1/100 Sigma protease inhibitor cocktail). The plate was
then placed on ice for 30 minutes before using a rubber cell scraper to ensure all cells
were removed from the plate. The supernatant was then moved into tubes and
centrifuged at 10 000 x g for 10 minutes at 4°C to pellet cell debris.
The protein concentration of the supernatants was then determined using a Bradford
Assay kit (Pierce). Standards were made using a lOmg/ml stock of bovine serum
albumin (BSA) and performing a serial dilution to provide a 10, 5, 2.5, 1.25, 0.63,
0.31, 0.16 and 0 mg/ml. lOpl of either standard or supernatant were added to wells of
a 96 well plate in duplicate, to which the colourmetric detection buffers were added.
The 96 well plate was incubated at 37°C for 30 minutes and then analysed on a
spectrophotometer with a measurement filter of 450nm.
Protein gels of various concentrations (12%, 9%) were made as follows: for 20ml of
a 9% Tris/glycine SDS-Polyacrylamide running gel, 5ml 1.5M Tris pH8.8, 6ml 30%
bis-acrylamide, 200pl of 10% sodium dodecylsulphate (SDS), 60pl 1,2-Bis
(dimethylamino) ethane (TEMED), 120pl of 10% ammonium persulphate (APS) and
8.62ml of water were mixed and then poured between glass plates on the Biorad
Mini Protein II electrophoresis kit, and overlayed with butanol saturated water and
left to set. Following this, the butanol saturated water was removed and 4.5%
stacking buffer overlaid on the running gel (0.5 TRIS pH6.8, 30% acrlamide/bis,
10% SDS, 0.3% TEMED, 0.6% of 10% APS and made to volume by the addition of
water).
Supernatants were diluted in 4x sample buffer and 30pl of each sample was pipetted
into each well. The samples were run at 80V through the stacking gel and 120V
through the running gel.
Following electrophoresis, the gels were electroblotted onto nitrocellulose by
forming a sandwich of blotting paper, gel, nitrocellulose membrane and blotting
paper within a cassette. The proteins were then transferred from the gel to the
nitrocellulose by passing a current of 80V through the gel to the membrane in
transfer buffer (25mM Tris, 0.2M glycine, 20% methanol) for 1 hour.
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The membrane was then incubated in blocking buffer (1 x TBS, 0.1% Tween 20, 5%
w/v nonfat dry milk) at room temperature for 1 hour. The buffer was then replaced
with the primary antibody, diluted in blocking buffer and incubated at 4°C overnight
on a rocking platform. Following three, 10 minute washes in 1 x TBS, 0.1% Tween
20, the membrane was incubated with the secondary antibody diluted in blocking
buffer for 1 hour at room temperature. Following three further washes the membrane
was incubated with ECL reagents (Amersham Biosciences) for 5 minutes, exposed to
X-ray film (Kodak) and developed using an X-ograph imaging system, compact x4.
Assay for detection of activated Rac
MDMO were cultured for 5 days as detailed above. The cells were rinsed gently with
F1BSS and then the media was replaced with 200pl/well of ice-cold RIPA buffer
(50mM Tris pH7.2, 500mM NaCl, lOmM MgCl2, 1% TritonX-100, 0.5% sodium
deoxycholate and 0.1% SDS). The plates were put on ice for 30 minutes. PAK-1
agarose beads (a gift from Neil Hotchin, Birmingham or Upstate, New Jersey, USA)
were prepared by using 1 vial per well of cells and adding 50pl of cold RIPA lysis
buffer and mixed thoroughly. The supernatants were then removed from the plates
into tubes on ice, and then centrifuged at 10 000 x g for 15 minutes. 200pl of
supernatant were then placed into clean tubes on ice, with lOpl kept back to run as
whole cell lysate. The total volume of beads was divided by the number of
supernatants and the appropriate volume transferred to the 190pl lysates. The
lysate/bead mixes were then mixed on a rotary agitator at 4°C for 60 minutes,
followed by 3 washes with Buffer B (50mm Tris pFI7.2, 150mM NaCl, lOmM
MgCli and 1% TritonX-100) with centrifugation at 10 000 x g for 2 minutes. 20pl of
2.5x reducing sample buffer was then added to each pellet and lOpl added to each of
the lOpl whole cell lysates, followed by a brief vortex. The samples were then heated
for 15 minutes at 95°C followed by centrifugation for 2 minutes at lOOOOg. 20pl of
each sample were loaded onto and run on 12% polyacrylamide gels, blotted and
proteins detected as described in western blotting section.
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RNA isolation and RT-PCR
MDMO cultured for 24 hours or 5 days in the wells of 6 well plates were washed
once in HBBS to remove non-adherent cells and the media then replaced with 0.5ml
of Trizol. Following 5 minutes incubation at RT the Trizol lysed cells were then
transferred to 1.5ml Eppendorf tubes. 0.2ml of chloroform per ml of trizol used to
lyse the cells was added and the tubes shaken vigorously by hand for 15 seconds,
followed by an incubation at RT for 3 minutes. The tubes were then centrifuged at
12,000g for 15 minutes at 4°C. The supernatants settled out into an upper RNA rich
phase, an interphase of protein and a lower phase of DNA and protein. The upper
phase was collected into fresh tubes and 0.25ml of isopropanol was added to each
tube and the RNA incubated on ice for 10 minutes. After centrifugation at 12,000g
for 10 minutes at 4°C, a pellet formed which was washed once in 75% ethanol, with
a centrifugation at 7,500g for 5 minutes at 4°C. The ethanol was then removed and
the pellet air dried for 10 minutes, after which it was dissolved in 20pl of RNAse free
water and incubated at 55°C for 10 minutes.
RNA was then DNAse treated to remove any contaminating DNA using a DNAse kit
(Ambion). 0.1 volume (of the RNA) oflOx DNAse 1 buffer and lpl of DNAse 1
enzyme was added to the RNA, and mixed gently and incubated at 37°C for 30
minutes. 5pl DNAse inactivation buffer beads were then added to each tube of RNA
and incubated at 37°C for 2 minutes and centrifuged at 10,000g for 1 minute to pellet
the inactivation buffer beads. The supernatant containing the RNA was then
transferred to fresh tubes and stored at -80°C
The isolated RNA was then reverse transcribed to generate cDNA. The RNA was
initially assessed for purity and yield by measuring absorbance at 260 and 280A,.
The concentration of RNA = (total A260) x (40pg/ml) 40pg/ml = one A260 unit of
RNA. The yield of RNA = (Total sample volume) x (concentration), whilst purity
was calculated by A260 / A280.
1 pi of oligo DT and 2pg of RNA was made to a final concentration of 12pl by the
addition of dFEO and incubated at 70°C for 10 minutes. 4pl of 1st strand buffer, 2pl of
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0.1M DTT, 0.5jj.1 of 20mM dNTP and 0.5|il of RNAse inhibitor mix was then added
and incubated at 42°C for 2 minutes to equilibrate the mix, after which lpl of
superscript enzyme was added and the mix incubated at 42°C for 50 minutes and
then at 70°C for 15 minutes. The cDNA was stored at 20°C until required.
PCR
PCR reactions were carried out by making the following reaction mix for each 25pl
reaction: 19pl distilled water (dFFO), 2.5pl of lOx reaction buffer (Invitrogen), 0.5pl
of lOmM dNTP (Promega), 0.75pl of 50mM MgCh (Invitrogen), 0.5pl of x
concentration of forward and 0.5pl of reverse primer (MWG, Germany), lpl of
cDNA and 0.25pl of Taq polymerase (Invitrogen). Each time a PCR reaction was
run, a negative control reaction without template cDNA was also run, to confirm that
any product was derived from the cDNA.
The Primer sequences used as detailed below:
Caveolin 1 Forward Primer 5' -> 3' AGC|TGA|GCG|AGA|AGC|AAG|TG
Caveolin 1 Reverse Primer 5' -» 3' CGG|TGT|GGA|CGT|AGA|TGG|AA
pi60 Rock Forward Primer 5' 3' TTG|ATG|ACT|TGG|AAG|AAG|ATA|AAG|G
pi60 Rock Reverse Primer 5'-> 3' AGC|TGT|GAA|TTC|TGA|CTG|ACT|TTC|TT
PAK1 Forward Primer 5'-> 3' TAT|GAT|TGG|AGT|CGG|CAG|CA
PAK1 Reverse Primer 5' -» 3' AAT|TGT|AAT|CCT|CAG|CTG|AC
ICAM1 Forward Primer 5' -> 3' ATC|ACC|ATG|GAG|CCA|ATT|TC
ICAM1 Reverse Primer 5' -> 3' TGT|ATA|AGC|TGG|CCG|GCC|AC
p-Actin Forward Primer 5' 3' CCA|CCA|ACT|GGG|ACG|ACA|TG
P-Actin Reverse Primer 5' 3' GTC|TCA|AAC|ATG|ATC|TGG|GTC|ATA
For each gene a curve of product versus cycle number was produced. Following
optimisation of each pair of primers, a PCR was set up and a sample removed every
2 cycles between 20 and 34 cycles. The product was run on a 1% TBE agarose gel
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and the band intensity measured. The band intensity was then plotted against cycle
number and the linear phase of the graph where amount of PCR product increased
proportionally to cycle number identified (see Figure 2.5). Using cDNA from a
minimum of three donors, PCR reactions for P-actin and one of the genes above was
run for the number of cycles identified as being in the linear phase. This enables
direct comparison of 2 types of cDNA, and thus the amount of RNA present in the
cells.
Gene Array
The Atlas human cell interaction cDNA array (Clontec, Becton Dickinson)
consisting of 265 genes immobilised onto nylon membranes, was used to investigate
potential changes in HMDMO gene expression following 24 hours Dex treatment.
The array contained genes from a range of gene/protein classifications including
ECM proteins, cell surface antigens, cell-cell adhesion proteins, metalloproteinases,
protease inhibitors, immune system proteins, intracellular protein phosphatases,
GTP/GTP exchange proteins and kinasenetwork members. Purified mRNA from 2
samples were converted to labelled cDNA by specific primers and incubated
separately with 2 membranes. Comparison of the membranes bound by labelled
cDNA allowed assessment of relative expression of genes between the 2 samples.
Purification of mRNA
Adherence purified peripheral blood monocytes were cultured for 24 hours in the
presence or absence of 1 pM Dex, and were then washed in HBBS to remove non¬
adherent cells. The monocytes consisted of > 95% CD14-positive cells as assessed
by flow cytometry. The media was then replaced with 0.5ml of Trizol. RNA was
isolated from the Control and Dex-treated MDMO, and then DNAase treated as
described in the RT-PCR section. The concentration of the two mRNA samples was
calculated, and adjustments made to equalise concentrations in the two samples.
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Actin primers
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Figure 2.5 RT-PCR curves
In order to ensure that PCR reactions were occurring during the
linear phase, i.e. where product amount is directly related to cycle
number, product vs. cycle number analysis was carried out for each
set of primers. Following PCR reactions for different cycle num¬
bers, the product was run out on an agarose gel and the intensity of
the band calculated by densitometry. A curve of product vs. cycle
number was drawn as shown above. The cycle number for the
plbOROCK and actin PCR reactions was then chosen.
Conversion of mRNA to radioactive cDNA probe
The isolated mRNA was converted to radioactively labelled cDNA. Initially 500-
lOOOng of control and Dex-treated mRNA were separately pre-incubated with 2pl of
Atlas-array specific primer (a mix of primers against all genes on array) for 10
minutes at 70°C followed by 10 minutes at 52°C. 2pl of lOx RT buffer, 2pl of dNTP
mix, 3pi of a32P dATP (2000-4000 Ci/mMol) and 2pl of nuclease free water were
then added and all components mixed and incubated for 5 minutes at 52°C. 2pl of M-
MLV reverse transcriptase was added and the mix incubated at 52°C for 2 hours.
Following the conversion of the mRNA to cDNA, unincorporated nucleotides were
removed by spinning the mix through Atlas nucleospin columns. The eluted
radioactively labelled cDNA probes were measured on a scintillation counter to
ensure that the control and Dex-treated cDNA probes were of equal counts per
minute (cpm).
Probe hybridisation to array membranes
The two array membranes (one for the control MDMO sample and one for the Dex-
treated MDMO sample) were washed in 0.5% SDS for 30 minutes at 80°C and then
incubated with the hybridisation buffer for 30 minutes at 68°C. The buffer was
removed and replaced with 50pl of heat denatured salmon sperm (to lower cross
hybridisation) and fresh hybridisation buffer. lxlO6 cpm of heat denatured labelled
cDNA control MDMO probe was added to one membrane and lxl 06 cpm of heat
denatured labelled cDNA Dex-treated MDMO probe to the other and hybridised
overnight at 68°C. The buffer and cDNA probe was removed and the membranes




The membranes were wrapped (DNA side up) in Saran wrap and exposed to
phosphorimager screen for 36 hours. The screen was then imaged on a STORM 860
phosphorimager, the background subtracted from around each gene array spot, and
the intensity of each spot recorded. For each gene, a pair of cDNA spots are
immobilised on the membrane and an average intensity reading was therefore
generated for each gene. An average intensity of the housekeeping genes on the
control MDMO membrane (Con Housekeeping average) and Dex-treated MDMO
membrane (Dex Housekeeping average) were used as correction factors for the other
genes on the control and Dex-treated MDMO arrays respectively (Con Gene 1/ Con
Housekeeping average, Dex Gene 1/ Dex Housekeeping average). The value
calculated for control gene 1 and Dex gene 1 were then compared (corrected Con
gene 1/ corrected Dex gene 1). Owing to a small number of genes being regulated
following Dex-treatment, those 2 times up- or down- regulated were considered for
further investigation.
Rat and Mouse Bone Marrow isolation and macrophage culture
Following a schedule 1 killing of age and sex matched wildtype and knockout mice,
or wildtype rats, the femurs were dissected out, with care taken to remove enough
tissue to ensure that the femur was not cut into. The extracted femurs were then
washed in 70% ethanol and all tissue removed from the bone using a scalpel.
Following a further wash in 70% ethanol, the femurs were then transferred to a clean
dish. Using a scalpel, both ends of the femur were cut through to expose the marrow.
A 10ml syringe with a 25 gauge needle was fdled with DMEM F-12, 10% L929
media (M-CSF-rich supernatant obtained from cultured L929 fibroblasts as described
below) (Boltz-Nitulescu et ah, 1987), 10% FBS and the marrow flushed from the
bone into 15ml Falcon tubes.
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The extracted bone marrow cells were then resuspended through a 19G wide bore
needle and the stem cells then counted. The cells were then pelleted by centrifuged at
220 x g for 5 minutes and re-suspended in DMEM F-12, 10% L929 media, 10% FBS
at 4xl04 stem cells /ml and plated into 24 well plates. Following 2 days culture, the
media was replaced with fresh DMEM F-12, 10% F929, 10% FBS ± 125nM Dex.
Cells were then used in experiments at 5-7 days. The scavenger receptor A"" (SRA"")
mice were shown not to express SRA on their cell surface, unlike the wildtype
controls (see Figure 2.6).
L929 supernatant preparation
L929 murine fibrosarcoma cells spontaneously secrete macrophage-colony
stimulation factor (M-CSF). F929 fibroblasts in log growth phase were cultured until
confluent in 25ml of DMEM F12 Glutmax, 10% FCS, and 50 units/ml of
Penicillin/Streptomycin. The culture media containing the supernatant was then









Fiaure 2.6 Phenotyping SRA knockout and wildtype (WT) mice
Following isolation and differentation of BMDMO from SRA -/- and WT mice,
they were phenotyped to check for SRA expression. BMDMO were dual labelled
with the mouse macrophage marker F4/80 and SRA. Untreated WT F4/80
positive cells were SRA positive, and SRA expression was not affected by Dex-
treatment. The F4/80 macrophages from the SRA-/- mice did not express SRA on
their cell surface.
Flow Cytometry software
All flow cytometry data collected was analysed using the Becton Dickinson Cell
Quest software package or the EPICS Expo 32 software package.
Statistical Analysis
Data were analysed using the GraphPad Instat statistical package. Data were paired,
that is the control and Dex-treated MDM<j) were from the same donor. However, the
data were not normally distributed and was therefore normalised prior to analysis.
This was done by transforming the data (calculating log 10 of the raw data). This then
enabled data to be analysed upon the assumption that the data were paired and from
Gaussian distributions.
Data where only two conditions were compared were analysed by a paired t-test (2-
tail P value). When more than two conditions were compared, data were analysed by
repeated ANOVA with post t-test (Tukey-Kramer Multiple Comparisons Test).
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Endogenous glucocorticoids (GC's) are released following infection, the initiation of
inflammation or stress. These stimuli act on the hypothalamus to trigger the
hypothalamus-pituitary-adrenal (HPA) axis. The hypothalamus releases
corticotrophin releasing hormone, which stimulates the synthesis and release of
adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland. ACTH acts
on the adrenal cortex causing release of GCs such as Cortisol into the blood stream
(Newton, 2000). GCs regulate metabolic processes, for example, the modulation of
blood sugar levels, stimulation of gluconeogenesis, and mobilisation of amino and
fatty acids in the liver. Importantly, GCs also down-regulate inflammation, an effect
mediated in part via changes in transcription. Down-regulation in the transcription of
a number of pro-inflammatory mediators occurs, including iNOS, pro-inflammatory
cytokines, adhesion molecules and chemokines required for the migration of
inflammatory cells. GCs also increase transcription of anti-inflammatory genes such
as lipocortin-1, which potentially inhibits production of lipid mediators, and IkB-cx,
an inhibitor of the transcription factor NFkB (Barnes, 1998). Owing largely to the
transcriptional down-regulation of survival factors, GCs cause cell type specific
induction of apoptosis, for example GCs induce apoptosis in T-cells and eosinophils
but not in neutrophils (Amsterdam and Sasson, 2002; Distelhorst, 2002).
GCs mediate their anti-inflammatory and metabolic effects through the
glucocorticoid receptor (GR). GCs are believed to passively enter cells via lipophilic
regions in their protein structure and once in the cytoplasm they bind to the GR. The
GR is held in the cytoplasm via a complex of chaperone proteins which include heat
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shock protein-90 (Sanchez et al., 1987). GC binding to the GR induces a
conformational change in the GR, which results in the loss of the chaperone proteins
and exposure of a nuclear localisation signal.
One mechanism by which neutrophils may evade GC-mediated apoptosis is through
the over-expression of the inactive isoform of the glucocorticoid receptor (GR). GC
effects are mediated through the binding of the active a-GR isoform and high relative
expression of the inactive P-GR isoform in relation to the active a-GR isoform
prevents GC- a-GR binding, allowing evasion of apoptosis by neutrophils. The pro¬
inflammatory cytokine IL-8 acts to up-regulate expression of the P-GR isoform,
thereby enhancing neutrophil survival during inflammatory responses (Strickland et
al., 2001).
A second level of GC regulation is performed by the enzyme 11 P-hydroxysteroid
dehydrogenase (11P-HSD). There are two isoforms of this enzyme, 11P-HSD1 which
predominantly converts inactive cortisone to activate Cortisol, and 11P-HSD2 which
works in the opposite direction, inactivating Cortisol. Therefore the differential
expression of the two isoforms, in different tissues, affects the amount of active GCs
available to act on cells (Morris et al., 2003).
Mechanisms of Glucocorticoid Action
Transactivation
Ligand-activated GR dimerises and once translocated to the nucleus can bind to 5'-
upstream promoter regions of genes at specific DNA sequences called glucocorticoid
responsive elements (GRE), promoting gene transcription of anti-inflammatory genes
such as lipocortin-1 and P2 adrenoceptors in a process known as transactivation.
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Transrepression
Binding of the GR to negative GRE (nGREs) in promoter regions of genes results in
a down-regulation in the transcription of pro-inflammatory genes (Sakai et al., 1988;
Zhang et al., 1997). However, very few genes have been shown to contain nGREs
and therefore this is not thought to be a common mechanism of action (Barnes,
1998). Transrepression by GCs is predominantly mediated by GR binding directly
and indirectly to transcription factors, preventing them from promoting the
transcription of pro-inflammatory genes (Adcock et al., 1995; Ray and Prefontaine,
1994).
NFkB and AP-1 are transcription factors implicated in the up-regulation of a large
number of inflammatory genes. The GR-GC complex has been shown to bind
directly to, and thus inhibit, the actions of NFkB. In some cell types, the GR acts to
increase transcription of the NFkB inhibitor, IkB-(x (De Bosscher et al., 1997). IkB-cx
binds to and prevents NFkBs translocation from the cytoplasm to the nucleus, thus
inhibiting transcription of pro-inflammatory genes. The AP-1 transcription factor is a
complex of Jun, Fos and other protein families. Pro-inflammatory cytokine activation
of the p38 MAPkinase signalling pathway results in the activation of AP-1 via
phosphorylation of c-Jun (Shaulian and Karin, 2002). In HeLa cells, TNF-a driven
phosphorylation of c-Jun was inhibited by Dex (Gonzalez et al., 2000). The GR also
binds to AP-1, resulting in a mutual inhibition of AP-1 and GR activated gene
transcription (Barnes, 1998).
GC transrepression effects are also mediated through changes to chromatin structure.
DNA is normally tightly associated with histone proteins, forming nucleosomes.
Acetlyation of the histone residues results in unwinding of the DNA, allowing
increased access of transcription factor to gene promoters, and thus increased
transcription. Ligand-activated GRs, via co-repressor proteins such as CREB binding
protein, cause deacetlyation of the histone residues and tighter coiling of DNA. This
limits the access of transcription factors, causing a general down-regulation in the
transcription of inflammatory genes (Kagoshima et al., 2001).
70
GC treatment of monocytes results in the production and secretion of an anti¬
inflammatory agent, thymosin-P 4 sulfoxide. In vitro this agent counters neutrophil
chemotaxis to FMLP, whilst in vivo administration is associated with decreased
swelling in a mouse model of inflammation. Together, this data presents a novel
anti-inflammatory GC-mechanism by preventing neutrophil recruitment to an
inflammatory site during chronic inflammation (Young et al., 1999).
The use of synthetic glucocorticoids in the treatment of inflammation
Synthetic GCs such as dexamethasone (Dex) and prednisolone are the most widely
used and effective clinical treatment for a wide range of acute and chronic
inflammatory diseases such as rheumatoid arthritis, asthma and multiple sclerosis.
Many of these inflammatory disorders are driven by the continued presence of
chemokines, pro-inflammatory cytokines and lipid mediators which propagate
inflammatory cell recruitment. The anti-inflammatory consequences of GC
administration interrupt this inflammatory cycle, abating the effects of the disease
(Pelaia et ah, 2003). However, their long term use is limited by both the development
of GC resistance and severe side effects. The side effects induced by GCs depend on
the length of and route of administration of therapy, with the most severe side effects
being associated with prolonged systemic treatment. Side effects include atrophy of
the skin muscle and adrenal gland, poor wound healing, osteoporosis, glaucoma and




Current consensus is that the severe systemic side effects of long term use of steroids
are mainly associated with GC transactivation whilst the beneficial anti¬
inflammatory and immunosuppressive effects largely associated with
transrepression. All currently used therapeutic GCs, including Dex are classed as
symmetrical, that is they display activity derived from both transactivation and
transrepression.
In order to further examine this theory, Vayssiere and colleagues screened steroids
for compounds which displayed reduced transactivation activity. They found three
compounds which maintained their transrepression activity but had reduced
transactivation activity when compared to Dex. These "dissociated' glucocorticoids
were shown two in vivo models to mediate immunosuppressive and anti¬
inflammatory effects (Vayssiere et al., 1997). A follow-up study demonstrated that
these compounds are capable of inhibiting TNF-a induced IL-6 secretion in human
Hela and mouse fibroblast cells by a direct interaction with NFkB gene activity,
without altering IkBcx levels (Vanden Berghe et ah, 1999). However, a recent study
using these dissociated GCs has shown that in in vivo models they elicit side effects
such as weight loss, thymus involution, and osteopenia of femur growth equally as
well as the symmetrical GC budesonide (Belvisi et ah, 2001). Another recently
identified dissociated GC, which demonstrated full anti-inflammatory properties, was
associated with a reduction but not total abolition of side-effects. For example, a
decrease in blood glucose levels, a risk factor for Diabetes mellitus, was reduced
(Schacke et ah, 2004). Seemingly some of the side effects previously coupled to GC
transactivation are in fact due to transrepression. Whilst the use of'dissociated' GCs
does not abolish all side effects, their ability to reduce many along with a reduction
in risk factors for associated diseases whilst maintaining anti-inflammatory
properties may provide additional therapeutic benefit.
In this chapter, data from experiments which examined the mechanism by which Dex
treatment of MDMO resulted in an augmentation in phagocytosis of apoptotic
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neutrophils will be presented. In addition, experiments investigating whether the
potential anti-inflammatory process of GC-augmented MDMO phagocytosis was a
consequence of transactivation or transrepression will also be shown.
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Results
Dex augments MDMO phagocytosis of apoptotic neutrophils
It has previously been demonstrated that the differentiation of human peripheral
blood monocytes in the presence of the synthetic steroid Dex, augments MDMO
phagocytosis of apoptotic neutrophils (Giles et ah, 2001; Liu et ah, 1999). To verily
this result, human peripheral blood monocytes were differentiated for 5-7 days in
Iscove's DMEM + 10% autologous serum (AS) ± 125nM or lpM Dex and incubated
with overnight 'aged' neutrophils as described in Chapter 2, prior to assessment of
phagocytic capacity by flow cytometry. Figure 3.1 A shows that the Dex-treated
MDMOs have a significant upregulation in the ability to phagocytose apoptotic
neutrophils, compared to the untreated, control MDMO.
In view of the paired nature of the data, i.e. one donor's monocytes were
differentiated in the presence or absence of Dex, the phagocytosis data is presented
as a correlation plot (Figure 3.IB). A best fit line through the data points was drawn
and the equation for the line is shown. The R2 value, however, demonstrates that the
data points fit poorly to the best fit line, indicating that the level of control MDMO
phagocytosis does not serve to predict the level of augmentation following Dex-
treatment. However, Dex always increased the phagocytic ability of the MDMOs
above that of the control MDMOs.
Interestingly, a correlation plot of control or Dex-treated MDMO phagocytosis
versus the percentage of apoptosis in the neutrophil population also yielded a poor
correlation - R2 values for both graphs are near zero (Figure 3.2). Thus, the
percentage of apoptotic cells in a population of overnight aged neutrophils does not


















y = 0.4013x +61.401
R2 = 0.2651
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Figure 3,1 Dcx augments human MDMO phagocytic ability
(A) 5 day control and Dex MDMO phagocytosis of overnight 'aged', fluorescently
labelled human neutrophils during a 1 hour assay. The phagocytic ability of the
MDMO was assessed by flow cytometry. Analysis of transformed data by a 2-tail
t-test demonstrated that the Dex treatment significantly augmented phagocytosis of
apoptotic neutrophils, *** p <0.0001, (n=45).
(B) A correlation plot for the percentage phagocytosis of control vs. Dex MDMO
was plotted. The R: value, which ranges from 0 tol, predicts how closely the best fit
line fits the data, with a value of 1 being the best predictor. For this data R" = 0.27,
suggesting that the extent of Dex-augmentation of phagocytosis is unrelated to the
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Figure 3.2 The level of apoptosis does not correlate with the level of phago¬
cytosis
The graphs show the correlation of the percentage of control and Dex
phagocytosis with the percentage of apoptosis in the neutrophil population,
as assessed by morphology. n=9 for % control phagpcytosis and n=10 for
% Dex phagocytosis vs % apoptosis .
The R2 (coefficient of determination) is a value between 0 and 1, which
shows how closely the trendline fits the data points. The trendline is most
reliable at or near an R2 value of 1. However the value for both graphs is
near to zero, revealing that the best fit line is a poor description of the data
points.The the percentage of apoptosis does not correlate with the percent¬
age phagocytosis and therefore percentage apoptosis does not appear to
limit the extent of phagocytosis.
Monocyte mRNA changes induced by 24 hour treatment with Dex
The phagocytic augmentation by Dex is appreciable following only 24hrs of
peripheral blood monocyte culture (Giles et al., 2001; Liu et ah, 1999). These data
suggest that early changes in gene expression occur that make the Dex-monocytes
competent phagocytes. Since GCs mediate anti-inflammatory effects through
changes in gene expression, mini cDNA arrays were chosen as a preliminary screen
for changes in mRNA following 24 hours culture in control conditions or in the
presence of 1 pM Dex. Appendix 1 shows an image of the scanned gene arrays,
whilst the genes on the cDNA array and the changes detected are listed in Appendix
2. Figure 3.3 compares the corrected spot intensity for all genes examined. Points
shown above the bisecting line indicate genes which were up-regulated by Dex
treatment, whilst those below the line show those down-regulated by Dex treatment.
Interestingly, the majority of genes on the array were found to be unaltered by Dex
treatment. However more genes showed up-regulated expression than down-
regulation following Dex treatment. Owing to the small number of genes
investigated, 2 fold changes were considered for further investigation and are
presented in a table in Table 3.1.
Verification of changes predicted by the cDNA array
A selection of the Dex-regulated genes (Table 3.1) were chosen for further
verification by PCR and either immunoblotting or flow cytometry.
Caveolin-1 and pl60ROCK (predicted to be up-regulated by Dex) and p21 activated
kinase (PAK-1) and ICAM-1 (predicted to be down-regulated by Dex) were chosen
because of their involvement in adhesion, migration and phagocytosis.
Caveolin-1 was detected by RT-PCR in monocytes and, although the PCR reaction
was optimised, the bands were at the limit of detection. Attempts to identify
Caveolin-1 by Western blotting repeatedly failed and thus no confirmation of the
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Figure 3.3 Genes up- and down-regulated following 24 hour treatment of peripheral
blood monocytes with Dex
Following 24 hours culture of monocytes in the presence or absence of Dex, mRNA
was extracted and used to make labelled cDNAs. These were bound to membrane
arrays and the relative amount of mRNA from the control or Dex monocytes com¬
pared.
The graph shows that more genes were up-regulated than down-regulated by Dex,
but that any changes were relatively subtle.










Metastasis associated protein 1 V
Matrix Metalloproteinase 18(19) V
CDC42 V
Protein expressed in nonmetastatic cells 4 V
Protein expressed in nonmetastatic cells 2 V
Focal adhesion kinase 1 V
Pyk2 V
Prostate specific membrane antigen V
RHOB V
Glycogen synthase kinase 3 alpha V
Cell surface glycoprotein MUC18 (CD 146) V
Zinc finger DNA binding protein Y
Corneodesmosin V
WNTlOb y
CDC42 GTPase activating protein s
Nucleoside diphosphate kinase A V
PI60 ROCK V
ELAV like neuronal protein 1 V
Matrix metalloproteinase 9 V
P21 activated kinase V(1.5 x)
ICAM-1 V
Table 3.1 Genes differentially transcribed following 24 hours Dex treatment
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Dex induced up-regulation of Caveolin-1 was possible. In contrast, the up-regulation
of pl60ROCK was verified at both mRNA and protein levels. cDNA from untreated
and Dex-treated monocytes from 4 further donors was used as template for
pl60ROCK PCR. Actin levels were used as a control for any changes in the
efficiency of extraction of mRNA, and in 3 of the 4 donors, an increase in
pl60ROCK was detected. When control levels were corrected to 100%, those in the
four Dex-treated monocytes populations were: 180%, 130%, 80% and 170%.
Examination of pl60ROCK protein following 24 hours or 5 days culture under either
control conditions or Dex-treatment demonstrated that the increased transcription of
pl60ROCK was translated into protein (Figure 3.4).
PAK-1 was also examined. Whilst the down-regulation in transcription levels
following Dex treatment was predicted to be smaller than ICAM-1, PAK-1
expression was of interest because of its role in cellular migration (see chapter 5).
Western blotting of 24 hour and 5 day lysates revealed little difference between
control and Dex at 24 hours, but an increase in expression following Dex treatment
was seen by 5 days, contrary to the effect predicted by examination of the gene array
data.
ICAM-1 is known to be regulated by GCs, and surface expression was found to be
down-regulated on 5 day Dex-treated MDMO (K. Giles, personal communication).
Surface expression profding of 24 hour and 5 day control and Dex-treated MDMO
showed that the small down-regulation observed at 24 hours, was more exaggerated
by 5 days.
In vivo mouse macrophage phagocytosis is not augmented by Dex
Given the in vivo use of therapeutic steroids, it was of interest to determine whether
the phagocytic augmentation found for Dex-treated MDMOs in vitro was apparent in
an in vivo environment. Mice from different strains have inflammatory responses
with different predominating cytokine profdes (Mills et al., 2000), so to ensure that
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Control 24hrs Dex 24 hrs Control 5-7 days Dex 5-7 days
Figure 3.4 Protein expression of molecules predicted by gene array
(A) PAK-1 showed little change at 24 hrs but was upregulated by Dex following 5
days differentiation, pi 60 ROCK was upregulated in MDMO following both 24
hour and 5 day incubation with Dex. A representative blot from 2 experiments for
PAK 24 hours, 4 experiments for PAK 5 days and 2 donors for both ROCK experi¬
ments is shown.
(B) ICAM-l expression was profiled at 24hrs and 5 days by flow cytometry. Dex
induced a small down-regulation at 24hrs but by 5 days a significant down-
regulation was observed. n=4 separate donors. Data analysed by 2-tail t-test,
**, p < 0.001 vs. control
two different strains; C57B1/6 and Balb/c which predominantly have either a Thl and
Th2 cytokine profile respectively. A model of interperitoneal (IP) inflammation was
induced by IP injection of thioglycol late into 6-8 week old mice. 24 hours later, at
the peak of neutrophilic inflammation (Bellingan et al., 1996), mice were injected
interperitoneally with either sterile PBS or lpM Dex. 4 days later the mice were
sacrificed and peritoneal cells retrieved by lavage. Interestingly, no significant
difference was observed between the number of macrophages/ml lavaged from
control and Dex-treated mice from each strain (control BALB/C 1.4x106
macrophages/ml ± 0.3 SEM; Dex BALB/C 2.4xl06 macrophages/ml ± 0.4; control
C57bl/6 2.5xl06 macrophages/ml ±0.1; Dex C57bl/6 2.3xl06 macrophages/ml ±
0.4). The macrophages were plated into tissue culture plates overnight, prior to
assessment of phagocytosis of fluorescently labelled human apoptotic neutrophils.
Examination of the Fl-1 staining of the F4/80 labelled macrophages enabled
phagocytosis to be assessed. Regardless of the strain, the macrophages obtained by
peritoneal lavage from mice injected with Dex did not have an augmented
phagocytic ability when compared to the mice injected with PBS (Figure 3.5), and
thus an ex vivo model for macrophage phagocytosis was not generated.
Transrepressor-steroids augment MDMO phagocytosis of apoptotic
neutrophils
As discussed earlier, GC actions occur through transactivation and transrepression
mechanisms. There is evidence supporting the hypothesis that transactivation
mediates many of the metabolic side-effects associated with GCs whilst
transrepression responses mediate the beneficial anti-inflammatory effects (Barnes,
1998). Whilst Dex-augmented phagocytosis of apoptotic cells is a potentially
beneficial and anti-inflammatory mechanism in the resolution of inflammation, it
remains unclear how Dex treatment of MDMO results in this augmented
phagocytosis. It was therefore of interest to determine whether Dex-augmented
MDMO phagocytosis occurred through a transrepression or transactivation

























Figure 3.5 Mouse peritoneal macrophage phagocytosis is not affected by Dex-
treatment in vivo
6-8 week old Balb/c and C57B1/6 mice were injected interperitoneally (IP) with thio-
glycolate. 24 hours later the mice were injected with either PBS or lpM Dex IP.
4 days later the peritoneal was lavaged and the macrophaes plated down in tissue
culture plates overnight. Following this, the macrophages were labelled with F4/80
antibody and then used in a 1 hour phagocytosis experiment with Fl-l labelled human
neutrophils. The levels of phagocytosis were detected by analysing the FL-1 +ve F480
+ve cells by flow cytometry.
Data shown are mean ± standard error of the mean (SEM) for 4 separate experiments.
specific GSK transrepressor CC12382 compound. This compound is a specific
transrepressor, demonstrated to have much reduced transactivation effects in reporter
assays with comparison to symmetrical steroids of similar IC50 such as Dex (S.
Farrow, GlaxoSmithKline, personal communication). We therefore used rat bone
marrow-derived macrophages (BMDMO) cultured in control conditions or either
Dex or GSK CC 12382 for 7 days. Following differentiation of the BMDM®,
phagocytic ability was assessed using overnight aged human neutrophils as apoptotic
targets. Interestingly, the control BMDM® were much more capable phagocytes than
either the human MDM® or mouse peritoneal MDM®s (Figure 3.6). A significant
augmentation in phagocytosis was observed following treatment of the BMDM®
with either Dex or the GSK-transrepressor steroid. This data suggests that GC
transrepressor activity alone is sufficient to induce the augmentation in phagocytic
ability.
IxB-a protein levels and phosphorylation of c-Jun are associated with
Dex treatment of human peripheral blood monocytes
As discussed in the introduction to this chapter, one of the main ways in which
steroid transrepressor action is achieved is by interference with the pro-inflammatory
transcription factors, NFkB and AP-1. In order to examine whether either of these
transcription factor pathways was associated with the augmentation of MDM®
phagocytosis, the levels of IkB-o, an inhibitor of NFkB translocation to the nucleus,
and the phosphorylation of c-Jun, a component of AP-1, were examined. Lysates of
peripheral blood monocytes cultured for 30, 60, 90 minutes or 24 hours either in
control conditions or 125nM Dex were prepared and tested for the levels of proteins























Figure 3.6 Dex- augmented phagocytosis is a result of
transrepressor activity
7 day rat BMDMO were differentiated in vitro in control condi¬
tions or !25nM Dex or GSK CC12382 transrepressor steroid. The
phagocytic ability of apoptotic neutrophils was assessed in a plate
assay. A minimum of 300 cells were counted per well, and each
condition was performed in duplicate and the mean value used.
Transformed data were analysed by Tukey repeated ANOVA. ** p
<0.01 vs. control. Both Dex and the transrepressor significantly
increased phagocytosis levels above that of the control macro¬
phages, demonstrating that the transrepressor element of steroid
action is sufficient for the augmentation of phagocytosis. Data
shown are mean phagocytosis ± SEM for 3 bone marrow prepara¬
tions from separate rats.
than time-matched control lysates, although no differences were detected between
control and Dex-treated MDMO samples at subsequent time points (Figure 3.7). This
suggests that a relatively rapid effect of Dex is either induction of transcription of, or
protection against the degradation of IkB-cx protein. This may provide a mechanism
for the inhibition of the transcription of pro-inflammatory genes. Phosphorylated c-
Jun was only detected once in three experiments although the bands were very faint.
The blot where phosphorylated c-Jun was detected showed an up-regulation
following 24 hour Dex treatment, but the control and Dex-treated MDMO lysates
showed identical levels at time points prior to this. This data suggests that total IicB-a
protein levels are controlled by Dex at early stages of monocyte-MDMO
differentiation, where NFkB would be predicted to alter early gene expression.
MDMO differentiated in the absence of serum have a reduced
phagocytic ability
There is increasing evidence that serum components are involved in the phagocytosis
of apoptotic cells (Hart et al., 2004). It was therefore of interest to establish whether
serum components affected MDMO phagocytosis. To this end, peripheral blood
monocytes were differentiated in the presence of 10% autologous serum ± 125nM
Dex or in serum-free media + 250U GMCSF ± 125nM Dex. The differentiation
under serum-free conditions or serum-plus conditions did not induce apoptosis in the
MDMO populations as assessed by morphology (data not shown). The phagocytosis
of overnight 'aged', apoptotic neutrophils by the resultant MDMO populations was
then examined by flow cytometry. Serum-free differentiated MDMO exhibited low
levels of phagocytic ability either with or without Dex treatment. However,
phagocytic capacity was restored by the re-addition of serum on day 0 to the serum-
free conditions (Figure 3.8). This data suggests that serum components play an
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Figure 3.7 Monocyte IkB-(x protein levels increase following Dex treatment
Lysates were prepared from peripheral blood monocytes cultured in Iscove's
DMEM + 10% AS ± 125nM Dex for 30, 60, 90 minutes or 24 hours. Following
30 minutes culture, IkB-cx protein levels were increased in Dex macrophages
compared to control macrophages, although levels were equal by 24 hours.
Representative gel from 1 experiment of 3 that were performed is shown.
Low level detection of phosphorylated c-Jun was detected in both control and
Dex-treated monocytes at 30, 60 and 90 minutes. At 24 hours Dex but not
control lysates showed an up-regulation in phosphorylation of c-Jun. Blot is
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Activation of PKC increases MDMO phagocytosis
The PKC signalling pathway has been shown to be required for engulfment
following receptor-ligand binding of the apoptotic cell to the MDMO (May and
Machesky, 2001) and it was therefore of interest to examine the role of PKC during
Dex-augmented phagocytosis. Human MDMO were differentiated in Iscove's
DMEM + 10% autologous serum ± 125nM Dex for 5 days and then incubated with
30nM PMA (specific PKC activator) for 1 hour prior to phagocytosis of apoptotic
neutrophils. Control MDMO showed an augmentation in phagocytic ability
following treatment with PMA greater than that observed with the inert 4-a PMA,
raising the possibility of a role for PKC in the regulation of phagocytosis. However,
phagocytosis by Dex MDMO was unaffected by PMA treatment, suggesting that
Dex-treated MDMO either exhibited maximal activation of PKC or that PKC activity
was not important in Dex-treated MDMO (Figure 3.9A).
To further investigate the role of PKC in MDMO phagocytosis, 5 day control and
Dex-treated MDMO were incubated with the PKC inhibitor, RO 31-8220 compound
(Figure 3.9B). Interestingly, inhibition of PKC was also found to augment
phagocytosis by control MDMO, suggesting that a critical balance of PKC activation
may be required. However, the Dex-augmented phagocytosis was unaffected by
inhibition of PKC, further suggesting that this pathway is not involved in Dex-
augmented phagocytosis.
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Figure 3.9 PKC activation augments untreated but not Dex-treated MDM(|)
phagocytosis of apoptotic neutrophils
(A) Untreated and Dex-treated 5 day MDM(j) were treated with 30nM PMA (PKC
activator) or (B) 1 pM RO 31 -8220 (PKC inhibitor) or 80nM 4-a PMA (inert
compound) for I hour. The ability of the MDM(j) to phagocytose apoptotic
neutrophils was then assessed by flow cytometry. Data shown are mean %
phagocytosis for 3 experiments (A) and 2 experiments for RO (B) ± SEM and 1










































Dex-augmented phagocytosis of apoptotic cells
My results confirm that there was a large inter-donor variability in the phagocytic
ability of the untreated macrophage population (2.7% - 52.6%) and that Dex-
treatment consistently up-regulated phagocytic ability, whilst reducing variability in
phagocytic ability within the population (53.5 % - 87%). However, this decrease in
phagocytic 'range' following Dex-treatment may also be explained by the presence
of a 'ceiling' in phagocytic ability. Dex-treatment may cause this 'ceiling' in
phagocytic ability to be reached for each of the MDMO populations and therefore
Dex-treatment can only induce a small augmentation in phagocytosis in control
MDMO with a high baseline phagocytic ability. It might be expected that the
baseline phagocytosis in control MDMO would dictate the extent of Dex-
augmentation if the processes used for control and Dex-treated phagocytosis were the
same. Somewhat surprisingly, examination of the phagocytic abilities of untreated
and Dex-treated MDMO from the same donor revealed that the percentage of
apoptotic cells phagocytosed by the untreated macrophages did not predict the extent
to which Dex was able to augment phagocytic ability. Furthermore, it was also
demonstrated that the percentage of apoptosis in the overnight 'aged' neutrophil
populations did not correlate with either control or Dex-treated MDMO
phagocytosis. Experiments investigating the effect of the concentration of apoptotic
neutrophils (8, 4, 2, and lxl06 cells per ml) on phagocytosis demonstrated that a
reduction in the concentration correlated with a step-wise decrease in both control
and Dex-treated MDMO phagocytosis for concentrations below 4 xl06/ml (data not
shown). This raises the possibility that the lack of correlation between
(morphologically defined) percentage apoptosis and phagocytosis was due to an
excess of target cells. A second explanation is that the control and Dex-treated
MDMO phagocytose a range of apoptotic and necrotic cells and that levels of
necrosis need to be taken into account too. This suggestion is in accordance with data
92
from Devitt and colleagues. They demonstrated that maximal human MDMO
phagocytosis of apoptotic Mutu I Burkitf s lymphoma cells correlated with later time
points in apoptotic cell culture, where the majority of target cells had become
necrotic (Devitt et al., 2003). The idea that control and Dex-treated MDMO
phagocytose both apoptotic and necrotic targets could be investigated by carrying out
similar studies to those of Devitt and colleagues, where levels of phagocytosis could
be correlated with both the number of apoptotic nuclei and PI uptake at different time
points during 20 hour culture of the neutrophils.
Glucocorticoid Modulation of Gene and Protein Expression
I used an 'interaction' array which included cytoskeletal signalling proteins such as
Rho GTPases and their effector molecules, extracellular matrix proteins,
metalloproteinases, cell-cell adhesion proteins and cell surface antigens to screen for
gene changes that might be important for adhesion, migration and phagocytosis.
Only a small proportion of the genes included on the array showed a two fold change
following Dex-treatment (9% of the genes analysed when compared with untreated
monocytes), with the majority of these genes being up-regulated. One of the
mechanisms by which steroids mediate anti-inflammatory actions is by deacetylation
of histones, reducing transcription factor access to promoter regions of pro¬
inflammatory genes and thus reducing the transcription of pro-inflammatory genes
(Wolffe, 1997a; Wolffe, 1997b). The very small overall up-regulation of genes seen
in Figure 3.1, suggests that many of the genes included on the array are not regulated
by this mechanism.
The gene array data was verified for a selection of molecules, at the gene or protein
level. Interestingly, the changes observed at 24 hours were not always maintained by
5 days. Indeed, ICAM-1, shown to be down-regulated on the gene array following
Dex-treatment was detected at reduced levels on the Dex-treated monocyte cell
surface at 24 hours compared to control expression. However, the extent of the Dex-
mediated inhibition in ICAM-1 expression was increased by 5 days. The gene array
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data predicted a down-regulation in PAK-1, but protein studies showed a small up-
regulation in expression at 24 hours and a further increase by 5 days following Dex-
treatment. The gene array was chosen as a tool to search for changes to gene
expression induced by Dex-treatment and whilst mRNA levels matched protein
expression for some genes such as pl60ROCK, it does not for others such as PAK-1.
The use of an antibody-protein array may solve some of these problems but would
not account for protein synthesis, turnover, localisation or post-transcriptional
modifications such as phosphorylation, all of which affect the function of a particular
protein. However, the use of a large scale antibody-protein array would enable a
large number of proteins to be screened for differential regulation by Dex, and may
therefore prove useful in highlighting changes to key molecules of signalling
pathways or structures.
The data showed a two fold or greater change in a range of genes following 24 hours
Dex-treatment (Figure 3.4). They included known regulators of migration and actin
polymerisation, such as pl60ROCK, Pyk2, Cdc42 GTPase activating protein and
Cdc42, a Rho GTPase family member which regulates actin polymerisation during
migration, adhesion formation and phagocytosis. Cdc42 is necessary for
phagocytosis of apoptotic cells (Leverrier and Ridley, 2001) and, during Fc-mediated
phagocytosis, Cdc42 appears to be required for pseudopodia extension around the
ligand bound cell (Hoppe and Swanson, 2004). Extension of these studies would
allow for examination of Cdc42 protein levels and activation. Experiments using
agarose-beads coupled to the Cdc42-binding domain of PAK-1 could be used to
examine the percentage of active Cdc42 following Dex treatment. Furthermore,
immunofluorescence studies may determine if there is increased presence of Cdc42
at the phagocytic cup in Dex-treated MDMO.
A recently published gene array experiment, investigating changes in human
peripheral blood monocytes following 18 hours Dex treatment confirmed my
observed down-regulation in MMP9, and also showed that Dex did not alter
transcription of CD36, CD44, MMP 7, 10 and 16 (Galon et al., 2002). My gene
array results showed differential regulation of two matrix metalloproteinases (MMP);
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MMP18 was up-regulated whilst MMP9 was down-regulated. MMP9 is a terminal
member of the protease cascade which degrades extracellular matrix during
processes such as wound healing (Opdenakker et al., 2001) and interestingly it is also
known to be down-regulated by GCs in rat mesangial cells (Eberhardt et ah, 2002)
and by anti-inflammatory cytokines such as IL-4 and IL-10 (Lacraz et ah, 1994). A
down-regulation in MMP9 following Dex-treatment is therefore in agreement with
the anti-inflammatory effects of steroids, and with studies demonstrating steroid
inhibition of wound healing. Interestingly, both caveolin-1 and -2 were also predicted
by the array to be up-regulated by Dex. They are proteins which form a scaffold at
the plasma membrane at which signalling molecules assemble. Caveolin proteins
therefore concentrate signalling molecules and can also govern the activation of
some of the signalling molecules (Harris et ah, 2002). One speculation would be that
augmentation of phagocytosis by Dex increases the efficiency of assembly of
scaffolds containing receptors required for the phagocytosis of apoptotic cells.
The augmentation in MDMO phagocytosis of apoptotic neutrophils was observed
early during the differentiation process, following only 24 hours of Dex treatment,
suggesting that this period was critical for augmenting phagocytosis. The gene array
was therefore used to search for early changes to mRNA levels following Dex
treatment. However, following the results demonstrating that protein expression can
alter later during the differentiation process, it may be interesting to examine changes
present in the MDMO following 5 day's culture. Adherence purified peripheral
blood monocytes were used for the array as they provide a high purity of monocytes
with typically only 3-5% of the adherent cells being contaminating lymphocytes.
Despite the fact that Dex treatment can selectively induce apoptosis in certain cells
such as T cells and eosinophils (Amsterdam et al., 2002), no difference in the number
of contaminating lymphocytes was found between the untreated and Dex-treated
MDMO following 24 hours of culture. The detection of CD4 and FAK on the cDNA
array but failure to detect FAK by Western blotting from cells purified by the same
technique, suggests that the array is very sensitive to low level contamination. This
presents some problems with the interpretation of results obtained from the array and
it may therefore be prudent to verify future array results by analysis of protein.
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Methods for the removal of lymphocytes from mononuclear cell preparations, such
as MACS purification (Miltenyi Biotech), result in 85-90 % monocyte purity (results
not shown) and the removal of further contaminating lymphocytes by adhesion
purification may help to reduce the total number of contaminating cells. However,
based upon my experimental data using purified cells, even if the gene array
experiment was to be carried out using 5 day MDMO, a significant lymphocyte
contamination would be expected, possibly as a result of proliferation.
Transrepression activity in augmentation of phagocytosis of apoptotic
cells
Dex-induced gene changes investigated include a down-regulation in the NFkB-
dependent genes ICAM-1 and MMP9 (Eberhardt et al., 2002), suggesting that
alterations to the NFkB transcription factor signalling pathway are induced in
monocytes following 24 hours of Dex treatment. Using a rat-specific dissociated
glucocorticoid (transrepression activity only), the augmentation of phagocytosis of
apoptotic cells was demonstrated to be exclusively a result of transrepression. As
discussed in the Introduction, transrepression processes occur via the inhibition of
pro-inflammatory transcription factors, NFkB and AP-1. Further studies investigated
changes in these transcription factor signalling pathways, demonstrating a clear up-
regulation in protein expression of the NFkB inhibitory protein, IxB-a. IxB-a binds
and retains NFkB in the cytoplasm, preventing NFKB-promoted gene transcription. It
would seem that a down-regulation in the expression of pro-inflammatory genes,
ultimately results in changes to the Dex-treated MDMO whereby they up-regulate
signalling pathways and/or receptor expression necessary for phagocytosis of
apoptotic cells. Whilst Dex treatment of MDMO has been associated with alterations
in Rho GTPase family members, the mechanism by which this is achieved is
unknown. Changes to the cytoskeleton and in actin polymerisation are clearly
important to phagocytosis, and I have demonstrated that the up-regulation in
phagocytosis is a result of transrepression. Therefore, whether directly or indirectly,
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changes to the levels and activation status of Rac, Cdc42 and Rho must be a result of
this. It would be very interesting to investigate changes in these Rho GTPases after
inhibition of either the NFkB or AP-1 transcription pathways by specific inhibitors.
GCs can inhibit NFkB activity by induced transcription of iKB-a (Barnes and Karin,
1997) (Scheinman et al., 1995) and by direct protein-protein interaction between the
GR and NFkB (Marx, 1995). IkB-cx has been shown to bind to NFkB and prevent its
translocation to the nucleus in HeLa cells, lymphocytes and vascular smooth muscle
cells (Scheinman et ah, 1995) but not in rat mesangial cells or brain cells (Bourke
and Moynagh, 1999), suggesting this is a cell-specific mechanism. My data
demonstrate very early increases in IkB-cx levels following Dex treatment that were
not maintained later during differentiation (24hours or 5 days). This may suggest that
the process of GC transrepression, acting through blockade of NFkB activity, sets in
action an altered monocyte to macrophage differentiation pathway, leading to
augmented 5 day MDMd> phagocytosis of apoptotic cells. Flowever, the transient
nature of hcB-a up-regulation seems unlikely to fully account for all Dex-mediated
changes. Further insight into the role of IkB-oi inhibition of NFKB-promoted gene
transcription could be gained. Blocking NFkB by using specific inhibitors or by
over-expressing IkB-ch in control MDMO, perhaps by using a TAT- IkB-cx fusion
protein, may allow examination of the changes induced by this signalling pathway in
MDMO. Follow-up studies could also include electrophoretic mobility shift assays
(EMSA) to confirm whether the increased protein levels of IkB-cx do in fact inhibit
NFkB binding to DNA in the Dex-treated MDMO.
Dex represses AP-1 activity by inhibition of c-Jun phosphorylation (Gonzalez et al.,
2000), by the GC-inducible leucine zipper (Mittelstadt and Ashwell, 2001) or by
direct protein-protein binding of the GR to AP-1 (Jonat et al., 1990). The result
demonstrating an up-regulation in c-Jun phosphorylation following 24 hours Dex
treatment, but identical low levels in control and Dex lysates at time points prior to
this clearly warrants more detailed examination, but suggests that GC transrepression
is not acting via inhibition of c-Jun phosphorylation. Again, EMSA could also be
employed to detect if AP-1 binding of DNA is down-regulated. Finally,
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immunofluorescence studies or co-immunoprecipitations would allow examination
of the interaction between the GR and NFkB or AP-1 to be investigated.
Mediators of GC phagocytosis
Serum components are implicated in the phagocytosis of apoptotic cells, both as
bridging molecules such as thrombospondin and MFG-E8 and in opsonisation of the
apoptotic cell (Hart et al., 2004). The experiments presented here demonstrate that
lack of serum during the differentiation of both control and Dex- treated MDMO
strongly inhibits phagocytic ability without inducing apoptosis in the MDMO. In
these experiments the neutrophils were cultured overnight to induce apoptosis in the
presence of serum, which should allow time for them to become opsonised. This may
also mean that there are enough serum components during the phagocyte-apoptotic
cell interaction to provide bridging components. This could be addressed by carrying
out experiments to add serum back during the phagocytosis assay, with a failure to
restore phagocytic ability confirming this idea. Instead, my data suggests that serum
components are required during the differentiation process for a phagocytic MDMO
since phagocytic ability was rescued by addition of serum to the cultures. Further
identification of the component(s) in the serum responsible for the phagocytic
phenotype could be achieved by biochemical fractionation of serum.
Roles for protein kinase C (PKC) during phagocytosis of apoptotic cells as well as
Fc-mediated phagocytosis have been described (Hu et al., 2002; May and Machesky,
2001). The results presented in this chapter show that activation of PKC by PMA
increases the phagocytic ability of control MDMO above that of the inert 4-aPMA.
A small increase in phagocytic ability (lower than that induced by PKC activation)
was also observed following treatment of the control MDMO with the PKC inhibitor,
RO 31-8220, which suggests that PKC activation is a determinant of phagocytic
ability in these cells. However, inhibition by RO 31-8220 failed to inhibit
internalisation of apoptotic neutrophils. My results contradict studies such as those
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by Hu et al., which demonstrated an inhibition in internalisation but not binding of
apoptotic thymocytes by murine tissue macrophages (Hu et al., 2002). However,
contradictory results have been found for the involvement of PKC in Fc-mediated
phagocytosis (Allen and Aderem, 1996; May and Machesky, 2001). Inhibition of
PKC can prevent focal adhesion formation in fibroblasts in association with a
dispersal in adhesion components such as talin and actin (Woods and Couchman,
1992). PMA activation of PKC may regulate adhesion formation (Woods and
Couchman, 1992) and studies also suggest that PKC activation may increase
integrin-mediated adhesion (Gladwin et al., 1990). In my studies, control MDM<D,
activated by PMA, became more spread and adherent (data not shown) suggestive of
altered adhesion regulation.
Dex-treated MDMO lack podosome adhesions concomitant with a loss in
phosphorylation and recruitment of key adhesion components (Giles et al., 2001) and
coupled with the PKC data presented here may suggest that Dex causes a block on
the PKC pathway. Dex-treated MDMO phagocytosis was unaffected by the
activation or the inhibition of PKC, and it is therefore likely that Dex augments
phagocytosis via a PKC-independent mechanism. In light of this interesting result I
would investigate the roles of other signalling pathways implicated in internalisation
of apoptotic cells such as PBkinases and tyrosine phosphorylation (Leverrier and
Ridley, 2001; May and Machesky, 2001; Stephens et al., 2002; Todt et al., 2004).
One method employed by Greenburg and colleagues, investigating tyrosine
phosphorylation events during Fc-mediated phagocytosis, was to examine tyrosine
phosphorylation by immunoblotting and immunoprecipitation lysates from Fc-
receptor stimulated macrophages (Greenberg et al., 1994).
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CHAPTER 4: MDM4> BINDING AND INTERNALISATION OF
APOPTOTIC NEUTROPHILS
Introduction
The process of apoptotic cell phagocytosis begins with the recognition of the
apoptotic cell by the macrophage, most probably by receptors directed against 'eat
me' signals, such as PS, or carbohydrate modifications on the surface of the
apoptotic cell. A selection of the described receptors (see chapter 1) have been
implicated in human MDMO recognition of apoptotic cells. Recognition of apoptotic
B cells (Flora and Gregory, 1994) requires CD 14 (Devitt et al., 1998) whilst the
vitronectin receptor/CD36/thrombospondin complex (Savill et al., 1990) is thought to
be the major receptor for apoptotic neutrophils, with minor roles for scavenger and
lectin receptors (Fadok et al., 1998b).
The identification of multiple, apparently redundant receptors can perhaps be
explained by specific roles for the different receptors. Some receptor recognition
mechanisms may be specific to particular tissues, for example the phenotype of SRA
deficiency is particularly evident during peritoneal inflammation but not in the
thymus (Piatt et al., 1996). Secondly, receptors may be species-specific or recognise
changes to specific apoptotic cell types (Savill and Fadok, 2000). CD 14, for
example, is chiefly implicated in recognition of lymphocytes (Devitt et al., 1998) and
lectin-like receptors in mouse macrophage recognition of thymocytes (Duvall et al.,
1985). The 'tether and tickle' hypothesis put forward by Henson and colleagues
(Flenson et al., 2001) suggested that redundancy can be explained by a two-step
recognition mechanism. They proposed that apoptotic cell removal required 5
separate events (see Figure 4.1): cell surface changes and ligand expression on the
apoptotic cell; macrophage receptor recognition of these ligands; instigation of
macrophage signalling events, triggered by the 'tethering' receptor or by a separate
'uptake' receptor; engulfment and finally digestion of the apoptotic cell within the
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Figure4.1Propos dmechanismfap ptoticcellrecognitionnngulfme t AdaptedfromtextfHenson,P.Ml2001
phagosome. The initial tethering of the apoptotic cell may therefore be independent
from the initiation of signalling events required for engulfment, which potentially
utilises a second set of receptors, engaged after the apoptotic cell is bound (Henson et
al., 2001). This two-step recognition model could explain the large number of
potential phagocytic receptors, with some functioning as 'tethering' receptors and
others as 'uptake' receptors.
Erythrocytes modified to express defined ligands or antibodies against known
phagocytic receptors on MDMO were used to examine individual receptors roles in
binding and uptake (Hoffmann et ah, 2001). They demonstrated a 'tethering' role for
many of the previously described phagocytic receptors, including CD36, avp3, CD 14
and CD68. SRA induced low but equal levels of engulfment and tethering. However,
PS did not mediate tethering, although PS-PSR interaction was required for uptake of
the erythrocytes, suggesting that it provided the 'tickle' or signalling required for
actin polymerisation and engulfment. However, this data appears at odds with
previous demonstrations that PS was not involved in the phagocytic cell uptake by
unstimulated MDMO (Fadok et ah, 1992b; Savill et ah, 1990), raising the possibility
that PS expression on the surface of erythrocytes is recognised differently to PS on
the surface of an apoptotic cell. Nevertheless, the proposed model is attractive
because it makes signalling via low avidity PS-binding feasible and confers
specificity on the process of recognition by having multiple binding receptors
followed by a separate signalling receptor. Furthermore, the 'tether and tickle' model
negates the potential problem causing by recognition and signalling following
binding to transiently expressed PS on non-apoptotic cell surfaces (Somersan and
Bhardwaj, 2001).
However, the idea of a two-step recognition process poses many questions. PS is
potentially recognised by multiple receptors which include CD36, the OxLDL and
the PS-receptor (for which the data is equivocal), and many molecules have been
proposed to bind PS, including annexins and MFG-E8. Since PS can potentially be
recognised by both the proposed 'binding' and 'signalling' receptors, the model
requires that the receptor determines whether signalling is induced. The current
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suggestion that multiple ligand-receptor interactions serve to bind the apoptotic cell
to the surface of the macrophage, whilst only one receptor is capable of triggering
signalling seems lacking, particularly since many of the putative 'binding' receptors
have been shown to initiate signal transduction within the cells, for example,
integrins (Akakura et al., 2004; Albert et al., 2000), CD36 (Trezzini et al., 1990) and
the receptor tyrosine kinase MerTK (Todt et al., 2004). For the proposed model to
hold true, it seems likely that further signalling receptors remain to be defined.
Firstly, PS recognition is not involved in human MDMO engulfment of apoptotic
cells (Fadok et al., 1992b), and secondly, as both necrotic and apoptotic cells express
PS on their surfaces, it is unclear how can signalling via the same PS interaction can
mediate both pro and anti-inflammatory cytokine responses from the phagocyte?
In conclusion, verification of the two-step recognition model is required together
with clearer definition of the roles of phagocytic receptors. Experiments examining
the roles of putative phagocytic receptors have used apoptotic cell binding or
phagocytosis, or both as read out, and examination of the literature allows some
refinement as to whether receptors are 'binding/tethering' receptors or
'signalling/tickling' receptors. CD 14 lacks intracellular signalling domains, thus it is
reasonable to suggest that the role for this receptor would be involved in tethering of
cells whilst SHPS-1 has been recently proposed as tethering receptor for the ligand
CD47 on apoptotic thymocytes (Tada et al., 2003). Studies by Duvall and colleagues
which suggested the presence of a lectin-like receptor on the surface of the
macrophage, which recognised carbohydrate molecules on the apoptotic cell,
examined binding not internalisation (Duvall et al., 1985). Whilst this does not
exclude a dual role for a lectin-like receptor it certainly implicates it as a binding
receptor.
In this chapter I will present data investigating the stages and receptors involved in
MDMO receptor-mediated internalisation of apoptotic neutrophils. Furthermore,
experiments will be shown which examined the effect of Dex-treatment on MDMO
binding and internalisation of apoptotic neutrophils.
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Results
Neuraminidase treatment augments MDMO phagocytosis of apoptotic
neutrophils
In order to investigate the nature of changes to the MDMO surface induced by Dex-
treatment which would be conducive to phagocytosis of apoptotic cells, 5 day
MDMO were incubated with the sialidase enzyme neuraminidase prior to a
phagocytosis assay. Neuraminidase cleaves sialic acid from glycoproteins exposed
on the surface of MDMO. The proportion of control MDMO (differentiated in the
presence of 10% autologous serum) capable of phagocytosis of apoptotic neutrophils
was increased to levels similar to that of Dex-treated MDMO following incubation
with neuraminidase (Figure 4.2). However, neuraminidase treatment of Dex-treated
MDMO had no effect on phagocytic ability. These results demonstrate that cleavage
of sialic acid from the surface of the control MDMO increases the percentage of
control MDMO that phagocytose, converting non-phagocytic cells into phagocytic
cells, whereas neuraminidase treatment has no effect on Dex-treated MDMO
phagocytosis.
Dex treatment of MDMO augments the binding step of phagocytosis
Neuraminidase augmention of control MDMO phagocytic capacity for apoptotic
neutrophils, led me to test the hypothesis that Dex induces changes to the surface of
the macrophage, making it a more capable phagocyte. Phagocytosis is a multi-step
process requiring initial binding of the apoptotic cell to the surface of the
macrophage, followed by intemalisation. I then investigated whether surface changes
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Figure 4,2 Neuraminidase augments Control MDMO phagocytosis of apoptotic
cells
5 day MDMO were pre-treated with O.lU/ml of neuraminidase (diluted in PBS)
for 20 minutes at 37°C. The media was removed and fluorescent labelled "aged'
apoptotic neutrophils added. To control for any effect of changing the media,
other MDMO had the media replaced with PBS . Following l hours incubation,
the phagocytic ability of the different macrophage populations was assessed by
flow cytometry.
Transformed data were analysed by Tukey-Kramer repeated ANOVA. * p <0.05
vs. Control Isc and Control Isc/PBS (n=3).
* * *
By overlaying apoptotic neutrophils onto adherent monolayers of MDMO at 4° C,
apoptotic neutrophils bound to MDMO but were not internalised. Low level binding
of'fresh' neutrophils (typically comprising less than 1% apoptotic cells) by both
untreated and Dex-treated 5 day MDMO was observed (Figure 4.3). TNF/gliotoxin-
treated neutrophils, which typically comprised 85-100% apoptotic cells, bound to
untreated 5 day MDMO poorly. However Dex-treated MDMO showed an
augmentation both in the percentage of the MDMO binding neutrophils (Figure 4.3)
and in the number of apoptotic cells bound to each MDMO (Binding Index ± SEM:
control 5.9 ± 2.6; Dex 80.7 ± 22.2; n=8). These initial experiments show low
percentage binding, but subsequent optimisation of the binding conditions
demonstrated higher percentage binding for both control and Dex-treated MDMO,
with the significant up-regulation in apoptotic neutrophil binding being maintained
following Dex-treatment (see Figures 4.6 and 4.7).
Figure 4.4 shows scanning electron micrographs (SEM) of untreated and Dex-treated
5 day MDMO bound to apoptotic neutrophils. (A) and (B) show untreated MDMO
binding one or two apoptotic cells, whereas the Dex-treated MDMO were observed
to bind numerous apoptotic cells (C and D). Interestingly, apoptotic cells could be
seen binding to both the cell body and the membrane extensions from the Dex-
treated MDMO.
Binding and internalisation are two separate events distinguishable by
requirement for cations
Many receptors have been implicated in the phagocytosis of apoptotic neutrophils by
human macrophages and previous studies have failed to identify a receptor or
receptors which were responsible for the augmentation of phagocytosis induced by
Dex treatment (Giles et al., 2001). A selection of the cell surface molecules
implicated in phagocytosis have been described as cation-dependent or -
independent, and by examining phagocytosis in the presence or absence of





























Figure 4.3 Dex augments MDMO binding of apoptotic neutrophils
5 day MDMO were overlayed with 'fresh' or TNF/glio-treated apoptotic
neutrophils and incubated at 4°C for 1 hour. 'Fresh' neutrophils typically
comprised < 1% apoptotic cells, TNG/glio treatment resulted in 85-100%
apoptosis. Following washes to remove unbound apoptotic neutrophils, the
percentage of MDMO with one or more neutrophil bound were counted. A
minimum of 500 MDMO were counted per well, with each condition
being carried out in duplicate and the mean value calculated. Data shown
are the mean percentage binding for three separate donors ± SEM. Trans¬
formed data were analysed by Tukey Kramer repeated ANOVA. * p<0.05
vs. Control MDMO + fresh neutrophils (n=3).
Figure 4.4 SEM images of apoptotic neutrophils bound to 5 day Control and Dex
MDMO
Untreated or Dex-treated 5 day MDMO were overlaid with apoptotic neutrophils and
incubated at 4°C for 1 hour. Following washing to remove unbound neutrophils, the
cells were fixed and dehydrated by washing through graded acetones and coated with
gold/palladium. Cells were viewed and imaged using a Philips 505 Scanning
Electron Microscope. Representative images from three separate donors are shown,
control MDMO shown (A and B) are representative of the highly spread cells with
multiple membrane extensions. The majority of control MDMO has no apoptotic
neutrophils bound. Typically, only one or two apoptotic neutrophils were bound to
the control MDMO which had bound the apoptotic neutrophils. Dex-treated MDMO
(C and D) are small, round and highly ruffled cells. They bound to high numbers of
apoptotic neutrophils, with apoptotic cells also seen attached to the membrane
extensions. 1 white section of the scale bar is equal to 10pM
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may be elucidated. Incubation of Iscove's DMEM medium with Chelex resin
removes the divalent cations as demonstrated in Figure 4.5(A). Binding of antibody
24 to CD11/18 on neutrophils requires the presence of divalent cations, particularly
Mg2+ and Mn24(Dransfield et al., 1992). To test the effective removal of divalent
cations from the Iscove's DMEM media, antibody binding was examined in the
presence of Iscove's DMEM alone, Iscove's DMEM with added divalent cations, the
cation chelator EDTA and Iscove's DMEM treated with Chelex resin. CD11/18
fluorescence was detected in Iscove's DMEM containing divalent cations, and
binding increased with the addition of extra MnCF>. No binding was detected in the
presence of EDTA or Chelex treated Iscove's DMEM demonstrating the successful
removal of the divalent cations from the media.
Figure 4.5(B) shows that MDMO phagocytosis of apoptotic neutrophils required the
presence of extracellular divalent cations. A significant inhibition of both control and
Dex phagocytosis was observed in the absence of divalent cations, with the re-
addition of both Ca2^ and Mg2+ to the Chelex-treated Iscove's restoring phagocytosis.
Interestingly, re-addition of Mn24 restores control but fails to fully restore Dex-
treated MDMO phagocytosis. However, the binding of apoptotic neutrophils to
untreated or Dex-treated MDMO was cation-independent (Figure 4.6). The binding
assay measured the number apoptotic cells tethered to the surface of the macrophage
whereas the phagocytosis assay measured the percentage of internalised apoptotic
cells. The binding stage was shown in Figure 4.6 to be cation independent, whilst the
subsequent internalisation was cation dependent (Figure 4.5). This data demonstrates
that the initial binding and subsequent receptor-triggered internalisation are readily
distinguishable steps, requiring two or more distinct receptors.
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Figure 4,5 Phagocytosis is a cation-dependent process
(A) Binding of cdl 1/18 to neutrophils requires the presence of divalent cations and
was used to confirm the removal of divalent cations from Chelex treated Iscove's.
Binding was carried out in the presence of Iscove's DMEM alone, Iscove's DMEM
+ MnCl, Chelex treated Iscove's DMEM or EDTA before analysis by flow
cytometry. Binding of cdl 1/18 was not detected when the assay was carried out in
Chelex treated Iscove's or EDTA.
(B) Control and Dex treated 5 day MDMO were used in a 1 hour phagocytosis assay
with fluorescent overnight aged neutrophils. Following overnight culture the
neutrophils were washed and then re-suspended in Iscove's, Chelex treated Iscove's
(no divalent cations), or Chelex treated Iscove's with Mg, Ca, Mn or Mg+Ca added
back.
Transformed data were analysed by Tukey repeated ANOVA. * p<0.05, ** p<0.01,
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Figure 4,6 Binding of apoptotic neutrophils to MDMO is cation indepen¬
dent
5 day control or Dex-treated MDMO were over laid with apoptotic neutro¬
phils at 4°C for 1 hour in Iscove's DMEM (divalent cations) or Chelex-
treated Iscove's DMEM (no divalent cations). Following washes to remove
unbound apoptotic neutrophils, the percentage of MDMO with one or more
neutrophil bound were counted. A minimum of 500 MDMO were counted
per well, with each condition being carried out in duplicate and the mean
value calculated. Data shown are the mean percentage binding for three
separate donors ± SEM. The binding of apoptotic neutrophils to both
control and Dex-treated MDMO was not dependent on the presence of
divalent cations.
Inhibition of known receptors does not inhibit binding of apoptotic cells
Having demonstrated that the binding of the apoptotic neutrophil to the MDMO is
cation-independent, I sought to investigate if any of the known cation-independent
receptors for apoptotic cells were involved in the binding. It is important to note that
all reagents used here were tested to be functional in other systems used within the
CIR (Dr. A. Devitt and Dr. S. Brown, personal communication) and were observed
to bind to MDMO in indirect immunofluorescence assays (data not shown). A
blocking antibody against CD 14 (61D3) along with a control antibody (non-
blocking) against CD 14 (63D3) were used to pre-treat 5 day MDMO prior to use in a
binding assay. However, blocking CD 14 did not inhibit MDMO binding of apoptotic
neutrophils (Figure 4.7A).
Although there are no suitable reagents to investigate the role of SRA in binding of
apoptotic neutrophils to human MDMO, I sought to use murine BMDMO to test for
the role of SRA. Bone marrow was extracted from SRA" " or WT background-
matched mice, and macrophages differentiated for 7 days in the presence or absence
of Dex prior to use in a binding assay with human apoptotic neutrophils. An increase
in binding of apoptotic neutrophils was observed in the Dex-treated MDMO
compared to untreated MDMO, demonstrating that GCs also augment mouse
BMDMO phagocytosis of apoptotic cells ex vivo. However, untreated or Dex-treated
BMDMO lacking SRA, showed no defect in their ability to bind to apoptotic
neutrophils (Figure 4.7B).
Homophilic ligation of CD31 on apoptotic neutrophils and CD31 on MDMO
promotes binding whilst CD31-CD31 binding between viable leukocytes and
MDMO promotes detachment, preventing ingestion of non-apoptotic cells (Brown et
al., 2002). It was therefore of interest to determine if inhibition of CD31 on the
untreated and Dex-treated MDMO blocked binding of apoptotic neutrophils. Pre-
treatment of control and Dex-treated MDMO with an IgG2a control antibody or
Hec7.2 CD31 blocking antibody (Brown et al., 2002) followed by binding of
apoptotic neutrophils showed no inhibition in control or Dex-treated MDMO
binding. Binding of apoptotic neutrophils, following MDMO incubation with isotype
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Fiuure 4,7 Inhibition of known receptors does not inhibit binding of apoptotic cells
(A) 5 day control and Dex-treated MDM(j> were pre-treated with a blocking antibody
against CD 14 (61D3) and a non-blocking, control antibody against CD 14 (63D3).
The MDM<)> were then overlaid with apoptotic neutrophils at 4°C for 1 hour, then
washed to remove unbound apoptotic neutrophils. The percentage of MDMO with
one or more neutrophil bound were counted. A minimum of 500 MDMO were
counted per well, with each condition being carried out in duplicate and the mean
value calculated. Data shown are the mean percentage binding for three separate
donors ± SEM. Blocking CD 14 on the MDMO did not inhibit either control or Dex-
treated MDMO binding of apoptotic cells.
(B) Bone marrow was extracted from age and sex matched SR.A"" mice and
background control mice (WT). BMDMO were differentiated over 7 days with
125nM Dex added on day 2. Phenotyping the 7 day untreated and Dex-treated SRA"'
and WT BMDMO, demonstrated that the SRA" "BMDMO did not express SRA on
their cell surface (see Materials and Methods). 7 day BMDMO were overlaid with
human apoptotic neutrophils in a 4°C binding assay as described above or in a 37°C
phagocytosis assay. Data shown are the mean percentage binding for three separate
experiments ± SEM. Loss of SRA did not affect Control or Dex-treated MDMO
binding of apoptotic neutrophils
(C) 5 day control or Dex-treated MDMO were plated onto virgin tissue culture
plastic, or onto a-2-macroglobulin coated plastic, a-2-macroglobulin binds to and
sequesters CD91 from the surface of the MDMO. The MDMO were then used in a
binding assay as described above. Data shown are the mean percentage binding for
three separate donors ± SEM. Blocking CD91 on the MDMO did not inhibit control
or Dex-treated MDMO binding of apoptotic cells
(D) 5 day control and Dex-treated MDMO were used in binding assays as described
above but with alteration to the pH of the media used in the assay. Lowering the pH
had no effect on the control MDMO binding of apoptotic neutrophils. Lowering the
1 15
pH attenuated Dex-treated MDMO augmentation of apoptotic cell binding. Data
























matched IgG2a was assumed to be 100%, and in three separate experiments binding
to control MDMO treated with Hec7.2 was 112%, 160%
and 87% whilst binding to Dex-treated MDMO treated with Hec7.2 was 85%, 118%
and 93%.
A role has been described for CD91 in phagocytosis of apoptotic cells. To investigate
whether this receptor is an apoptotic cell binding receptor, tissue culture plates were
either left virgin, or coated with a solution of alpha-2-macroglobulin as described in
a previous study (Ogden et ah, 2001). Alpha-2-macroglobulin is a ligand for CD91,
and so by plating 5 day MDMO onto the ligand CD91 expressed on the MDMO
should be sequestered to the basolateral surface of the cell where it binds the alpha-2-
macroglobulin and therefore will not be available on the surface of the macrophage.
No inhibition of binding ability was observed by plating untreated or Dex-treated
MDMO onto alpha-2-macroglobulin (Figure 4.7C). Together these data suggest that
none of the previously identified receptors are involved in untreated or Dex-treated
MDMO binding of apoptotic neutrophils.
One of the mechanisms by which neuraminidase treatment caused an increase in
control MDMO phagocytosis may have been that cleavage of sialic acid altered the
surface charge of the macrophage, reducing electrostatic repulsion between cell
types, and thereby increasing the binding of apoptotic cells. Indeed previous studies
have suggesting a link between surface charge and recognition of apoptotic cells
(Savill et ah, 1989a), therefore I sought to further investigate this possibility. By
altering the pH of the media used for the binding assay, a role for surface charge may
be established. Interestingly, lowering the pH had no effect on the binding of
apoptotic cells by untreated MDMO, but it did lower the percentage of Dex-treated
MDMO binding apoptotic cells (Figure 4.7D).
Role of avp3 integrin in the internalisation of apoptotic cells
The demonstration that internalisation of apoptotic neutrophils was a cation-
dependent process, coupled with studies showing human MDMO phagocytosis of
apoptotic cells primarily involves the cation-sensitive avp3 integrin, led to a re-
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examination of the role of this integrin as an internalisation receptor for Dex-treated
MDMO. 5 day untreated and Dex-treated MDMO were incubated with blocking
antibodies against av and avP3 prior to phagocytosis of apoptotic neutrophils.
Despite effective binding of the antibodies to the MDMO (see Figure 5.4), there was
no inhibition of phagocytosis (Figure 4.8 A). Figure 4.8(B-E) shows the
immunofluorescence staining of 5 day Dex-treated MDMO for the active (33 integrin,
using LIBS1 antibody. LIBS1 staining was punctuate and often polarised in MDMO
regardless of whether or not they were binding apoptotic neutrophils (Figure 4.8B).
Flowever, the binding or internalisation of apoptotic neutrophils was associated with
LIBS 1 staining in all examined cells e.g. in image C and also D and E, where
staining is shown on membranes extending towards the apoptotic neutrophils.
The extent of phagocytosis of apoptotic neutrophils is dependent on
the method by which apoptosis is induced
Neutrophil apoptosis was induced by two different methods. The first was by
overnight culture of neutrophils in Iscove's DMEM + 10% AS, resulting in a
population of neutrophils containing 45-60% morphologically-defined apoptotic cells
(Figure 4.9A). 2 hour culture of neutrophils in Iscove's DMEM + 10% AS, with the
addition of TNF-a and gliotoxin, induced apoptosis in 85-100% of the cells (Figure
4.9B). Intriguingly, these two populations of apoptotic cells were phagocytosed to
different extents by macrophages from the same donor. A small reduction in
phagocytosis of the TNF/gliotoxin-treated neutrophils by untreated MDMO was seen
compared to 'aged' neutrophils. Flowever, despite Dex-treated MDMO
demonstrating augmented phagocytosis of'aged' neutrophils compared to untreated
MDMO, Dex-treated MDMO did not demonstrate an augmented phagocytosis of the
TNF/gliotoxin-treated neutrophils. This finding is interesting since the TNF/gliotoxin



























Figure 4.8 Control and Dex MDM<I> phagocytosis of apoptotic neutrophils is not
inhibited by blocking antibodies against av or av-33.
(A) 5 day MDMO were pre-incubated with isotype control or blocking antibodies
against av or avp3 before being used in a 1 hour phagocytosis assay with overnight
aged neutrophils. Data shown is the mean percentage phagocytosis ± SEM (n=2).
(B)-(E) show 5 day Dex-MDMO which were phagocytosing labelled apoptotic
neutrophils (green), before being fixed and labelled with an antibody against active
P3 integrins (red). (B) is a composite image of immunofluorescence and phase
contrast, (C) is an immunofluorescence image and (E) is the phase contrast image
for (D), showing membrane extending towards the apoptotic cell. Active P3 integ¬
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Figure 4.9 Phagocytosis of different apoptotic neutrophil populations
(A) is an H&E stained cytospin of neutrophils cultured overnight in Iscove's + 10%
AS. Apoptotic neutrophils (Ap), defined morphologically, have a condensed nucleus,
whilst the non-apoptotic cells have multi-lobed nuclei (ML). The neutrophil popula¬
tion typically contains 45-60% apoptotic cells definied by morphology.
(B) is an H&E stained cytospin of neutrophils cultured TNF-a + Gliotoxin for 2
hours. Apoptotic cells contain condensed nuclei (Ap.) and these typically comprise
85-100% of the population as defined by morphology. An apoptotic eosinophil (eo) is
also seen in this image.
(C) Control and Dex MDMO were cultured for 5 days, before phagocytosing either
fresh neutrophils (<1% apoptosis), overnight aged neutrophils as described in (A) or
TNF/glio neutrophils as described in (C). Neutrophils were FL-1 labelled and the
data were analysed by flow cytometry. Data shown are the mean percentage phagocy¬
tosis ± SEM, (n=3).
cells as the overnight 'aged' population.
These data indicated that TNF/gliotoxin treatment potentially induced a differential
surface phenotype to that of overnight aged neutrophils, leading to altered
recognition by the Dex-treated MDMO. I therefore compared the cell surface
phenotype of the two neutrophil populations (Figure 4.10A). No obvious changes in
expression were observed between the two populations in any of the surface antigens
examined. However, examination of apoptosis-induced surface expression of
phosphatidylserine (PS) by annexin V staining showed a difference in expression
between the two populations (Figure 4.10 B and C). The overnight 'aged' neutrophils
had an annexin V positive population which correlated with the morphologically
apoptotic population and an annexin V negative, non-apoptotic population. By
contrast, the TNF/gliotoxin-treated neutrophils had a lower median fluorescence than
the annexin V positive 'aged' neutrophils (49.4 and 5.7 median fluorescence
intensities respectively). Confirmation of this result was seen by examination of
annexinV immunofluorescence staining by microscopy. Bright cell surface annexin
V staining of the 'aged' neutrophils was associated with condensed nuclei (Figure
4.10D) whilst a lower level of staining was detected on the apoptotic TNF/gliotoxin-
treated neutrophils (Figure 4.10E).
Dex-treated MDMO internalisation of apoptotic neutrophils can be
inhibited by annexinV
The previous experiments led me to consider the following hypothesis: Down-
regulation of PS exposure on the surface of the TNF/glio neutrophils results in
reduced Dex-treated MDMO phagocytosis of these cells. To test this hypothesis
neutrophils were aged overnight as previously described, resulting in a high level of
PS exposure on the outer membrane. These PShlgh apoptotic neutrophils were
incubated with annexin V which bound to the surface expressed PS, prior to the
phagocytosis assay. Figure 4.11 shows that pre-incubation of the neutrophils with
annexin-V attenuated Dex-treated MDMO phagocytosis. However, annexin V
binding did not alter untreated macrophage phagocytosis.
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Figure 4.10 Surface phenotyping of 'aged' and TNF/gliotoxin treated neutrophils
Overnight 'aged' and 2 hour TNF/Gliotoxin treated neutrophils were phenotyped for
the expression of surface antigens (A) or for expression of PS (B-E)
(A) shows the average mean fluorescence expression for surface antigens from three
experiments ± SEM.
(B and C) show representative annexin V profdes from 3 experiments. Annexin V
binds to PS on the surface of the neutrophils.
The 'aged' neutrophils are a mix of apoptotic and non-apoptotic cells (typically 45-
65% apoptotic) whilst TNF/Gliotoxin induces between 85-100% apoptosis by 2
hours. The apoptotic cells are marked on the flow profdes. Comparison of the
median fluorescence intensity for the apoptotic aged and apoptotic TNF/Gliotoxin
neutrophils (49.5 and 5.7 respectively) demonstrates a down regulation in annexin V
binding on the TNF/Gliotoxin cells. This was confirmed by immunofluorescence co-




Surface Mean Fluorescence: overnight aged Mean Fluorescence: TNFa/glio
Antigen neutrophils ± SEM neutrophils ± SEM
CDlla 4.1 ± 1.7 2.5 ± 0.4
CDllb 11.8 ± 1.1 18.5 ± 2.5
CD 16 4.5 ± 0.9 6.3 ± 3.6
CD18 7.8 ± 5.7 6.1 ± 4.7
CD29 0.5 ± 0.5 0.2 ± 0.1
CD31 4.4 ± 0.6 2.8 ± 0.1
CD32 9.5 ± 2.2 5.0 ± 0.2
CD43 20.2 ±11.7 9.0 ± 4.3
CD45 10.9 ± 2.2 10.6 ± 0.3
CD62L 0.2 ± 0.1 1.4 ± 1.3
CD66 9.6 ± 3.9 13.3 ± 2.1
'Aged'Neutrophils
Median Fl of A
apoptotic cells 1
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Figure 4.11 Blocking neutrophil PS expression attenuates Dex-treated MDMP
phagocytosis
Overnight 'aged' neutrophils were spun down and resuspended in Iscove's,
Annexin V buffer (HBSS + 5mM CaCI) or Annexin V buffer plus Annexin V and
incubated on ice for 20 minutes. The neutrophils were pelleted and resuspended
in Iscove's DMEM. Phagocytosis of the 'aged' neutrophils by Control and Dex-
treated 5 day MDMO was examined by flow cytometry. Data shown were the
mean % phagocytosis of three separate experiments ± SEM. Transformed data
were analysed by Tukey-Kramer repeated ANOVA. * p <0.05 is vs. Dex Iscove's
(n=3).
One interpretation of these results is that the Dex-induced augmentation (above that




Dex-treated MDMcD have an increased ability to bind apoptotic
neutrophils
Viable cells, including MDMO, are thought to carry a net negative surface charge
(Papadimitriou, 1982), resulting in an electrostatic repulsion between two cells.
Induction of apoptosis in thymocytes has been associated with a decrease in the
surface charge density (Miyazawa et al., 1981; Morris et ah, 1984) which may
therefore reduce the electrostatic repulsion between the apoptotic cell and the
MDMO. Interestingly, a charge-sensitive mechanism has been demonstrated for the
uptake of apoptotic neutrophils (Savill et ah, 1989a). Exposure of the untreated-
MDMO (but not Dex-treated MDMO) to neuraminidase augmented phagocytosis of
apoptotic cells. Neuraminidase cleavage of sialic acid from glycoproteins on the
surface of the MDMO may cause the unmasking or inactivation of surface antigens
or may act to alter the net surface charge of the MDMO, potentially reducing
electrostatic repulsion between the apoptotic neutrophil and MDMO. The change that
was induced on the surface of the untreated MDMO by neuraminidase treatment,
which led to augmentation of phagocytic ability, was not observed with Dex-treated
MDMO. One possible explanation for this observation is that the surface of the Dex-
treated MDMO already has changes similar to those induced by neuraminidase, and
this could be examined by the use of fluorescently labelled sialic acid-binding lectins
to examine sialic acid expression on the surface of the control and Dex-treated
MDMO. Dex-treated MDMO may exhibit an altered charge, when compared to the
untreated MDMO, with reduced repulsive forces between the phagocyte and
apoptotic neutrophil. As a consequence the Dex-treated MDMO may bind apoptotic
neutrophils more successfully or readily. A Dex-induced MDMO surface charge
alteration may be tested by examining the binding of latex beads, carrying different
charges, to control or Dex-treated MDMO, or by microelectrophoretic mobility,
which allows the charge on the surface of a single cell to be measured.
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One possibility raised by the neuraminidase data was that Dex-treated MDMO were
more capable of binding apoptotic cells. In order to examine this, I developed a
binding assay. By allowing the interaction of apoptotic cells and MDMO at 4°C,
binding between the two cells was permitted but internalisation was not (presumably
because signalling and subsequent actin polymerisation were inhibited). Binding
studies clearly demonstrated that Dex-treatment induced changes to the MDMO
which facilitated binding of apoptotic cells. Whilst the increased phagocytosis of
apoptotic cells by Dex-treated MDMO has been suggested to be a consequence of
increased Rac activity and altered cytoskeletal dynamics (Giles et al., 2001), my data
clearly indicate that the increased phagocytosis also reflects increased binding of
apoptotic neutrophils to the MDMO surface.
Binding and internalisation are two clearly distinguishable events in
apoptotic cell uptake
Further experiments demonstrated that the process of binding was cation
independent, whilst internalisation of the apoptotic neutrophils required extracellular
divalent cations. This data demonstrates for the first time that there are two clearly
distinguishable steps in the recognition and uptake of an apoptotic neutrophil by
MDMO. Furthermore, because only internalisation requires divalent cations, it is also
apparent that these two steps utilise different receptors.
Investigation of the involvement of possible receptors for the binding step yielded
largely negative data, failing to demonstrate a role for receptors previously suggested
to be involved in apoptotic cell uptake. A role for the integrin avP3 'vitronectin
receptor'/CD36/ thrombospondin complex was ruled out, as ligand binding to the
avP3 is dependent on divalent cations. Interestingly, Hoffman and colleagues
presented data to the contrary, suggesting a role for this complex in binding but not
internalisation (Hoffmann et al., 2001). However, the data presented in Hoffman's
study used erythrocytes coated with antibody against avp3 or with the ligands
thrombospondin or vitronectin. Whilst their data shows much greater binding than
engulfment when these erythrocytes were presented to MDMO, some engulfment
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was observed. For example, an average of two erythrocytes with vitronectin on the
surface bound to one MDMO, whilst only one was engulfed. An average of 7.5
erythrocytes with anti-CD36 and anti-avP3 antibodies on the surface bound to one
MDMO, with only one being engulfed per MDMO. There are several possible
interpretations of these data. One explanation is that when only a single ligand or
receptor is involved in uptake (as in the erythrocyte (Ebab) system), the receptors are
able to perform dual roles in the binding and internalisation process. Secondly,
Hoffman's data does show higher average binding compared to engulfment, but this
antibody-based system discounts the role of the receptor, whereas engulfment of
apoptotic cells may be critically dependent on either the receptor affinity or the
receptor distribution.
Based upon published data CD 14 is a candidate binding receptor with no reported
requirement for cations in its recognition of apoptotic cells. However, a blocking
antibody against CD 14 failed to inhibit binding in my system, potentially excluding a
role for CD 14. SRA"" BMDMO, demonstrated to express no SRA on their cell
surface (see Materials and Methods), were slightly more effective at binding to
apoptotic cells than BMDMO which expressed SRA on their cell surface.
Furthermore, SRA"" BMDMO showed no inhibition in internalisation of apoptotic
neutrophils either. Although these studies used mouse macrophages as phagocytes
and human apoptotic neutrophils as target cells, the fact that relatively high levels of
phagocytosis were observed suggests that cross-species recognition is not a problem.
This data effectively rules out a role for the SRA receptor in uptake of apoptotic
neutrophils and in Dex-augmentation of apoptotic cell clearance. I also examined
CD91 recognition of apoptotic cells. No inhibition in binding of apoptotic
neutrophils was observed following MDMO binding to alpha-2-macroglobulin,
suggesting this receptor is not involved in the binding step. However, it is possible
that not all of the CD91 on the macrophage surface was sequestered, and therefore
some interaction with apoptotic cells may have occurred through this receptor,
indirect immunofluorescence staining for CD91, would reveal the extent to which
MDMO binding to alpha-2-macroglobulin sequestered CD91 to the bastolateral
surface of the cell. Finally a role for CD31 was investigated. Binding of a viable cell
via a homophilic CD31 interaction at 37°C and under low shear has been shown to
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induce signalling which leads to dissociation of the cell (Brown et al., 2002). My
binding assay was conducted at 4°C in the absence of shear, and therefore would
have only allowed examination of CD31 as a binding receptor, and not as a receptor
conveying a dissociation signal. However, a role for CD31 in MDMO binding of
apoptotic neutrophils was not observed. Interestingly, when the binding studies were
performed at 4°C with subsequent warming to 37°C, and examination by real-time
video microscopy, many of the bound apoptotic cells were observed to detach and
consequently were not always engulfed (data not shown).
Phagocytosis of apoptotic cells has been associated with alterations in surface
charge. Savill and colleagues identified a recognition mechanism that was inhibitable
by amino sugars and basic amino acids neutralising the anion charge on the apoptotic
cell surface (Savill et ah, 1989a). Apoptotic cell engulfment was inhibited by a
reduction in pH, again probably by neutralising the anionic charge on the neutrophil.
Negatively charged ligands such as PS and OxLDL have been identified on the
apoptotic cell surface. I therefore investigated the effect of pH on the binding of
apoptotic cells to MDMO. Interestingly, lowering the pH to levels that has been
previously demonstrated to inhibit engulfment had no effect on untreated MDMd)
binding. Anionic changes (such as exposure of PS) to the surface of the apoptotic cell
may therefore not be involved in this step of recognition. In contrast, lowering the
pH reduced Dex-treated MDMO binding to apoptotic neutrophils. Whilst this data
may suggest that Dex treatment augments binding through altered properties of the
MDMO surface, this result must be interpreted cautiously. Dex-treatment reduces the
adherence of MDMO to tissue culture plastic, and it was noted that lowering the pH
caused a percentage of the MDMO to 'lift' from the plate. It is possible, therefore,
that selective loss of 'high-binding' Dex-treated MDMO was responsible for this
result. This could be tested by either, the recovery and microscopic examination of




It has been proposed that this second stage of receptor engagement signals for the
engulfment of the apoptotic cell (Hoffmann et ah, 2001). My data provides the first
demonstration that the MDMO phagocytosis of apoptotic neutrophils is governed by
two or more receptors, acting in a sequential manner to first tether and then
internalise the cell. The requirement for divalent cations in the internalisation step,
suggested a role for the integrin av(33 'vitronectin receptor'/CD36/ thrombospondin
complex. Using antibodies which blocked either av and avP3 function I failed to
demonstrate a role for this complex in either untreated or Dex-treated phagocytosis
of apoptotic neutrophils, in direct contrast with other studies which have successfully
demonstrated this (Fadok et ah, 1992b; Savill et ah, 1990). However,
immunofluorescence studies using LIBS1, an antibody specific for the ligand
occupied conformation of av[33, did show apparent co-localisation of active (33 to the
MDMO membrane adjacent to partially engulfed apoptotic neutrophils. My data did
not confirm or refute a role for the vitronectin receptor complex as an internalisation
receptor. It would be important to confirm whether this receptor complex is involved
in the internalisation step. One possibility would be the use of the RGDS peptide
ligand, which binds to multiple integrins, including avp3. Ligation of the av(35
integrin on 293T cells evokes signalling via CrkII-DOCK180-Racl during
phagocytosis of apoptotic cells (Albert et ah, 2000), whilst retinal epithelium cell
phagocytosis requires both prior activation of avP5 and actin polymerisation to bind
particles (Finnemann and Rodriguez-Boulan, 1999), demonstrating that integrin
receptor complexes are involved in phagocyte signalling, and that the integrin avp3
'vitronectin receptor' could potentially signal in a similar way. However, active P3
was localised throughout the phagocytosing MDMO, and as phagocytosis requires
the delivery of new membrane to the site of particle internalisation (Aderem, 2002),
it is possible that the P3 localises there as a bystander.
I developed the binding assay using neutrophils treated with TNF/gliotoxin, a
method which induced apoptosis in 85-100% of the cells, with very little evidence of
necrosis. In binding assays no difference in the binding of TNF/Gliotoxin neutrophils
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compared to 'aged' neutrophils was observed (data not shown). However, a clear
difference was observed when these two apoptotic populations were used in
phagocytosis assays. The observed Dex-treated MDMO augmentation of
phagocytosis of'aged' neutrophils was attenuated when TNF/gliotoxin-treated
neutrophils were used as targets. The untreated MDMO showed only a small down-
regulation in phagocytosis of the TNF-gliotoxin neutrophils compared to the
overnight 'aged' neutrophils. Comparison of the surfaces of the two apoptotic cell
populations revealed few molecular changes except for the extent of PS expression.
The 'aged' neutrophils, which had morphological characteristics of apoptosis,
expressed high levels of PS on their surface. However, the TNF/gliotoxin-treated
neutrophil population, whilst showing morphological characteristics of apoptosis,
had a broad range of PS expression, with a greatly reduced overall expression when
compared with the apoptotic 'aged' neutrophils.
In order to examine whether this change in PS expression was responsible for the
altered phagocytosis of these cells by the Dex-treated MDMO, PS h'sh 'aged'
neutrophils were labelled with annexin V, which has previously been shown to block
PS-mediated recognition (Callahan et al., 2003). Annexin V binding of PS on the
surface of an apoptotic cell attenuated Dex-augmented phagocytosis. My data
suggests that the augmentation in phagocytic capacity provided by Dex-treatment is
mediated via recognition of PS. Because pre-incubation of neutrophils with annexin
V did not completely inhibit phagocytosis it may be that Dex-treatment induces the
PS-PSR recognition mechanism in addition to another, as yet unknown, receptor-
ligand recognition system utilised by the untreated MDMO. This induced switch
would not be unprecedented. P-glucan treatment of human MDMO has been shown
to switch the main recognition mechanism from avp3 to PS (Fadok et al., 1992b). It
would be of great interest to obtain the antibody to the proposed PS-receptor and to
profile the surface of untreated and Dex-treated MDMO to examine if there is an up-
regulation in expression following Dex-treatment. It has been reported, although
evidence was not shown, that PS recognition by phagocytes is cation independent
(Fadok et al., 1998b). However, my data suggests a role for PS during the cation
dependent internalisation process and not the cation independent binding stage.
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Several receptors, including CD36, have been reported to potentially recognise PS
and perhaps the requirement for divalent cations in PS recognition may alter
depending on the receptor.
A suggestion by Pradhan was that the avP3 'vitronectin' receptor complex uptake
was associated with cells in the later stage of apoptosis (Pradhan et ah, 1997).
However, PS expression is an early marker on the apoptotic cell (Martin et ah, 1995),
raising the possibility that Dex-treated MDMO may recognise a different subset of
apoptotic neutrophils to the control MDMO. I therefore carried out some preliminary
experiments to attempt to address whether Dex-treated MDMO recognise different
subsets of apoptotic cells to control MDMO. This was investigated by fluorescently
labelling aged neutrophils for CRP (C-reactive protein), a marker of late apoptosis
(Dr. S.P. Hart, unpublished) whilst also staining all neutrophils with a cell tracker
dye, and then examining what proportion of total control or Dex-treated MDMO
phagocytosis were FITC-CRP labelled neutrophils. The results showed that 35 ±
14% SD of control MDMO phagocytosis were FITC-CRP labelled neutrophils,
whereas 22 ± 3% SD of the Dex-treated MDMO phagocytosis were FITC-CRP
labelled neutrophils, suggesting that control MDMO were more efficient at
phagocytosing late apoptotic cells than the Dex-treated MDMO. These interesting
preliminary findings would clearly require further testing, but may provide insight
into reported differences in molecular pathways implicated in the phagocytic process.
Summary
I propose the following model based upon the results presented in this chapter:
(Figure 4.12). Untreated-MDMO binding of apoptotic cells occurs in a cation-
independent manner. For internalisation of the bound apoptotic cell, a second
receptor which requires divalent cations to function, also binds the apoptotic cell.
The second 'internalisation' receptor may be pre-expressed by the MDMO, or may
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The iigand binding of the internalisation receptor(s) triggers signalling events
required for engulfment.
I have demonstrated that Dex-treatment up-regulates binding of apoptotic
neutrophils. No receptor has been identified, but pH experiments may suggest that
Dex-treatment results in changes to the cell surface which alters the charge on the
MDMO, favouring binding of apoptotic neutrophils. Dex also induces important
changes to the internalisation receptor, possibly recruiting a PS recognition
mechanism not used by untreated MDMO. I hypothesise that the up-regulation of
this second stage is essential for the increased signalling required for the
augmentation in internalisation apparent following Dex-treatment. My results
(presented in chapter 5) coupled with those of previous studies (Giles et al., 2001)
show that Dex-treatment critically up regulates Rac GTPase activation. Seemingly,
Dex-treatment enhances the binding and signalling receptor stages, as well as
inducing changes to the cytoskeleton conducive to internalisation.
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CHAPTER 5: ADHESION AND MIGRATION
Introduction
Podosomes
Podosomes are specialised adhesion complexes which were originally identified in
Rous sarcoma virus-transformed fibroblasts (Tarone et ah, 1985), and are now
known to be restricted to monocyte-derived cells such as macrophages, dendritic
cells and osteoclasts (Marchisio et ah, 1987). Podosomes consist of a central core
which is enriched for F-actin. Actin regulators such as Cdc42H, WASp and the Arp
2/3 complex, alongside intermediate filaments and their associated proteins (Babb et
ah, 1997) are also located in the core region. Surrounding the core is a ring of actin-
and integrin-associated proteins which include: a-actinin, paxillin, talin, vinculin, the
scaffolding protein and Src substrate, Fish and kinases such as Pyk2 (Abram et ah,
2003).
Podosomes are structurally and functionally related to adhesions found in other cells
such as focal adhesions (for a recent review on different adhesion types see
(Kaverina et ah, 2002)). Both contain the proteins a-actinin, vinculin and talin and
many of the podosomal ring proteins are also conserved in focal adhesions. Since
ring proteins serve as complexes linking the cytoskeleton to the core, this suggests a
conservation in structural linkage of adhesions to the cytoskeleton (Linder and
Aepfelbacher, 2003; Pfaff and Jurdic, 2001). However, F-actin and the actin-linker
protein fimbrin are unique to podosomes. A further disparity is the requirement for
de novo synthesis for focal adhesion but not for podosome formation (Tarone et ah,
1985). Podosomes are involved in the adhesion and migration of myeloid cells and
have also been shown to play a role in forming the sealing zone in osteoclasts
(Vaananen and Horton, 1995), and metalloproteinases in the core of podosomes are
involved in local extracellular matrix (ECM) degradation (Sato et ah, 1997) (Chen et
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al., 1984). Focal adhesions too are important in adhesion and migration, whilst also
sensing elasticity and force via connection to stress fibres (Wehrle-Haller and Imhof,
2002).
The focal adhesion links the cytoskeleton to ECM proteins via integrins. The integrin
family are heterodimer receptors comprising an alpha and a beta subunit (Miranti and
Brugge, 2002), which bind to ECM proteins mediating cellular adhesion and
signalling, pi integrin subunits have been shown to localise to the core, and P2 and
P3 to the ring structure, as well as being found adjacent to the podosome (Johansson
et al., 1994). During adhesion, Pyk2 and paxillin bind the tail of the P3 subunit of the
avP3 integrin in osteoclasts (Pfaff and Jurdic, 2001) (McHugh et al., 2000) or to p2
integrins in macrophages (Duong and Rodan, 2000). In summary, podosomes
provide a link between the ECM and the actin cytoskeleton, acting as scaffolding for
the assembly of signalling complexes which are required for actin-controlled
processes such as migration.
Regulation of podosomes formation, growth and disassembly
Podosomes are highly dynamic structures, with a half life of between 2 and 12
minutes (Linder and Aepfelbacher, 2003).They are found in polarised and migrating
cells, where their formation and turnover at the leading edge and dissociation at the
cell rear are critical for migration. Evans and colleagues studied podosome regulation
in the lamellipodia of macrophages. Fluorescent-actin and -fimbrin were used to
show that podosomes form de novo in a microtubule-independent manner at the
leading edge of the cell. The lifetime of short-lived podosomes can be extended by
fusion with another podosome or by fission of a podosome into daughter podosomes.
A further mechanism observed was the formation of a large indistinct structure, they
termed a podosome cluster precursor (PCP), from a single podosome which then
forms a cluster of daughter podosomes. These microtubule-dependent processes
provide a mechanism for the generation of podosomes at an extending leading edge,
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since the branching and forming of daughter podosomes always occurs towards the
leading edge of the cell (Evans et al., 2003).
Studies into the regulation of focal adhesions and podosomes have implicated a
number of different pathways in their formation and turnover (see Figure 5.1). The
GTPases Rac and Cdc42 mediate the formation of small focal complexes in
fibroblasts (Hotchin and Hall, 1995; Nobes and Hall, 1995), whereas Rho and Cdc42
are involved in the formation of osteoclast and human Hela cell podosomes
respectively (Dutartre et ah, 1996; Zhang et ah, 1995). Studies in the CSF-1-
dependent macrophage cell line, Bac.l, also demonstrated the requirement for Rac
and Cdc42 in the formation and distribution of podosomes, with Cdc42 signalling
upstream of Rac in this pathway (Allen et ah, 1997). Work in primary human
macrophages, demonstrated that Cdc42 co-localised and bound to WASp in the core
of podosomes where they mediated the disassembly and formation of podosomes.
This was demonstrated both by the injection of the c-terminal of WASp, leading to
sequential loss of WASp, actin and vinculin from podosomes and by studies
demonstrating that macrophages from WAS patients, whose cells contain no WASp,
have no podosomes. WASp is known to bind the Arp2/3 complex and this may result
in a concentration of Arp2/3 complex at the site of adhesion, where it mediates actin
assembly (Finder et ah, 1999). Finder and colleagues further demonstrated that
microtubules, linked to WASPs via the Cdc42 interacting protein CIP4, are essential
for podosome formation, although loss of podosomes does not affect microtubular
structure (Finder et ah, 2000). In addition, microtubules have also been shown to
cross-talk with focal adhesions (Krylyshkina et ah, 2003).
Kinases such as FAK, Pyk2 and Src also play an important role in the regulation of
adhesions. FAK was shown to be important in adhesion disassembly in a Rho and
Rac independent manner by the increased size and numbers of peripheral focal
adhesions in FAK" " mice fibroblasts. Webb and colleagues demonstrated that the
FAK-Src signalling complex phosphorylates the adaptor proteins, paxillin and
pl30cas, and postulated that this could alter binding of other adhesion components
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Figure 51 Schematic diagram of potential pathways involved in macrophage
adhesion and migration
specific sites is carried out by members of the Rho GTPase family. For example, Rho
directs localisation to focal adhesions whilst Racl and Cdc42 target localisation to
focal complexes associated with lamellipodia and filopodia respectively, providing a
mechanism for directing adhesion turnover at specific regions in a cell (reviewed in
(Frame et al., 2002)). A further mechanism regulated by the FAK-Src complex was
demonstrated using inhibitor studies in fibroblasts. The activation of the MAP kinase
signalling cascade by the FAK-Src complex resulted in activation of ERK, which in
turn activates myosin light chain kinase (MLCK). MLCK activates acto-myosin
based contractility which may sever linkages and result in the disassembly of
adhesions required for migration (Webb et al., 2004). Interestingly, studies of the IC-
21 macrophage cell line showed that Pyk2, which may functionally substitute for
FAK (Duong et al., 1998), became phosphorylated following adhesion to fibronectin,
and that the phosphorylation was dependent on aMp2 integrin (Duong and Rodan,
2000). In a manner similar to FAK-src, p21-Activated Kinase (PAK) has a role in
cell adhesion and contraction via MLC phosphorylation in endothelial cell migration
(Kiosses et al., 1999).
Migration is essential for macrophage function
The migration of monocytes into infected tissues is necessary for the clearance of
bacteria and apoptotic neutrophils during an inflammatory response (Chae et al.,
2002; Nakano et al., 1994). Monocytes leave the bone-marrow as non-differentiated
cells and circulate in the blood for 1-3 days before migrating from blood vessel
lumens into the inflamed tissue (Nichols et al., 1971). Monocytes initially form
transient adhesions via selectins to the endothelial cells which results in the 'rolling'
of the monocytes along the blood vessel wall. Following stimulation by chemokines
such as CCR2, the monocytes become firmly adhered or 'tethered' to the endothelial
cells via pi and P2 integrins, e.g. LFA-1 and VLA-4, expressed on their surfaces.
The polarised monocytes then migrate through tight junctions between the
endothelial cells into the inflamed tissues where they differentiate into monocyte-
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derived macrophages. In order to phagocytose target cells, be they bacteria or
apoptotic neutrophils, MDMO migrate towards them following chemoattractant
gradients, such as FMLP released by bacterial cells. It was also recently shown by
Lauber and colleagues that apoptotic cells release the phospholipid,
lysophosphatidylcholine (LPC), in a caspase-3 dependent manner which resulted in
monocyte migration towards them (Lauber et al., 2003).
For full resolution of inflammation the recruited macrophages themselves need to be
removed from the inflammatory site. Any persistence of aged macrophages may
result in the leakage of their histotoxic contents into the tissue. Following the
discovery that macrophages can be induced to undergo apoptosis (Albina et ah,
1993; Mangan and Wahl, 1991), it was proposed that macrophages underwent
apoptosis and were phagocytosed in situ (Savill et ah, 2002). However, recent
examination of the fate of the inflammatory macrophages by Bellingan and
colleagues illustrated that the macrophages emigrate to the draining lymph nodes
(Bellingan et ah, 1996) in a tightly controlled manner mediated by the integrins
VLA-4 and VLA-5 (Bellingan et ah, 2002a).
Migration
Cellular migration is a highly organised multi-step process which is fundamental to
many functions including embryogenesis and development, immune responses and
wound healing (Lauffenburger and Horwitz, 1996).
Initially a cell becomes polarised in response to a stimulus, e.g. a cheomattractant
such as FMLP. Lamellipodia and filopodia form at the leading edge and a uropod
(retracting tail) at the rear of the cell. The lamellipodium is a thin sheet of cytoplasm
which extends from the front of the cells supported by an actin meshwork. Filopodia
are short protrusions extending out of the lamellipodia which are composed of actin
bundles (Figure 5.2C). The extension of the lamellipodia is stabilised by the
formation of adhesions in this region (Figure 5.2B), which is followed by actin-
myosin based contraction of the cell body. Completion of migration requires the
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disassembly of adhesions in the uropod and recycling of the adhesion components to
the leading edge of the cell. Thus, adhesion and migration are intimately linked, with
the disruption of adhesion-associated proteins disrupting migration (Kiosses et al.,
1999) (Jones et ah, 2002).
Migration is driven by actin polymerisation, with members of the Rho family
GTPases central to the regulation of this process (Allen et ah, 1997; Ridley, 2001).
They act as molecular switches which cycle from an active GTP form to an inactive
GDP form. A cell binding to chemoattractant via uniformly distributed receptors,
interprets the gradient via the production of lipid products e.g. PIP3, in an
asymmetrical manner, correlating to the chemoattractant gradient. PIP3 can generate
GEFs which activate the Rho GTPases in a localised manner within the cell (Weiner,
2002). Rho GTPases have been implicated in the nucleation and polymerisation of
actin during lamellipodia and filopodial formation in macrophages (Small et ah,
2002). The growth of filopodia in macrophages requires the activation of Cdc42
which, via N-WASP, activate the ARP2/3 complex. The ARP 2/3 complex promotes
the directed nucleation and polymerisation of actin filaments as branches from
existing filaments (Figure 5.1).
Experiments using constitutively active and dominant negative Rac demonstrated a
role for this protein in adhesion, ruffling and lamellipodia growth (Allen et ah, 1997).
Rac drives activation, via the adapter protein IRSp53 (Miki et ah, 2000), of a second
member of the WASp protein family, Wavel, which like WASp binds to the ARP2/3
complex. Recent studies in BMDMO from RACE7" mice demonstrated that the Rac-
1 isoform is not involved in macrophage migration (Wells et ah, 2003), thereby
implicating Rac-2 in the regulation of this process.
Additionally, Rho activated pi60 Rho-kinase (ROCK) phosphorylates MFC causing
cell body contraction (Ridley and Hall, 1992) (Feung et ah, 1996). Thus the co¬
ordinated responses of Rho-GTPases orchestrate central aspects of cellular
migration. In addition, other signalling pathways such as the MAPkinase signalling
cascade, PI(3)Kinase pathway (Vanhaesebroeck et ah, 1999) and calcium
concentrations have also been associated with migration ability of leukocytes. For
example, ERK1/2 becomes activated and is required for human peripheral blood
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monocyte migration following stimulation by the monocyte chemoattractant proteins
(MCPs) in a potentially PIP3 Kinase-dependent manner (Srinivasan et al., 2003;
Wain et al., 2002).
Migration plays a fundamental role in the function of a macrophage; from the initial
migration of a monocyte into the inflammatory tissue, to migration of the
differentiated macrophage towards apoptotic target cells and emigration of the spent
macrophage to the draining lymph nodes. Consequently a breakdown in any of these
processes would result in the failure in the resolution of inflammation. Therefore, the
experiments presented in this chapter aim to investigate the effect of Dex on
macrophage adhesion and migration, by studying both the process of migration and
the underlying signalling pathways.
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Results
Macrophages have distinct adhesions which are important in migration
Cellular adhesions are important for the migration of a macrophage, stabilising the
extending lamellipodia, allowing for communication via integrins with the
underlying substratum and their disassembly being a requirement for the detachment
of the retracting tail. In view of this critical link, I investigated the association
between podosomes and the migratory morphology of 5 day monocyte-derived
macrophages (MDMO), allowing the 'normal' process of macrophage migration to
be described. Thus, peripheral blood monocytes were cultured on glass cover slips
for 5 days in 10% AS, whereafter they were fixed and then either processed for
immunofluorescence staining, or dehydrated and prepared for scanning electron
microscopy by coating with gold particles. The MDMO seen in Figure 5.2A is a
'giant' multinucleated MDMO, with typical cortical podosome staining. The
podosomes, as discussed in the introduction, are composed of a core of proteins
which include F-actin, surrounded by a ring of proteins including paxillin. The top
third of the figure shows the MDMO stained for the protein paxillin, which defines a
ring-like structure with a central core that is negative for paxillin. The middle third of
the image shows the punctate F-actin staining in the core region. The bottom third
shows an overlay of the top two images with the core of F-actin surrounded by a ring
of paxillin staining, typical of 'podosome-like' structures. Figure 5.2B shows a
scanning electron micrograph (SEM) of migrating 5 day MDMO. The macrophage is
polarised with extending lamellipodia (L) and filopodia (F) at the leading edge, and a
retracting tail (T) at the back behind the highly ruffled cell body. Figure 5.2C shows
a 5 day migrating MDMO which has been stained for the podosomal proteins,
paxillin and actin. In this example, the MDMO was observed to have a similar
morphology to that depicted in Figure 5.2B, exhibiting polarisation with a leading
edge at the top of the cell.
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Figure 5.2 Podosome staining and images of migrating macrophages
(A) shows a 5 day MDMO stained for podosomes. The top third shows the staining
for the ring protein, paxillin (green), the middle third for the core protein F-actin and
the bottom third is an overlay of the two. The image was captured using a Zeiss
Immunofluorescence microscope x63 lens.
(B) is a scanning electron microscopy image of a migrating 5 day MDMO. The
lamellipodia (L) and fdopodia (F) seen at the leading edge are areas of active actin
polymerisation, with the retracting edge (T) at the rear of the cell.
(C) shows a migrating 5 day MDMO stained for paxillin (green) and F-actin (red) to
label the podosomes. The podosomes were present at the leading edge, where they
stabilised the extending lamellipodia (L). The image was captured using a Zeiss
immunofluorescence microscope using x63 lens.
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The podosomes are present through the leading edge, where they are known to be
required for stabilisation of the extending lamellipodia (L). The filopodia, which
extend from the front of the cell, also contained paxillin and actin, although the
proteins are not organised into podosomes in these areas.
An organised microtubule network is absent from Dex-treated MDMO
The observation that the Dex-treated MDMO lacked podosomes (Giles et ah,
2001)(Figure 6.7), together with the study by Linder and colleagues which
demonstrated that microtubules are necessary for the formation of podosomes
(Linder et ah, 2000) led me to investigate the microtubule network in the untreated
(control) and Dex-treated MDMO by staining for the microtubule subunit, (3-tubulin,
in conjunction with F-actin staining of the podosomes. Figure 5.3A shows a control
MDMO labelled for the podosomal marker protein F-actin and Figure 5.3B shows
the P-tubulin labelling for the same cell. The P-tubulin was seen to radiate out from
the centre of the cell in an organised network of fine 'threads'. Figure 5.3C shows the
overlay of Figure 5.3A and B, where the podosomes were present either along the
length of, or at the termination of the microtubules.
Figure 5.3D shows a 5 day Dex-treated MDMO labelled for F-actin, which was
present in the ruffles at the edge of the cells only with no punctate staining of
podosomes. Figure 5.3E shows the P-tubulin staining of the microtubules. The
organised structural microtubule network observed in the control MDMO was not
apparent in the Dex-treated MDMO. The P-tubulin appeared as a diffuse staining
with occasional short strands of microtubules, which did not appear to link up with
other microtubules into an organised network. The absence of a highly organised
microtubule network accounts for the lack of podosomal structures associated with
the microtubules.
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Figure 5.3 Microtubules are associated with podosomes in Control but not Dex-
treated macrophages
(A) and (D) are F-actin stained 5 day untreated (control) and Dex-treated MDMO
respectively, confirming the previous observation that control but not Dex-treated
MDMO have podosomes. (B) and (E) are P-tubulin stained microtubules in control
and Dex cells respectively. The control macrophages had an organised network of
microtubules, whereas the Dex-treated MDMO microtubules were short and
unorganised. (C) and (F) are images for the control and Dex-treated MDMO
respectively; with the F-actin staining in red and P-tubulin in green. The podosomes
in the control cells were present either along the length or at the termination of the
microtubules. The Dex-treated MDMO have no obvious connection between the
microtubules and the F-actin staining.




Dex-treated MDMO exhibit decreased surface expression of integrins
Integrins are important in the relaying of signals between the ECM and the cell via
the podosomes, as well as playing an important role in migration, and I therefore
wished to profde surface integrins to examine any differences in expression between
the control and Dex-treated MDMO.
5 day MDMO grown in 10% AS ± 125nM Dex were gently removed from the tissue
culture plates and labelled for the surface expression of a panel of different integrins,
before analysis by flow cytometry.
The alpha subunits otL (CD1 la), ocm (CD1 lb), and ax (CD1 lc), and P2 subunit
(CD 18) which together form LFA-1, Mac-1 and pi50,95 respectively were
examined. a4 (CD49d) and a5 (CD49e) along with the pi subunit (CD29), which
pair to form VLA-4 and VLA-5, were also investigated alongside av (CD51) and av-
[33 (CD51/CD61) (Figure 5.4A).
aL and aM were expressed at high levels on the surface of the control MDMO, and
were dramatically down-regulated on the Dex-treated MDMO surface, whilst ax was
expressed at similar levels on the control and Dex-treated MDMO. Down-regulation
of aL and aM is likely to contribute to the reduced expression of P2 on MDMO
following Dex-treatment. Examination of a4 and a5 showed that they were both
expressed on the surface of the resting control or Dex-treated MDMO at fairly
similar levels, pi levels were also unchanged following Dex treatment, although
staining levels were low and given that a5 showed high expression this may suggest
that the pi antibody was not working well. Nevertheless, the failure of Dex-treatment
to alter pi, a4 or a5 expression levels suggests that VFA-4 and VFA-5 levels were
consistent between control and Dex-treated MDMO. Phenotyping av and avP3
integrins demonstrated a decrease in expression following Dex treatment. The
significant down regulation of aL on Dex-treated MDMO observed by flow
cytometry was confirmed by immunofluorescence microscopy using the WAC70
clone (Figure 5.4B). The control MDMO had specific aL staining around the cell
periphery along with some diffuse intracellular staining. However, contrary to the
flow cytometry results no peripheral surface staining was detected on the Dex-treated
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Figure 5.4 Integrin surface staining of 5 day MDMO
(A) In order to examine changes in integrins following Dex treatment, 5 day
control and Dex MDMO were stained for the following integrins and analysed by
flow cytometry: the alpha subunits aL, aM and aX and beta subunit, (12, of
LFA-1, MAC-1 and LeuCamc respectively. The cells were also stained for the
alpha subunits a4 and a5 and pi which form VLA-4 and VLA-5, along with
avP3. Data shown are the mean fluorecence ± SEM, (n=3).
To confirm the significant down-regulation of aL in Dex-treated MDMO, control
(B) and Dex-treated (C) MDMO were stained for aL using WAC70 clone. Images
were captured by Zeiss Immunofluorescence microscope using a xlOO objective
lens.
MDMO by immunofluorescence, suggesting that the flow cytometry is a more
sensitive technique for detecting low levels of antigen.
Establishment of a migration assay
In order to examine the process of migration, I sought to establish an assay which
would allow the movement of the different populations to be studied. Although
transwell assays (Boyden chamber) have been used in the laboratory, I decided that
the best option would be to use time lapse video microscopy as it would provide
insight into MDMO migratory behaviour. The MDMO monolayers were 'wounded'
using a pipette tip and then imaged over a period of several hours as cells migrated
into the 'wound'.
Preliminary observations suggested that the MDMO at the edge of a wound became
polarised and migrated, presumably in response to loss of cell-cell adhesion. In order
to establish key assay parameters such as the length of time the MDMO took to
migrate, initial experiments were carried out in which cells were wounded in a tissue
culture plate and then returned to the tissue culture incubator before examination by
light microscopy. These initial trials established that approximately 9 hours was
required for the control MDMO to completely 'fill' the wound.
I also investigated the possibility of looking at chemotactic migratory responses of
MDMO. However, this was not easily studied by time-lapse microscopy as the stage
was moved following 'capture' of each image, resulting in agitation of the media in
the flask. Thus chemoattractant added to one end of the flask would rapidly become
distributed throughout the media, making assessment of directed migration difficult.
The possibility of adding chemoattractant into an agarose plug was also investigated
but owing to the small flask neck this was only plausible in a tissue culture dish
without the ability to image via time lapse microscopy. Initial experiments used
highly migratory monocytes as a test system. Agarose was carefully pipetted onto
gelatine-coated glass slides to form a uniform layer; then, using a metal punch, three
linear and equidistant holes were made in the agarose. Iscove's DMEM was added to
the top well, monocytes to the middle well and a chemoattractant diluted in Iscove's
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DMEM to the bottom well. The monocytes adhered to the tissue culture plate at the
bottom of the well and could then migrate towards the stimulus (Nelson et al., 1975).
However, the small volumes of media, coupled with the length of time needed for the
assay often meant that the wells dried out. A decision was taken to concentre on the
time-lapse wounding method as it provided temporal information relating to the
migratory process.
Dex-treated MDMO have an altered migratory potential
The data in Figure 5.5 shows the rate of migration and number of control MDMO in
the wound, with the wound fdled by the end of the assay. This can be seen in an
example video in Figure 5.6 Video 1. The control MDMO became polarised, formed
large lamellipodia and migrated slowly in the direction of the newly formed
lamellipodia (Figure 5.6 Video 3).
The migration of Dex-treated MDMO was different to that observed for the control
MDMO. The Dex-treated MDMO were observed to display an initial 'burst' in
migratory activity (Figure 5.5 and Figure 5.6 Video 2), migrating much faster than
the control MDMO (For donor 1 MDMO migratory rates during the 1st hour of
migration were: control = 9 cells/hr, Dex = 54 cells/hr). Careful analysis of the time-
lapse microscopy images revealed that the Dex-treated MDMO also responded in a
very distinctive manner (Figure 5.6 Video 4), whereby they, apparently randomly,
rapidly extended and retracted multiple membrane protrusions, often as long as the
cell itself. Occasionally lamellipodia, similar to those observed in control MDMO
were formed with a small uropod at the rear of the cell, and a short period of
directional migration occurred (Figure 5.6 Video 4). Another difference between
Dex-treated and control MDMO was that Dex-treated MDMO failed to sustain
























Figure 5.5 Dex treated macrophages have an alterered migratory potential
5 day MDMO were cultured in microscopy flasks and, prior to the assay, a wound
was scored down the middle of the monolayer. The media was changed to remove
any unadhered cells and the migration captured by time-lapse micrscopy. An image
was taken every 5 minutes for 9 hours. Data were analysed as described in Materials
and Methods.
The figure shows that Dex MDMO show an initial burst in migratory potential
which has slowed down by around 3 hours. The control MDMO showed a slow and
steady rate of migration until the wound was filled. Data are shown for mean of 3
experiments + SEM
Figure 5.6 Video microscopy showing the migration of 5 day control and Dex-
treated MDMO
Monolayers of 5 day untreated (control) and Dex-treated MDMO were wounded and
then washed to remove the non-adherent cells. The migration of the MDMO back
into the wound was imaged by phase contrast microscopy, with one image captured
every five minutes.
Video 1: control MDMO migration over a 20 hour period
Video 2: Dex-treated MDMO migration over a 20 hour period
Video 3: Clip of control MDMO migration demonstrating formation of lamellipodia
and migratory phenotype.
Video 4: Clip of Dex-treated MDMO migration, showing the altered migratory
phenotype following Dex treatment, * marks the lamellipodia.
Representative videos shown for each condition from 5 experiments, each from a
separate donor.
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However, they continued to rapidly extend and retract processes, suggesting that
cytoskeletal regulation was not compromised.
Owing to a difference in size between the control MDMO and Dex-treated MDMO
the 'wound' required a larger number of Dex-treated MDMO in it for it to be fdled.
Thus, despite the increased number of Dex-treated MDMO in the wound compared
to control MDMO shown in the graph in Figure 5.6A, the Dex 'wound' is less full
than the control 'wound'.
Images of migrating control and Dex-treated MDMO, taken from captured images
during phase contrast time-lapse microscopy are shown in Figure 5.7. The control
MDMO form lamellipodia at the leading edge which differed in area, perhaps
reflecting the stage of lamellipodia formation (Figure 5.7 A-D), and in some cases
the lamellipodia surrounded the entire cell (Figure 5.7 E). The lamellipodia and
uropods did also form in some Dex-treated MDMO (Figure 5.7F and G), although
the filopodial-like extended membrane was a more common morphology (Figure 5.7
H-J).
F-actin is found predominantly at the leading edge of Dex-treated
MDMO
Following the observation that, despite a lack of podosomes, the Dex-treated MDMO
are capable of migrating and forming temporary lamellipodia, it was of interest to
examine the F-actin distribution and podosome formation during MDMO migration.
5 day MDMO, grown on glass cover slips, were wounded using a pipette tip to
induce migration. The cells were returned to the incubator for 2 hours and then fixed
and labelled for F-actin. The control MDMO formed a polarised morphology with
the F-actin present predominantly in podosomes at the leading edge of the cell, as
observed previously (Figure 5.7K and L). The Dex-treated MDMO had a distinct F-
actin distribution, with the majority of staining observed at the leading edge in
ruffles. Small punctate regions of F-actin were apparent in the uropod and cell body
and occasionally in the region behind the leading edge (Figure 5.7N). These
adhesions did not appear in as large a number as the control MDMO podosomes, nor
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Figure 5.7 The cellular morphology and F-actin distribution in migrating MDM®
(A-J) 5 day Dex-treated MDM® were imaged during a wounding assay by time-
lapse microscopy. Images are representative of control and Dex-treated MDM®
during migration from 5 experiments.
Images (A-E) show the lamellipodia and retracting tail in the polarised control
MDM®, required for migration. Images (F-J) show the morphologies adopted by the
Dex-treated MDM® during the migration assay. (F-G) show Dex-treated MDM®
with lamellipodia and uropods, whilst (H-J) show the membrane extensions which
were extended and retracted from the Dex-treated MDM® between periods of
migration.
(K-N) 5 day MDM®, differentiated in the presence of 10% autologous serum ±
125nM Dex were fixed and stained for F-actin. (K-L) are control MDM®,
demonstrating that the lamellipodia are stabilised by the formation of podosomes.
(M-N) are Dex-treated MDM® which contain F-actin predominantly in ruffles at the
leading edge of the cell, as well as in adhesions throughout the cell body. Images
were captured using a Zeiss Immunofluorescence microscope using a xlOO lens.
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did they stain as brightly (Figure 5.7M and N). This data provides evidence that
although Dex-treated MDMO form lamellipodia which are stabilised by small
adhesions, they do not form podosomes-like adhesion structures during migration.
Dex-treated MDM(t> have increased activation of Rac-GTPase
The Rho-GTPase, Rac has been implicated in the actin polymerisation during
adhesion formation, ruffling and cellular migration, and so I examined the levels of
total and active Rac within different macrophage populations, to investigate if any
changes in this important Rho family GTPase could explain the observed alterations
in Dex macrophages.
5 day MDMO, which had been cultured in 10% AS alone ± Dex were used in a Rac
pulldown assay as described in Chapter 2. Lysates were equalised for protein
concentration before the assay. Figure 5.8 shows a western blot which had been
probed for total and active Rac-1 in the macrophages. The levels of total Rac-1
showed some differences between the samples, with Dex-treated MDMO containing
lower levels of total Rac-1 protein than the control MDMO. Calculation of the
relative levels of the total Rac-1 compared with active Rac-1 (Figure 5.8B) suggested
that the relative levels of GTP Rac-1 were higher in the Dex-treated MDMO than the
control MDMO. However, levels of active Rac-1 could well be higher in the control
MDMO owing to a higher total amount of Rac-1 in these cells. It was also important
to consider the localisation of Rac within the MDMO, because this would impact on
the proteins Rac-1 could bind and therefore on downstream function. To this end
immunofluorescence imaging of macrophages for total Rac-1 was carried out in
control and Dex-treated MDMO (Figure 5.8C and D). The images shown are
maximum projections of confocal stacks where slices are taken through the cells. A
maximum projection adds together all positive staining in the cell, and so staining at
the basal and apical surface of the cell appears in the same image. Rac-1 (green)
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Figure 5.8 Rac-GTPase concentration is altered in Dex-treated MDMO
(A) and (B) Total Rac protein levels were compared between 5 day MDMO
differentiated in 10% AS ± 125nM Dex. The total Rac levels were lower in the Dex-
treated MDMO when compared to the control MDMO. 30% of the control MDMO
Rac was activated, but this rose to 75% in the Dex-treated MDMO.
(C) and (D) shows maximum projection images (shows all staining through all
sections of cells in one image) of control and Dex-treated MDMO respectively. The
MDMO were stained for F-actin (red) and Rac-1 (green). In both the control and
Dex-treated MDMO the Rac stained an area on the very top of the cells, and was also
seen in a diffuse pattern throughout the control MDMO. It did not associate with F-
actin rich ruffles in the Dex-treated MDMO.















localised to the apical surface of both the control and Dex-treated MDMO, as well as
being observed diffusely throughout the rest of the cell. Macrophages were co-
stained with F-actin (red), which was seen throughout the control MDMO and
specifically in podosomes on the basal surface. Interestingly, the F-actin mainly
localised to the ruffles on the apical surface of the Dex-treated MDMO, but the Rac-
1 and F-actin did not co-localise.
Macrophage re-adhesion alters MAP Kinase phosphorylation
During a wounding assay only a small number of cells are migrating at any point and
hence any protein changes associated with migration may have been lost amongst the
non-migrating cellular protein levels. In order to investigate changes in protein
modification associated with migration, a method was developed which allowed the
responding population of cells to be examined. Macrophages were 'lifted' from the
tissue culture plastic and allowed to re-adhere over an hour. During re-adhesion, the
macrophages re-form podosomes, which may be akin to podosome formation during
migration.
The MAP Kinase family member ERK1/2 has been shown to be involved in
podosome regulation and chemotaxis (Jimenez-Sainz et al., 2003; Riboldi et ah,
2003; Wain et ah, 2002),and I therefore investigated ERK1/2 protein levels and
phosphorylation in adherent and re-adhered MDMO. The two MDMO populations,
control and Dex-treated, were equalised for protein concentration before examination
by western blotting. ERK compromises a p42 and a p44 subunit which are resolved
under reduced conditions on a polyacrylamide gel. Levels of total ERK 1/2 were
consistent between all 4 samples (Figure 5.9). The adherent control MDMO
contained high levels of phosphorylated ERK 1/2 which did not alter upon re-
adhesion. The Dex-treated MDMO, which has been adhered to the tissue culture
plastic for 5 days prior to detection, showed low levels of ERK phosphorylation, but
this dramatically increased upon re-adhesion, particularly in p42.
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Total p42/p44 ERK Phosphorvlated p42/p44
Figure 5.9 MDMP readhesion alters the phosphorlyation of ERK1/2
5 day MDMO were either left adhered to, or lifted and re-adhered (RA) to, tissue
culture plastic over one hour. Cell lysates were made and protein concentrations of
all samples were equalised. Lysates were run reduced and blotted for total ERK 1/2
(A) and P-ERK1/2 (B). Representative blot of 2 shown.
Role of MAP Kinase in the initial burst in Dex-treated MDMO migration
Migration assays were carried out in the presence of the MEK Kinase inhibitor,
PD98059, for three different macrophage donors. Two of the three donor's Dex-
treated MDMO showed no inhibition following PD treatment. However, analysis of
the third donor's Dex-treated MDMO resulted in a loss of migration (Figure 5.10).
Intriguingly, these preliminary results suggest that other factors may be important in
determining whether MAP kinase has a role in Dex-treated MDMO migratory
response.
Re-adhesion does not affect phagocytic ability
The process of adhesion, migration and phagocytosis are closely linked, due to a
conservation of mechanisms between these different functions (Leverrier and Ridley,
2001; May and Machesky, 2001). Since they all require actin polymerisation and
share many of the same proteins and pathways it was of interest to examine the
phagocytic ability of the re-adhered macrophages.
5 day MDMO were differentiated in 10% AS ± 125nM Dex ± lOng/ml IL-4 or
lOng/ml IFN-y, differentiating to form phenotypically distinct MDMO (see chapter
6). The MDMO were either left attached to the tissue culture plate or lifted and
allowed to re-adhere for 1 hour at 37°C 5% CCE, a time point at which podosomes
are clearly visible in control MDMO and ERK phosphorylation showed clear
differences in re-adhered Dex-treated MDMO The MDMO were then used in a 1
hour phagocytosis assay and the extent of phagocytosis examined by flow cytometry.
Figure 5.11 demonstrates that no significant change in phagocytic ability was
observed between the MDMO which had been left adhered or those re-adhered
within any of the 6 MDMO populations. This data suggests that the proteins required


















Figure 5.10 Effect of ERKl/2 inhibitor on Dex-treated MDMQ migration
Dex MDMO were pre-treated with the ERKl/2 inhibitor PD98059 (PD),
prior to the wounding assay. From the three donors analysed, only one
shown above demonstrated an inhibition following PD treatment.
Figure 5.11 Readhesion of macrophages has no effect on phagocytic ability
5 day MDMcJ) were lifted and then allowed to readhere to tissue culture plastic
for 1 hour. Following a 1 hour phagocytosis assay, the internalisation of fluores-
cently labelled apoptotic neutrophils was examined by flow cytometry. Readhe¬
sion caused no significant alteration in any of the MDMO population's phago¬
cytic ability.
Data shown are mean % phagocytosis ± S.E. Tukey Kramer repeated ANOVA on
the transformed data showed, (n=3) no significant difference was observed
between any of the adhered vs re-adhered pairs.
Discussion
Loss of adhesions is associated with altered migratory phenotype
Examination of MDMO migration by video microscopy revealed that Dex-treatment
resulted in an altered migratory ability when compared to untreated (control)
MDMO. The migratory morphology exhibited by the 5 day control MDMO involved
formation of lamellipodial membrane extensions that appeared to determine the
direction of subsequent migration, and a retracting tail at the rear of the cell. In all
cells examined, migration was preceded by the adoption of this morphology and any
subsequent change in direction required the formation of lamellipodia in that
direction. The Dex-treated MDMO exhibited an initial period of directed migration
during which they adopted a distinct migratory morphology. However, lamellipodia
formed were less extensive and subsequent directional migration was short-lived,
with the studies examining the F-actin staining of the migrating MDMO revealing a
distinct cytoskeletal architecture when compared with untreated MDMO.
It was notable that migrating Dex-treated MDMO formed very few large organised
adhesions compared to the control MDMO. One possibility is that the difference in
cytoskeletal organisation may play an important role in the observed migration
patterns. Firstly, Linder and colleagues have demonstrated that a microtubule
network is required for the formation of podosomes (Finder et al., 2000) and the lack
of a highly organised microtubule network in the Dex-treated MDMO may therefore
have resulted in the failure to stabilise podosomes-like adhesions. In the absence of
podosomes behind the leading edge, and presumably with a lack of supporting
adhesions, the extending lamellipodia would be expected to be short lived. Secondly,
the less intense staining of the adhesions present in the Dex-treated MDMO may
suggest that they are smaller, although not necessarily weaker, than those in the
control MDMO. Examination of other known adhesion components, such as pyk2,
talin and vinculin would allow the adhesions associated with Dex-treated migrating
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MDMO to be distinguished from those found behind the leading edge of the
untreated migrating MDMO. Correlations between the extent of adhesion contacts
and migration have been reported, with FAK"" fibroblasts exhibiting increased
numbers of focal adhesions whilst having a reduced migratory rate (Ilic et al., 1995).
Further, there is work suggesting that rapid cell migration is driven by small, often
undetectable adhesions at the leading edge (Webb et al., 2002). Therefore, the
reduced presence of podosomes at the leading edge of the Dex-treated MDMO may
have allowed for the initial period of rapid migration observed following wounding.
Dex-treatment of MDMO alters protein expression or phosphorylation of key
cytoskeletal components. The down-regulation of paxillin and pyk2 phosphorylation
in 5 day MDMO following Dex-treatment and the associated loss of podosomes
adhesions has been previously described (Giles et al., 2001). Significantly,
alterations in expression and phosphorylation of these adhesion components have
also been linked with defects in migration. Transfection of Chinese hamster ovary
K1 cells, MDA-MD-231 human breast cancer cells, and NBT-II cells with a
phosphorylation mutant of paxillin inhibited cell migration and prevented directed
migration required for wound closure (Huang et al., 2003). However, in contrast to
the Dex-treated MDMO, where loss of paxillin phosphorylation correlated with loss
of podosome adhesions, transfection of the mutant paxillin in these cells was
associated with the formation of large, stable adhesions, postulated to prevent the
cells from migrating. Studies examining Pyk2 mouse macrophages showed an
impaired chemokine-induced migration due to altered cell polarisation and reduced
cell contraction (Okigaki et al., 2003). Interestingly, loss of pyk2 in these
macrophages was associated with the protraction of multiple extensions, a
phenomenon also observed in the Dex-treated MDMO. One possibility, therefore, is
that pyk2 phosphorylation is required for orientation of extending membrane in the
direction of migration.
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In vivo consequences of Dex-treated MDMO altered migratory ability
There are a number of reports in the literature demonstrating that both in vitro and in
vivo treatment with GCs causes an inhibition in wound healing (Durmus et al.,
2003a; Polat et al., 2002). In a study of diabetes mellitus, wound healing in the
presence of GCs was inhibited concurrent with a reduction in infdtrating
inflammatory cells, fibroplasia and neovascularisation (Bitar et al., 1999). The
observed inhibition of wound healing by GCs could be attributed to its numerous
effects on different cells. For example, GCs prevent migration and activation of
inflammatory cells (Barnes, 1998), induce apoptosis of some cell types (Amsterdam
et al., 2002), as well as altering the cytokine profile (Hubner et al., 1996) and matrix
deposition at the wound site (Schacke et al., 2002). The wound-assay results
presented in this chapter suggest that the Dex-treated MDMO may fail to sustain
migration over a larger distance, as they often adopted a phenotype in which they
rapidly extended and retracted long processes in multiple directions and failed to
migrate. Therefore, Dex-treated MDMO's altered migratory phenotype is consistent
with the literature on GC-altered leukocyte migration. A study using a transsection-
induced bowel anastomoses model showed that wound healing was impaired by Dex
treatment and that ICAM-1 expression was down-regulated on the endothelial cells,
which would reduce leukocyte migration into the wound site and impair healing.
(Polat et al., 2002). Interestingly, the receptor for ICAM-1, ai_P2 was down-regulated
following Dex-treatment and this may therefore result in reduced monocyte
migration from the blood vessel into the inflammatory site.
Dex-treated MDMO have altered levels and activation of many key
adhesion and migration proteins
In this chapter, the levels of total Rac-1 in the Dex-treated MDMO were shown to be
down-regulated when compared to control MDMO. Flowever, the percentage of
activated Rac present relative to the levels of total Rac was higher in the Dex-treated
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MDMO. The assay was carried out on protein lysates from the different MDMO
populations which had been equalised to contain the same total protein
concentrations. Interestingly, the Dex-treated MDMO are much smaller than the
control MDMO (<10pm compared to >20pm diameter control MDMO), and
assuming the cells as spherical, the Dex-treated MDMO are nearly 8 times smaller in
volume than the control MDMO, and therefore the levels of total Rac may well be
sufficient to fulfil need of Dex-treated MDMO. Although it is possible that the
reduced total levels of Rac-1 present in the Dex-treated MDMO limits certain
functions, the presence of a large proportion of Rac-1 in the active form may drive
processes such as membrane ruffling. The SEM images seen in Figure 4.4
demonstrate an increased ruffling on the cell surface of the Dex-treated MDMO
compared to control MDMO. In addition to this, the Rac-1 staining in Figure 5.8D
shows a high level of Rac at the upper surface of the Dex-treated MDMO. The
localisation and turnover of Rac are important factors for actin polymerisation
required for lamellipodia formation and membrane ruffling. In light of the results
demonstrating altered levels of active Rac following Dex-treatment, it would be
interesting to compare and contrast Rac in migrating untreated and Dex-treated
MDMO, perhaps by microinjection and imaging of a fluorescently tagged Rac
protein or GFP-tagged PAK in these cells.
Adhesion and the tightly associated process of cellular migration share
commonalities in proteins and mechanisms including regulation of actin
polymerisation via the Arp2/3 complex. Gene array data presented in chapter one
demonstrated an up-regulation in the key signalling proteins, PAK-1 and pl60ROCK
associated with Dex treatment. PAK-1 is known to bind to and be activated by the
activated forms of Rac and Cdc42, with roles in the signalling pathways down¬
stream of these GTPases for filopodial formation and podosome turnover. Studies of
endothelial cell migration have demonstrated a potential role for PAK-1 in adhesion
formation at the leading edge, and the subsequent contraction and tail detachment
(Kiosses et al., 1999). Interestingly, I have also demonstrated an increase in Rac-1
activation following Dex-treatment, and the gene array data predicted a 3-fold up-
regulation of Cdc42 and a 2-fold up-regulation in Cdc42 GTPase activating protein.
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Signalling via the Rho-GTPase Cdc42 results in actin polymerisation and filopodial
extension (Allen et al., 1997), and in view of the result showing that the Dex-treated
MDMO demonstrate atypical extension and retraction of membrane during the
migratory response, it would be important to confirm an up-regulation of Cdc42
protein levels and activation status in the Dex-treated MDMO.
In addition, the formation of focal complexes and the maintenance of a spread
morphology in the macrophages cell line, Bacl, is dependent on Cdc42 signalling
upstream of Rac (Allen et al., 1997). A down-regulation in total levels of Rac
protein, such as was seen in the Dex-treated MDMO, would therefore be predicted to
result in loss of podosomes and rounding up of the cell, both of which were seen in
the Dex-treated MDMO.
pl60ROCK is a Rho associated kinase which is downstream of Rho-GTPase. Over
expression and thus over stimulation of this pathway has been shown to cause
contraction and rounding up of macrophages (Allen et al., 1997). The observed Dex-
treated MDMO morphology would be consistent with the predicted outcome of up-
regulation of a member of this pathway, with a small and rounded morphology,
perhaps due to increased myosin light-chain phosphorylation and contraction of acto-
myosin. Migration studies using Dex-treated MDMO treated with inhibitors of MLC
phosphorylation may help to address this question. pl60ROCK is also essential for
the retraction of the tail of migrating leukocytes, and inhibition results in attachment
of the cell to the substratum via the tail, whilst the cell body remains highly motile
(Alblas et al., 2001). In accordance with an upregulation in pl60ROCK, Dex-treated
MDMO have less prominent tail retraction when compared to control MDMO.
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Dex treatment causes the down-regulation of selected integrins on
MDMO
Phenotyping of the 5 day MDMO for the major families of surface integrins revealed
that ccl, oim and ax were down-regulated on the surface of the Dex-treated MDMO
when compared to the control MDMO. a4, a5 and [31, the subunits of VLA-4 and
VLA-5, which have been shown to be required for the emigration of macrophages
from the inflammatory tissue to the draining lymph nodes (Bellingan et al., 2002b),
showed no significant down-regulation following Dex treatment. However, it is
possible that the integrins surface expression may alter on MDMO following a
migratory stimulus. The stimulus for MDMO emigration from the inflammatory sites
is unknown and therefore it would currently be difficult to test if there were
differential changes in expression of integrins by control and Dex-treated MDMO
under conditions approximating inflammation in vivo. It would be interesting to
follow up the integrin phenotyping studies presented here with studies investigating
adhesion of MDMO to the principal integrin ligands, and further to examine MDMO
across these ligands. Tissue culture plates could be coated with ligands such as
ICAM-1 (receptors of which are LFA-1 and Mac-1), fibronectin or motifs of
fibronectin (receptors are Mac-1, VLA-4, VLA-5 and avP3) and collagen (receptor
is a2(31). Analysis of control and Dex-treated MDMO adhesion to these different
ligands may then provide information on whether Dex-mediated down-regulation of
integrins would impact on cellular adhesion. Furthermore, given the demonstration
that stimulation from both integrin binding to ECM and from Rho GTPase signalling
are required for focal adhesion formation in human fibroblasts (Hotchin and Hall,
1995), the down-regulation of integrins following Dex-treatment may be important in
explaining the adhesion morphology of these MDMO.
In the present analysis, I compared the integrin profiles of 5 day untreated and Dex-
treated MDMO. However, it would also be interesting to examine how rapidly Dex
alters the surface receptor patterns. Any rapid alterations in receptor expression or
activity might influence monocyte migration across endothelium into the
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inflammatory tissue. Further, the down-regulation of the P2 and avp3 integrins may
reflect the change in podosomes seen between the control and Dex-treated MDMO.
Certainly, the lack of podosomes and thus the concentration of integrins at sites of
adhesion where they signal from the ECM to the cell, suggests the Dex-treated
MDMO may have an impaired ability to interpret environmental signals.
MDMO migration is not dependent on MAP Kinase activation
A model experimental system was developed to investigate assembly of
adhesion/signalling complexes approximating those in MDMO. One of the major
differences between untreated and Dex-treated MDMO was the presence of
podosomes. However, continuous turnover of these structures in adherent cells
makes analysis of the mechanisms underlying control of their assembly difficult. I
found that detachment of MDMO from tissue culture plates followed by their re-
adherence, resulted in the formation of podosomes (data not shown). Thus, using this
system for detachment-reattachment, it might be possible to examine signal
transduction pathways biochemically in a synchronous population of cells. Western
blotting for the Map kinase ERK1/2 revealed that re-adhesion caused increased
phosphorylation (particularly of ERK2) in Dex-treated MDMcD. No change in
phagocytic ability of any of the MDMO populations examined was detected
following readhesion, indicating that increased ERK1/2 phosphorylation is not a
critical determinant of phagocytic ability. Whilst the interpretation of data from the
use of pharmacological inhibitors is difficult due to non-specific effects, I sought to
use the MAP Kinase inhibitor to investigate the role of p42/44 MAPK in the control
of adhesion. EInfortunately the results for these preliminary experiments were
equivocal, with a complete inhibition in migration in the case of one donor but in two
other experiments, migration appeared unaffected by the PD compound, raising the
possibility that the MAP kinases do not play a critical role in human macrophage
migration. A role for MAP kinases, and particularly for ERK1/2 have been
previously investigated during monocyte chemotaxis. The chemoattractants, MCP
(monocyte chemoattractant proteins) 1 -4 were shown to rapidly activate ERK2 in
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monocytes and incubation with the MAP Kinase inhibitor U0126, abrogated
monocyte chemotaxis (Wain et al., 2002). Studies using the specific MAP kinase
inhibitor PD98059 have reported contradictory results. Yen and colleagues
demonstrated an inhibition in monocyte MCP-1 chemotaxis following incubation
with PD (Yen et ah, 1997) but Fine and colleagues reported no defect in monocyte
chemotaxis to a variety of chemoattractants (Fine et ah, 2001). In light of these
studies it may be prudent to use a range of inhibitors to clarify the role of MAP
Kinases during MDMO migration. Interestingly, PD does not block phagocytosis of
apoptotic cells (I.Dransfield, unpublished data) supporting the suggestion that MAPK
activity may not be critical for phagocytosis either.
Consideration of the assay
The cell wounding assay, which may promote cell migration following the loss of
cell-cell adhesions, is a model system for real-time morphological analysis of
migration. One possible explanation for the altered migratory behaviour seen
between control and Dex-treated MDMO following wounding could be due to
differential responses to the wound stimulus, perhaps resulting in the release of a
signalling factor promoting migration. Untreated MDMO may continue to migrate
until cell-cell contact is re-established, whereas Dex-treated MDMO migration may
stop because of cessation of signals required for migration. Following 5 day
treatment of peripheral blood monocytes with Dex, expression of ICAM-1 and its
receptor aLp2 were down-regulated on the macrophage cell surface. One possibility
is that since untreated MDMO express both receptor and ligand, they are able to
interact with other MDMO via these molecules. The down-regulation following Dex
treatment may therefore inhibit cell-cell contact. Examination of Dex-treated MDMO
migration, initiated by other stimuli such as chemoattractants, would answer the
question of whether the altered migration presented in these studies was due to
differential response to the stimuli or a fundamental alteration in migratory ability.
Whilst it was difficult to control the exact width of the wound between experiments,
it is also worth noting that the wound size represented a greater number of cell body
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lengths for a Dex-treated MDMO than for a control MDMO. To test the possibility
that cell-cell contact provided signals that determined when MDMO migration
stopped it would be interesting to examine the migration of the MDMO when
wounds of different sizes were created, using custom built cell-scrapers.
The in vivo stimulus for migration can be the establishment of a chemoattractant
gradient, and further studies investigating the potential effects of steroids in
inflammation should certainly include Boyden chamber-type studies, where the
migration of MDMO towards different chemokines can be investigated.
Unfortunately, experiments to test chemokine guided migration failed to demonstrate
polarisation or migration of MDMO in response to the chemokine over and above
that seen for PBS.
Summary
The process of migration is highly complex, with many pathways integrating both
temporally and spatially. Given the protein changes detected in the Dex-treated
MDMO it is of little surprise that these cells exhibit an altered migratory phenotype.
The protein changes, and the potential consequences for signalling pathways and the
migratory phenotype in the Dex-treated MDMO have been summarised in Figure
5.12. The cells
seem capable of forming a transient lamellipodia, although this appears not to be
stabilised by adhesions. The leading edge contains F-actin rich ruffles, not detected
in control MDMO, and these may play an important role in migration. The small
numbers of adhesions present in the migratory Dex-treated MDMO may result from
a combination of losses of proteins required for, or involved in, podosome formation
(pl30 Cas, pyk2, paxillin phosphorylation, microtubule network and Rac). Together
with the rapid detachment of the retracting tail, most probably as a result of increased
pl60ROCK, this may aid the initial rapid migration seen in the Dex-treated MDMO.
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CHAPTER 6: THE EFFECT OF THE CYTOKINE
ENVIRONMENT ON GLUCOCORTICOID-TREATED MDMtj)
Introduction
Inflammation, and its resolution, is controlled by a family of 14-26 kDa polypeptides
called cytokines. The process of inflammation requires tight control, from allowing
responses that promote inflammation and cellular activation to ridding the tissue of
the pathogen, followed by the dampening down and healing phase. Cytokines act as
protein signalling molecules, allowing for temporal and functional control of
inflammatory cells. For example, the function of macrophages, as they differentiate
from infdtrating monocytes, is determined by the cytokine micro-environment within
the tissue. The resulting phenotype and function of macrophages exposed to either
pro- or anti-inflammatory cytokines is an area of active research, as therapeutic
manipulation may offer approaches to treating inflammatory disease (Dries and
Perry, 2002). Much like the cytokine-controlled development of the Thl and Th2
subsets of Th lymphocytes, macrophages too have been subdivided into classically
(caMO) and alternatively (aaMO) activated categories owing to contrasting
differentiation in the presence of different cytokines.
The development of the caMO phenotype is mediated by pro-inflammatory agents
such as LPS and the Thl cytokines IFN-y and TNF-a (Mosser, 2003). These cells
have defined surface profile and cellular functions. caMO function to phagocytose
and subsequently destroy pathogens. To this end it has been shown that caMO and
monocytes have upregulated FcRl and 2, and demonstrate an augmented FcR
mediated uptake (Becker and Daniel, 1990). In mouse, the caMO have an enhanced
production of nitric oxide (NO) following up-regulation of the enzyme inducible NO
Synthase (iNOS) by IFN-y, enabling increased production of NO from its substrate
L-arginine (Hesse et ah, 2001; Munder et ah, 1998). Together with production and
release of O2" and nutrient restriction, the ingested pathogen is destroyed.
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An up-regulation of all three MHC class II molecules, HLA-DR, HLA-DQ and
HLA-DP (Becker and Daniel, 1990; Cao et al., 1989) is induced on the caMO cell
surface, and, as a result of the increased expression of the MHC class II molecules,
caMO are more efficient at antigen presentation (Becker, 1985). The caMO up-
regulates inflammatory cytokine production e.g. TNF-a, IL-12, IL-1 and IL-6
(Cheung et al., 1990; Donnelly et al., 1990), and together these cytokines play their
part in the recruitment and polarisation of leukocytes during the inflammatory
response.
The effect of IL-4 on the differentiation and maturation of macrophages was
originally thought to be a 'deactivation' signal. IL-4 treatment does indeed appear to
be antagonistic in its effects on macrophage phenotype and function when compared
to IFN-y-induced caMO. IL-4 inhibits the secretion of pro-inflammatory cytokines
such as IL-1, TNF-a, and IL-8 from monocytes and macrophages (Donnelly et al.,
1990; Hart et al., 1989; te Velde et al., 1988), synergising with glucocorticoids in this
effect. In addition, the aaMO up-regulate secretion of anti-inflammatory cytokines
such as IL-10 and IL-1 receptor antagonist (Fenton et al., 1992; Mantovani et al.,
2002).
The idea that these cells are not simply deactivated in comparison to IFN-y
macrophages, but differentially activated, was championed by Gordon and
colleagues (Gordon, 2003; Stein et al., 1992). They demonstrated that the mannose
receptor, an endocytic receptor binding to mannosylated proteins known to be down-
regulated by IFN-y, was strongly induced by IL-4 and to a lesser extent by
glucocorticoids. They proposed that the mannose receptor was a marker of an
'alternatively activated' population of cells.
More recently, studies have shown the aaMO to have increased expression of a broad
repertoire of receptors important for innate immunity, such as the mannose receptor
(Stein et al., 1992), the P-glucan receptor and the scavenger receptor 1 (Gratchev et
al., 2001b). Despite this apparent capacity for phagocytosis of pathogen, the aaMO is
ill-equipped to kill ingested pathogens. The production of NO in the IL-4 induced
macrophages is reduced in favour of L-ornithine and urea expression (Modolell et
al., 1995). IL-4 causes increased expression of the enzyme arginase which competes
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for the substrate L-arginine with the NO synthases (Munder et ah, 1998; Noel et al.,
2004). Since L-ornithine is a key metabolite in polyamine and proline production,
required for cellular proliferation and collagen production respectively, the switch in
this pathway may be important in inflammatory resolution (Hesse et ah, 2001). In
addition, and in contrast to caMO, these macrophages only express the low-affinity
Fee receptor, with none of the Fey receptors found on their cell surface (Becker and
Daniel, 1990).
Like caMO, the aaMO have up-regulated expression of MHC class II molecules,
although in the case of aaMO this is restricted to a subset of cells and is only seen
with the antigens HLA-DR and HLA-DP (Cao et ah, 1989; Gerrard et ah, 1990).
Human MDMO cultured in the presence of IL-4 up-regulate the ECM proteins
fibronectin and pIG-H3 (a supposed ECM protein due to a secretory domain and
integrin recognition site) (Gratchev et ah, 2001a).
The literature has expanded the term aaMO to include those that have become
activated following exposure to the Th2 cytokines IL-4, IL-13 and IL-10, as well as
to glucocorticoids and TGF-P (Goerdt and Orfanos, 1999; Stein et ah, 1992).
Glucocorticoids have also been shown to suppress the production of pro¬
inflammatory cytokines (Agarwal and Marshall, 2001; Hart et ah, 1990), and to
induce CD 163, the haemoglobin scavenger receptor and receptor for activated
endothelium, that is used as a marker of alternative activation (Hogger et ah, 1998).
In contrast to IL-4, glucocorticoids suppressed expression of ECM proteins such as
PIG-H3 and fibronectin (Gratchev et ah, 2001 a), in agreement with suggestions that
glucocorticoids inhibit wound healing (Anstead, 1998; Barba et ah, 2000; Durmus et
ah, 2003b).
Whilst the up-regulation of receptors which have broad specificity for foreign
antigen, and the lack of functional ability to breakdown and kill pathogen may be at
odds, aaMO do express receptors suggesting they are capable of functional antigen
presentation. Therefore, they may be important in controlling differentiation of nai've
T cells towards a Th2 phenotype, perhaps in contrast to the potential differentiation
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of Thl cells by the caMO. Functionally, the aaMO are implicated in the later phases
of inflammation, in angiogenesis (Kodelja et ah, 1997), ECM deposition and wound
healing and the down-regulation of inflammation (Gratchev et ah, 2001b). This
suggestion is supported by the fact that these cells are found during the healing phase
of inflammatory reactions (Djemadji-Oudjiel et ah, 1996). In addition, however,
there is also evidence that aaMO are involved in Th2 cytokine-controlled
inflammatory diseases such as asthma and parasite infections (Noel et ah, 2004).
Futhermore, monocytes associated with tumours acquire an aaMO profde
(Mantovani et ah, 2002).
The definition of the caMO and the aaMO, two macrophage phenotypes that seem
suited to roles in early inflammation and the later resolution / healing phases
respectively, present two extremes of what must be a spectrum of phenotypes. The
current challenge is to begin to understand the effect of combinations of cytokines on
macrophage function which would match the complex micro-environment into which
the infiltrating monocytes migrate and differentiate.
In this chapter, the role of the cytokine environment on macrophage function will be
examined. IFN-y and IL-4 were chosen as representative Th 1 and Th2 cytokines
respectively, and studies examining the effects of these cytokines in combination
with Dex, upon macrophage adhesion, phagocytosis of apoptotic cells, expression of
surface receptors and cytokine production will be presented.
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Results
IFN-y suppresses glucocorticoid augmented phagocytosis of apoptotic
neutrophils
The observed in vitro augmentation of human MDMO phagocytosis by Dex
represents a mechanism by which apoptotic neutrophils may be rapidly cleared from
the inflammatory site. However, in vivo, macrophages would also be subject to the
cytokine environment at the inflammatory site, and I wished to examine the effect of
this on the phagocytic capacity of MDMO. I therefore compared the effects of Dex
with the Thl cytokine IFN-y and the Th2 cytokine IL-4 in single and combination
treatments on MDMO phagocytosis of apoptotic neutrophils (Figure 6.1).
In accordance with previous results (Giles et al., 2001; Liu et al., 1999) 5 day
treatment with Dex resulted in an augmentation in phagocytosis. Treatment with IL-4
alone inhibited phagocytosis below that observed in the control MDMO population,
whereas IFN-y alone had little effect over and above that seen in the control MDMO
population. Combination treatments of IL-4 and Dex resulted in a population of
MDMO with a reduction in phagocytic ability when compared to Dex treatment
alone. Most strikingly, combination treatment of Dex and IFN-y resulted in a
significant suppression of phagocytosis when compared to Dex treatment alone.
These results indicate that the presence of the pro-inflammatory cytokine IFN-y,
during the differentiation process from peripheral blood monocyte to macrophage,
suppresses the augmentation of apoptotic cell phagocytosis and hence any potential



























Figure 6.1 The effect of cytokines on MDMO phagocytosis of apoptotic neutrophils
Adherent periperhal blood monocytes were cultured for 5 days in the
presence of combinations of !25nM Dex, lOng/ml IL-4 and lOng/ml IFN-y. Phagocytic
capacity of the MDMO was determined in a l hour assay and analysed by flow cytometry.
Data shown as mean percentage phagocytosis ± SEM for 5 separate experiments.
* p<0.05, ** p<0.0l, *** p<0.00l vs. Dex-treated MDM<F, Tukey Kramer repeated
ANOVA with post tests performed on transformed data.
Checkerboards of treatments
Having established that co-culture of MDMO with either IL-4 and Dex or IFN-y and
Dex failed to augment phagocytosis of apoptotic neutrophils, I was interested in
establishing whether the cytokines were capable of inhibiting the phagocytosis either
before or after Dex treatment. Peripheral blood monocytes were treated for the first
24 hours in either control conditions, Dex or IL-4. They were then washed and
cultured in the second condition for a further 4 days. As shown in Figure 6.2A, IL-4
treatment can be administered within the first 24 hours and then removed, resulting
in the inhibition of phagocytic ability. IL-4 could also just be administered in the last
4 days of culture, and again phagocytosis was inhibited. This data suggests that the
cells remain susceptible to IL-4 at different points during differentiation with Dex.
The IL-4 checkerboard treatments demonstrate a trend showing IL-4 inhibition of
Dex-augmented phagocytosis irrespective of whether the MDMO were exposed to
IL-4 before or after Dex. More experiments are required to verify if this is a
significant down-regulation.
Data from the IFN-y checkerboard (Figure 6.2B) demonstrated a significant increase
in phagocytic ability of the cells exposed to Dex for the first 24 hours of culture only
when compared with control MDMO. In accordance with data presented in Figure
6.1, IFN-y had no effect on phagocytosis when compared to control MDMO and this
held true whether the IFN-y was administered for the first 24 hours only or for the
last 4 days only. Interestingly, the inhibition of Dex augmented phagocytosis by IFN-
y observed in Figure 6.1 was also seen when the cells were pre-exposed to IFN-y
before Dex, or vice versa, with 24 hours Dex treatment followed by 4 days of IFN-y
treatment. This data demonstrated that IFN-y treatment both blocks and reverses Dex


























<v Od> 0*V o
/ v<?
&Sj
Figure 6.2 Checkerboards of treatments with Dex and IL-4/IFN-y
Adherent monocytes were cultured for the first 24 hours in Iscove's DMEM
containing 10% AS alone, Dex, IL-4 (A) or IFN-y (B). Cells were washed and then
treated for the remaining 4 days in Iscove's DMEM containing 10% AS, Dex, IL-4
(A) or IFN-y (B) to give a checkerboard of combination treatments (24 hours/4
days). The phagocytic ability of the MDMO populations was then determined by
flow cytometry. Results are shown as mean percentage of macrophage phagocytosis
± SEM from 3 separate experiments.
* p<0.05, ** p<0.01, *** p<0.001 represented as * vs. Con/Dex; A vs. Dex/Con; □
vs. Con/Con, Tukey Kramer repeated ANOVA with post tests performed on trans¬
formed data.
Time-course of IFN-y effect on Dex phagocytosis
The inhibitory effect of IFN-y upon Dex-augmented phagocytosis was further
examined to investigate the temporal nature of the effect of IFN-y (Figure 6.3).
Peripheral blood monocytes were differentiated for 6 days in the presence of Iscove's
+ 10% AS (control) with the addition of 125nM Dex or lOng/ml IFN-y. For the time-
course, the macrophages were differentiated in 125nM Dex for all 6 days, with IFN-y
added into the medium on day 1, 3, or 1 or 3 hours prior to the phagocytosis assay on
day 6. The data demonstrates that the degree of inhibition observed, following
exposure to IFN-y, was directly related to the length of time of exposure. The
addition of IFN-y for a few hours prior to the phagocytosis assay had no inhibitory
effect upon the augmented phagocytosis. Therefore, to observe the full inhibitory
potential of IFN-y on the augmentation of phagocytosis induced by Dex, the MDMO
required prolonged exposure to the IFN-y.
Surface phenotype changes induced by IL-4 or IFN-y are altered by Dex
CD64 is the receptor for FcyRI, the high affinity receptor for IgG, and as such
functions to clear immune complexes as well as playing a role in antibody-dependent
cytotoxicity. CD64 has previously been shown to be up-regulated following
treatment with IFN-y (Becker and Daniel, 1990). The data presented in Figure 6.4
also shows an up-regulation in mean fluorescence of CD64 on MDMO that had
differentiated in the presence of IFN-y. IL-4 treatment resulted in the down-
regulation of CD64 from the surface of MDMO, and this was also seen, albeit to a
smaller degree, in the Dex-treated MDMO. Combination treatments of IFN-y and
Dex failed to inhibit the IFN-y up-regulation, demonstrating that Dex was unable to
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Figure 6.3 A time-course of IFNy treatment on Dex treated MDMO
Adherent monocytes were cultured in Iscove's DMDM containing 10% autologous
serum and 125nM Dex, with the subsequent addition of IFN-y on days 1 or 3, or 1 or
3 hours prior to the phagocytosis assay on day 6.
The phagocytic ability of the MDMO populations was then determined by flow
cytometry. Results are shown as mean percentage of macrophage phagocytosis ±
SEM from 3 separate experiments. * p<0.05 vs. Con values, Tukey Kramer repeated
ANOVA with post tests performed on transformed data.
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Figure 6.4 Surface phenotyping of 5 day MDMO treated with Dex and cyto-
kines
Adherent periperhal blood monocytes were cultured for 5 days in the combina¬
tions of !25nM Dex, lOng/ml IL-4 and lOng/ml IFN-y. Surface expression of
CD64 (n=3), HLA-DR (n=6), CD86 (n=6), CD 14 (n=5) and CD 163 (n=6) was
then examined by flow cytometry. Data shown are mean fluorescence, corrected
for isotype control fluorescence ± SEM.
The expression of MHC Class II - HLA-DR, a marker of antigen presentation, which
has previously been reported to be up-regulated on human monocytes by both IL-4
and IFN-y (Donnelly et al., 1990) was examined next. Accordingly, HLA-DR up-
regulation was observed following treatment with either IL-4 or IFN-y. Dex
treatment, however, led to a down-regulated surface expression of DR, and
combination treatments of IL-4 or IFN-y with Dex resulted in intermediate
expression levels, between those seen in Dex cells and IL-4 or IFN-y.
With respect to control, untreated MDMO, expression of the co-stimulatory
molecule, CD86, was induced by IL-4 whereas IFN-y had no effect. Dex treatment
resulted in a small down regulation in expression and was dominant over both IL-4
and IFN-y in combination treatments.
CD 14 expression was slightly down-regulated upon Dex treatment, and dramatically
so following IL-4 treatment. Combination treatment of IL-4 and Dex resulted in a
fluorescence of intermediate levels, providing evidence for Dex being dominant over
IL-4. IFN-y treatment slightly down-regulated CD 14 expression, matching the levels
observed following Dex-treatment.
Finally, levels of the haemoglobin scavenger receptor CD 163, a marker of alternative
activation, were examined. The data presented here showed no change in expression
in Dex cells compared to control untreated MDMO. Previously published results
report that Dex up-regulates CD 163 on the surface of macrophages (Schaer et al.,
2002). Although the low levels of expression suggest that the antibody may not have
been binding effectively to the MDMO, both IL-4 and IFN-y down-regulated
expression, and the presence of Dex prevented down-regulation in co-incubations of
IL-4 or IFN-y and Dex.
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Production of pro-inflammatory cytokines is inhibited in the presence
of Dex
Studies have previously demonstrated that IFN-y treatment of macrophages results in
the secretion of pro-inflammatory cytokines, and that IL-4 treatment inhibits this
(Donnelly et al., 1990). I set out to investigate the effect of Dex alone or in
combination with either IFN-y or IL-4 on cytokine production (see Figure 6.5).
Following 5 day culture the media from MDMO treated with 10% AS alone, or in
the presence of 125nM Dex ± lOng/ml IL-4 or IFN-y was collected. The media was
spun down to remove any debris and stored at -80°C until the assay was run. 6
cytokine levels were recorded for each sample using the BD cytometric bead array
kit, as described in the Materials and Methods section. Cytokine standards were used
to form a concentration curve for each cytokine.
IL-12p70 levels were low in all samples, with control MDMO supernatants
containing the highest concentration of all samples tested (12.6pg/ml± S.E 10.9).
Dex treatment resulted in a reduction in detected concentration (1.4+ 1.4) with
respect to control supernatants. Treatment with IL-4 or IFN-y also reduced IL-12
levels (4.2 and 6.4 respectively). Interestingly, combination treatments of IL-4 or
IFN-y with Dex slightly increased IL-12 levels above those seen in the single
treatments of the cytokines (6 and 8.9 respectively).
IL-1 levels in control MDMO supernatants were relatively high (119 + 38) and this
increased upon IFN-y treatment (715.9 ± 401.5) in accordance with previously
published results (Donnelly et al., 1990). IL-1 levels in the Dex-treated MDMO
samples were below the minimum detection level of the assay. IL-4 treatment
significantly reduced the levels of IL-1 detected compared with control MDMO, with
combination treatments of IL-4 or IFN-y and Dex also having IL-1 levels below that
of the control MDMO. The data from these experiments demonstrates a differential
effect of IFN-y and IL-4 on pro-inflammatory cytokine production, consistent with
the caMO/aaMO dogma. These results also demonstrate that Dex reduced pro¬


























































































Figure 6.5 Cytokine production by 5 day MDMQ treated with Dex ± cytokines
Supernatents were collected from the media of 5 day MDM®, differentiated from
periperhal blood monocytes in combinations of 125nM Dex, lOng/ml IL4 and
lOng/ml IFNy. The level of cytokines were detected using the BD Cytokine Bead
Array as detailed in the Methods and Materials section. Results shown are the mean
concentrations ± SEM, (n=3).
* p<0.05, ** p<0.01, *** pO.OOl vs. IFN-y MDMO, Tukey Kramer repeated ANOVA
with post tests performed on transformed data.
TNF-a levels were only up-regulated above control levels in the IFN-y supernatants
(5.4 ± 5.4 in control to 48.7 ± 7.6 in IFN-y). No TNF-a was detected in either the
Dex, IL-4 or IL-4 + Dex treated cell supernatants.
Interestingly, combinatorial treatment of IFN-y and Dex resulted in a significant
reduction in TNF-a levels (5 ± 3), demonstrating the dominant effect of Dex over
IFN-y in the secretion of TNF-a from macrophages.
IL-6 levels were high in the control supernatant, and these were significantly reduced
by treatment with Dex (2053.7 ± 1127.6 to 499.1 ± 465). Levels in the IL-4
supernatants were lower than Dex or control, and a synergistic effect was seen when
Dex and IL-4 are used in combination, significantly lowering the levels (60.3 ±41).
IFN-y treatment led to a large increase in IL-6 production (7044 ± 2955) when
compared to control macrophages. The combination of Dex and IFN-y reduced
production of the cytokine (1682 ±816), again demonstrating a dominant effect of
Dex over IFN-y.
IL-10 levels were low in all samples, with no significant changes seen between the
different conditions. Whilst, the lowest levels of IL-10 were recorded in the Dex
samples. Combination treatment of Dex and IFN-y did not decrease the concentration
below that detected in the IFN-y only sample.
Of all cytokines analysed, IL-8 levels were detected at the highest concentration. In
control, IFN-y and IFN-y ± Dex samples, the concentration was above the maximum
detectable, so although there may well be differences between these samples, in these
experiments the assay was unable to differentiate between them.
Dex alone and IL-4 alone resulted in a lower concentration than the control sample,
and combination treatments of IL-4 and Dex further lowered this.
In summary, the cytokines present at the highest concentrations were the pro¬
inflammatory cytokines IL-8, IL-1 and IL-6. In the case of all but IL-8, where the
levels were above the upper limit of detection, IFN-y induced secretion of the pro¬
inflammatory cytokines TNF-a, IL-6 and IL-1. Combination treatment of Dex and
IFN-y reduced the concentrations of these cytokines, demonstrating a dominant
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effect of Dex over IFN-y. Examination of the cytokines IL-12 and IL-10 showed that
the concentration in the IFN-y + Dex sample was not reduced below that measured
for IFN-y alone, suggesting that the IFN-y is dominant in these cases.
Morphological change induced by IL-4 and IFN-y are overridden by Dex
Figure 6.6 shows phase contrast light microscopy images of 5 day MDMO
differentiated from peripheral blood monocytes. (A) shows an image of control
MDMO. They formed a heterogeneous population of cells, with a mix of mono-
nucleated smaller cells and multinucleated giant cells. (C) shows an image of the IL-
4 population. Clumps of cells, such as those seen in the upper left corner of the
picture, were seen throughout the wells of IF-4 differentiated cells. Between the cell
clumps, single cells were observed, often with a polarised morphology, such as is
seen in IF-4/GMCSF induced-dendritic cell populations. (E) shows MDMO
differentiated in the presence of IFN-y for 5 days. IFN-y induced the formation of
multinucleated giant cells, which were seen in high numbers throughout the wells.
(B) shows the Dex-treated MDMO s. They formed a homogeneous population of
small and round cells which were observed by SEM to be more raised than the
'flatter' control MDMO. The IL-4 Dex and IFN-y Dex MDMO both shared the same




Figure 6.6 Phase contrast images of 5 day MDMO cultured in the presence of Dex ±
IL-4 or IFN-v
Adherent peripheral blood monocytes were cultured for 5 days in the 10% AS alone,
or with the addition of Dex ± IL-4 or IFN-y. Representative images are shown, (A)
control MDMO, (B) Dex MDMO, (C) IL-4 MDMO, (D) IL-4+Dex MDMO, (E) IFN-
y MDMO and (F) IFN-y+Dex MDMO. Images were viewed using a xlO objective
lens.
Dex is dominant over cytokines in adhesion status
Regions of adhesion found in macrophages are points of contact between the cell and
underlying extracellular matrix. The podosomes-like adhesions can be visualised by
immunofluorescence staining against F-actin and paxillin. F-actin is present as
punctate regions at points of adhesion and are surrounded by several interacting
proteins including paxillin and vinculin. In Figure 6.7, the podosomes are seen as red
dots of F-actin surrounded by green rings of paxillin.
Control MDMO, as seen in Figure 6.7(A), were strongly adherent to tissue culture
plastic and formed a large numbers of podosomes. In the multinucleated giant cells
which formed part of the heterogeneous population seen in the control MDMO, the
podosomes were seen as a cortical ring around the edge of the cell.
IL-4 induced a population of MDMO which included polarised MDMO, as seen in
Figure 6.7(C). The IL-4 MDMO contained a high number of podosomes and this was
reflected in their strong adherence to the tissue culture plates. IFN-y (Figure 6.7E)
induced giant cell formation and, as in the control MDMO, the podosomes were seen
in a cortical ring around the edge of the cell.
Figure 6.7(B), (D) and (F) represent paxillin and F-actin staining in Dex, IL-4/Dex
and IFN-y/Dex MDMO respectively. The MDMO had no clear podosomes and the
F-actin was present mainly around the edge of the cell or in ruffles. The F-actin was
often coincident with paxillin (see regions of orange staining), although the paxillin
appeared as a diffuse stain throughout the cells. Dex was dominant over IL-4 and
IFN-y in inhibiting the formation of organised podosomes in the MDMO. This was
reflected in the poor adherence of these cells to tissue culture plastic.
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Figure 6.7 Images of podosome adhesions in 5 day MDM®
Adherent peripheral blood monocytes were cultured for 5 days in 10
% AS (control) or with the addition of Dex ± IL-4 and IFN-y. Podo-
somes were visualised by staining with F-actin (red) and paxillin
(green). Image (A) control, (B) Dex, (C) IL-4, (D) IL-4+Dex, (E)
IFN-y and (F) IFN-y+Dex MDM®. Images were visualised with x63
objective lens. Control, IL-4 and IFN-y MDM® all contain podo-
somes, seen as punctate actin surrounded by ring of paxillin staining,
which are absent in Dex and IL-4/IFN-y + Dex MDM®.
IL-10 augments phagocytosis of apoptotic neutrophils by MDM<D
Adherent peripheral blood monocytes were cultured in the presence of recombinant
human IL-10, 1 pM Dex or combinations of the two for 5 days.
The phagocytic ability of the resulting populations of macrophages was assessed by
flow cytometry following a 1 hour assay. Figure 6.8 demonstrates that IL-10
significantly augmented the phagocytic ability of the macrophages in a concentration
dependent manner. I was unable to fully assess whether the mechanism of IL-10
augmented phagocytosis was the same as that utilised by Dex, because anti-IL-10
receptor antibodies failed to inhibit IL-10 augmented phagocytosis. However, IL-10
was not detected in the supernatants of Dex treated macrophages following
phagocytosis of apoptotic neutrophils (data not shown). This suggests that IL-10 is
not secreted in response to Dex treatment and therefore does not act in an autocrine
or paracrine fashion to stimulate phagocytosis of Dex-treated MDMO. Co-culture of
the MDMO with Dex and IL-10 further augmented the IL-10-induced phagocytosis.
It would be expected that we would observe an additive effect upon IL-10-
augmented phagocytosis if the mechanism of Dex was independent. However,
although the levels of phagocytosis observed following treatment with Dex + IL-10
were higher than with IL-10 alone, the level of phagocytosis was lower than with
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Figure 6.8 IL-10 induced augmentation of MDMO phagocytosis of apoptotic
neutrophils
Adherent peripheral blood monocytes were cultured for 5 days in the presence
of IL-10 or lpM Dex. Phagocytic ability of the MDMO was assessed by flow
cytometry. Data is shown as mean percentage phagocytosis ± SEM for 3
separate experiments (IL-10 + Dex n=2).
* p<0.05, ** p<0.01, *** p<0.001 vs. control MDM<I>, Tukey Kramer ANOVA
with post tests performed on transformed data.
Discussion
IFN-y inhibits the GC-augmented phagocytosis of apoptotic neutrophils
One important finding reported in this chapter is that low levels of IFN-y (lOng/ml)
are able to inhibit the augmentation of phagocytosis induced by physiologically
relevant levels of Dex (125nM). My data showed that IFN-y was able to both block
and reverse the pro-phagocytic phenotype within the first 24 hours of differentiation
from peripheral blood monocyte to macrophage. The time-course data demonstrated
that short-term culture with IFN-y following the differentiation of 5 day Dex-treated
MDMO failed to inhibit phagocytosis, but that when IFN-y was included from early
time points the augmented phagocytosis was inhibited. There could be two
explanations for this; firstly, that the cells are only 'open' to IFN-y inhibition of Dex-
induced functional alterations during the early stages of differentiation or,
alternatively, that following prolonged exposure to IFN-y, MDMO were more
sensitive to inhibition.
The observed inhibition of GC-induced phagocytosis by IFN-y, together with
previous studies which have shown Dex inhibition of IFN-y signalling (Hu et al.,
2003) suggests that IFN-y and Dex may have a reciprocal ability to inhibit each
other. Glucocorticoids signal via the glucocorticoid receptor and regulate the NFkB
and AP-1 transcription factors as discussed in detail in Chapter 3, leading to the
suppression of pro-inflammatory gene transcription such as the cytokines IL-8 and
IL-6 (Wilckens and De Rijk, 1997). IFN-y signalling occurs by ligand binding to the
ubiquitously expressed IFN-y receptor which activates the Janus Kinase (JAK) 1 and
2. These tyrosine kinases then activate the transcription factor STAT1, shown to be
responsible for the majority, but not all of, IFN-y signalling (Stark et al., 1998).
Previous investigations have demonstrated an interaction between GCs and
components of the IFN-y pathways, which have resulted in both attenuation and
inhibition of the IFN-y signal (Celeda et al., 1993; Girard et al., 1987; Stocklin et al.,
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1996). GCs have been shown to interact with Jak-STAT signalling both directly, for
example by GR binding to STAT-5 (Stocklin et ah, 1996), and indirectly by
regulating gene expression of STAT-1 in peripheral blood macrophages (Hu et ah,
2003). Although outside the remit of this work, it would be of interest to investigate
how IFN-y signalling interferes and inhibits Dex-mediated functional changes in
MDMO. It appears that early exposure of Dex-treated MDMO to IFN-y is required to
inhibit the Dex-induced phagocytic capacity, and this may suggest that IFN-y acts to
modify the Dex-induced differentiation pathway. As discussed, one of the major
mechanisms of GC action is the alteration of inflammatory gene transcription
(Barnes, 1998). IFN-y inhibition of Dex-augmented MDMO phagocytosis could
therefore be examined using a gene array to compare gene expression between Dex-
treated and IFN-y + Dex-treated MDMO. This may allow identification of genes
important for phagocytosis which are altered by IFN-y. However, IFN-y signalling
components such as JAK1, JAK2 or STAT 1 (Aaronson and Horvath, 2002) may
interact with GC signalling molecules such as the GR, inhibiting GC-mediated
effects. This could be tested by investigating whether there is increased binding
between IFN-y signalling components and GC signalling components.
GC inhibition of IFN-y signalling via a reduction in STAT-1 protein levels and
phosphorylation in human MDMO was shown to be dependent on lymphocyte co-
culture and required 24 hours exposure to Dex prior to IFN-y exposure to take effect
(Hu et ah, 2003). The authors proposed that Dex suppressed monocyte-lymphocyte
interactions, leading to low levels of IFN-y secretion by the lymphocytes which in
turn suppressed STAT-1 production by the monocytes, rendering them less
responsive to future IFN-y signalling. Interestingly, my experiments showing that
IFN-y suppressed Dex-treated MDMO phagocytosis were carried out in the presence
of lymphocytes, although a requirement for co-culture for IFN-y inhibition of Dex-
augmented phagocytosis was not tested. If the presence of Dex reduces monocyte-
lymphocyte interactions, then my data would suggest that this interaction is not
necessary for IFN-y inhibition of Dex-augmented phagocytosis. The described
indirect effect of GC inhibition of IFN-y signalling (Hu et ah, 2003) is therefore
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unlikely to be significant in helping unravel the mechanism of IFN-y inhibition of
Dex-mediated phagocytosis.
A study by Lucas and colleagues used the WEHI-3 and RAW 264.7 macrophage cell
lines to approximate an early and late stage of macrophage differentiation
respectively, as a means of investigating IFN-y signalling during macrophage
differentiation. They demonstrated that, despite known components of the IFN-y
pathway being present in both cell lines, STAT-1 failed to be tyrosine
phosphorylated in the WEHI-3 cells (Lucas et al., 1998). Results presented here
demonstrate that IFN-y was able to inhibit Dex-augmented phagocytosis only when it
was added for the first 24 hours of culture, i.e. to monocytes only, suggesting that
STAT-1 phosphorylation does occur in human peripheral blood monocytes.
However, this would require experiments to demonstrate that IFN-y signals via
STAT-1 in MDMO. If IFN-y signalling pathways are rapidly up-regulated in MDMO
during differentiation, addition of IFN-y after only a few hours would be predicted to
inhibit Dex-augmented phagocytosis.
The effects of Dex and IFN-y upon induction of non-phagocytic
functions
Further examination of the effect of IFN-y on Dex mediated changes revealed that
Dex is dominant over IFN-y in inducing morphological changes, adhesion status and
in inhibiting the secretion of pro-inflammatory cytokines.
Dex induced expression levels of CD86, DR and CD 14 were all retained in the IFN-
y/Dex co-cultures, with IFN-y only dominant in attenuating levels of CD64.
Interestingly, expression levels of the phagocytic receptor CD 14 showed no
correlation with the increased phagocytic ability observed in Dex-treated MDMO.
Although this may suggest that CD 14 is not a likely candidate in Dex-augmented
phagocytosis, the data does not exclude a role for CD 14 in apoptotic cell recognition,
as receptor expression does not necessarily equate to receptor function.
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The dominance of Dex over IFN-y in inhibiting the secretion of pro-inflammatory
cytokines suggests that either during a switch from initial inflammatory responses to
resolution of inflammation, where a tissue environment containing a mix of GC and
IFN-y might be envisaged, or following the administration of steroid drugs during a
chronic inflammation, GCs may dampen down pro-inflammatory responses. The
change in cytokine profde would then impact on future inflammatory events, such as
the differentiation of infdtrating monocytes and leukocyte migration.
IL-4 and Dex induce macrophages with distinct functions
MDMO differentiated in the presence of either IL-4 or IFN-y, in contrast to the Dex-
treated MDMO, were poor at phagocytosing apoptotic neutrophils. The differential
effect of IL-4 and Dex on this important macrophage function adds further weight to
published evidence for diverse roles for these two populations of macrophages, that
have been simply labelled as aaMO in many reviews and papers (Goerdt and
Orfanos, 1999; Schebesch et al., 1997) (Mosser, 2003). Dex-macrophages have been
shown to be divergent from IL-4 macrophages in some functions, e.g. ECM
deposition (Gratchev et al., 2001a), and data presented here re-enforces this idea with
incongruent levels of expression of FILA-DR, CD86 and CD 14 between IL-4 and
Dex-treated MDMO. The data endorses the previously described involvement of the
IL-4 MDMO in the later phases of inflammation, in antigen presentation and
differentiation of naive Th cells towards a Th2 population, as well as a clear role in
the healing of damaged tissue and angiogenesis. However, my data also suggest a re¬
definition of the role played by Dex-macrophages; they may be intimately involved
in the resolution stage of inflammation, clearing apoptotic neutrophils and
dampening the pro-inflammatory cytokine environment in preparation for healing of
damaged tissue. Dex MDMO are not, however, equipped with surface receptors that
would make them efficient antigen presenting cells.
The term 'alternatively activated', originally intended to demonstrate the point that
IL-4 differentiated macrophages are not simply a deactivated cell, but have an
alternative function to the classically activated macrophage, has come to include
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macrophages treated with the Th2 cytokines IL-10, IL-13 as well as glucocorticoids
and TGF-p. The usefulness of this categorisation is waning as the complexity of
different macrophage phenotypes involved in inflammation becomes clearer. So,
although both the IL-4- and Dex-macrophages could be generally described as 'pro¬
inflammatory resolution' macrophages they have different roles and possibly utilise
divergent pathways (Gratchev et ah, 2001a). It is important to appreciate that the
examples of IFN-y induced caMO and the IL-4 induced aaMO represent two
extremes of what will be a continuum of phenotypes within an inflammatory site,
where a complex mix of cytokines exists. The interplay between cytokines will be an
important determinant of inflammatory outcome. Interestingly, Erwig and
colleagues, using uncommitted rat BMDMO, showed that the initial cytokine
exposure determined the function of the BMDMO, and that they became
unresponsive to subsequent exposure to alternative activating signals (Erwig et ah,
1998). The in vivo implications would be that, for MDMO at least, the current
cytokine environment governs the differentiation and therefore the subsequent
function of the MDMO. My data would suggest that the initial exposure of cells to
either Dex or IFN-y does not determine function, as subsequent exposure to IFN-y or
Dex further modifies MDMO phagocytic ability. However, simultaneous exposure
of infiltrating monocytes to more than one cytokine may be expected to amplify
some responses and inhibit others, in line with the demonstration of a hierarchical
system of responses to some simultaneously expressed cytokines (Erwig et ah, 2003;
Wesemann and Benveniste, 2003).
Dex further increases IL-10 augmented phagocytosis
IL-10 significantly increased phagocytosis in MDMO when compared to the control
population. Levels of phagocytosis did not reach those observed in the Dex-treated
MDMO and this may reflect the induction of different pathways by IL-10 and Dex,
both resulting in augmented phagocytosis. There have been some reports suggesting
that Dex induces IL-10 secretion (Agarwal and Marshall, 1998; Mozo et ah, 2004),
and one possibility would be that the IL-10 was acting in an autocrine or paracrine
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manner, inducing phagocytosis in neighbouring cells. However, IL-10 levels in Dex-
treated MDMd> supernatants were lower than those observed in control MDM®
supernatants (Figure 6.5). In addition, the media of Dex MDMO following
phagocytosis of apoptotic cells did not show elevated IL-10 levels either (data not
shown). Furthermore, IL-10 and Dex co-cultured macrophages had a phagocytic
level above that seen with IL-10 only, but below that of the Dex-treated MDMO. It is
possible that Dex treatment may maximally stimulate phagocytosis and so further
increases in phagocytic ability would not be detected. However, levels of
phagocytosis were higher than in the IL-10 treated MDMO population and based
upon these data I would speculate that IL-10 and Dex induce phagocytosis by
separate mechanisms. The effect of Dex and IL-10 co-culture on phagocytosis of
apoptotic neutrophils over a range of concentrations may provide further insight.
Following the establishment of the concentration of IL-10 which resulted in 50%
maximal MDMO phagocytosis of apoptotic neutrophils (mid-concentration), Dex
could then be cross-titrated in, and vice versa, IL-10 could be cross titrated into the
mid-concentration of Dex. In addition, experiments to block the IL-10-induced
phagocytosis downstream from receptor/ligand binding would allow confirmation of
whether Dex was capable of inducing augmented phagocytosis.
A dissociation between adhesion and phagocytosis
The data presented in Figures 6.6 and 6.7 show the morphology and adhesion status
of the different MDMO populations. The three distinct phenotypes that were seen
following culture under control, IL-4 or IFN-y conditions were all over-ridden in the
presence of Dex in co-cultures, with all containing a homogeneous population of
small and rounded MDMO, which were only weakly adherent to the tissue culture
plastic. The presence of Dex was shown in Figure 6.5 to result in a down-regulation
in the secretion of pro-inflammatory cytokines, which may have prevented autocrine
and paracrine regulation of IL-4 and IFN-y induced morphologies in the co-cultures.
The dominance of Dex over the cytokines seen in the induction of adhesion
processes was also observed in the adhesion structures. The distinct podosomes
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structures that were present in the control, IL-4 and IFN-y cultures were lost in the
Dex ± IL-4 or IFN-y cultures. It has previously been suggested that adhesion and
phagocytosis may be related (McCutcheon et al., 1998), with the two processes
linked by shared proteins, e.g. DOCK-180, Crk and Rac, which may cause one
function to limit use in the other. I therefore hypothesised that the altered adhesion
observed in Dex-treated MDM<)) may be linked to augmentation of phagocytic
capacity. However, despite a shared morphological appearance and adhesion status
of the Dex and IFN-y Dex macrophages, the IFN-y Dex cells do not retain the
phagocytic capacity of the Dex cells. These observations provide the first evidence
for a dissociation between adherence status and phagocytic capacity.
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Chapter 7: SUMMARY AND FUTURE DIRECTIONS
The main aim of this thesis was to examine the mechanisms by which
glucocorticoids (GCs) regulate MDMO phagocytosis of apoptotic neutrophils.
Breakdown of the normal regulation of cellular apoptotic programmes or in the
controlled removal of apoptotic cells is associated with inflammatory/autoimmune
disease (Botto, 1998; Haslett, 1997). For the successful resolution of inflammation,
the large scale induction of apoptosis in neutrophils recruited during an inflammatory
response must be paralleled by increased clearance of the apoptotic cells. Previous
work examining 5 day Dex-treatment of MDMO demonstrated an augmentation in
phagocytosis of apoptotic cells, associated with changes to the cytoskeleton and
adhesion status of the macrophage (Giles et al., 2001). The hypothesis generated
from this data was that adhesion and phagocytosis utilised many shared proteins and
that, following Dex-induced disruption of adhesive processes, proteins were utilised
in the process of phagocytosis. Data presented in this thesis both confirms and
extends these studies by describing further alterations to cytoskeletal arrangement in
Dex-treated MDMO. Importantly, this work also describes novel changes to
macrophage receptor-mediated binding of apoptotic cells following Dex treatment,
and an induction of PS recognition required for Dex-augmented internalisation of
apoptotic cells. Thus, data presented here shows that Dex-treatment results in the
promotion of multiple key stages in macrophage phagocytosis of apoptotic cells.
One of the major findings of this study was the resolution of a cation-independent
'tethering' step from a cation-dependent receptor-mediated engulfment step during
phagocytosis. Dissociation of binding from internalisation has been critical for
defining mechanisms of phagocytosis via other well characterised receptors, e.g. Fc
and complement (Allen and Aderem, 1996; Caron and Hall, 1998; Crowley et al.,
1997; Greenberg et al., 1993). For example, binding via FcR or CR does not require
an intact cytoskeleton, unlike internalisation, which requires Rho GTPase- and
Arp2/3- dependent actin polymerisation at the phagocytic cup (May et al., 2000).
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Thus, the dissection of apoptotic cell phagocytosis into distinct binding and
internalisation steps, may allow detailed examination of the processes involved.
The cation-independent binding may occur through an, as yet unidentified receptor,
in both the untreated and Dex-treated MDMO. However, Dex treatment was
demonstrated to augment this initial binding step (with a 14-fold increase in the
binding index) in a pH-dependent manner. The differential effect of pH on Dex-
treated, but not control MDMO binding, may be a result of the engagement of a
different receptor following Dex treatment, or it could be that Dex-treatment
modifies the MDMO cell surface, lowering electrostatic repulsion between the
MDMO and the apoptotic target cell. This suggestion is supported by a ~60%
inhibition in Dex-augmented phagocytosis following incubation with the amino
sugar, glucosamine (Giles et al., 2001). The inhibition of Dex-treated MDMO
binding of apoptotic neutrophils at low pH may have important physiological
consequences. Sites of chronic inflammation have been associated with a low tissue
pH (Haslett, 1999 and references therein), which may reduce the beneficial
augmentation in Dex-treated MDMO phagocytosis of apoptotic cells.
A key focus of any future studies would be the identification of the receptor(s)
involved in this 'binding' step. Binding studies using apoptotic cells, or macrophages
isolated from mice deficient in the putative recognition receptors (Botto, 1998; Piatt
et al., 1996), would represent one strategy for screening receptors involved.
Similarly, the use of blocking antibodies or ligands could be used in parallel to
identify candidate receptors (Brown et al., 2002; Chang et al., 1999; Fadok et al.,
1992b; Savill et al., 1992). Screening of large numbers of hybridomas, or
recombinant antibodies, may allow the identification of novel receptors that mediate
apoptotic cell binding (Flora and Gregory, 1994). Subsequent expression cloning
could be used to further characterise those molecules identified (Fadok et al., 2000).
Although the putative 'binding' receptor has been assumed to simply 'tether' the
apoptotic cell, it could act in concert with later recruited 'signalling' receptors, with
the combination dictating the anti-inflammatory cytokine synthesis associated with
apoptotic cell engulfment. Therefore, following the molecular characterisation of this
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receptor(s), its role as either a 'binding' receptor or in addition, as a 'signalling'
receptor for apoptotic cell internalisation, could then be determined. A successful
method employed by Akakure and colleagues was the transfection of the receptor of
interest into a phagocytic cell line (Akakura et ah, 2004). They transfected wildtype
(WT) or P5 integrin cytoplasmic tail mutant constructs (incapable of signalling), and
showed that phagocytosis was associated only with the WT construct. Further studies
included the co-transfection of |35 integrin constructs with reporter constructs for
signalling molecules of interest, and the demonstration of Rac-1 activation, following
over-expression or ligand activation of the WT (35 integrin construct (Akakura et ah,
2004).
In this thesis, the increased binding of apoptotic cells by Dex-treated MDMO was
shown to be paralleled by an increased cation-dependent engulfment, with the
engagement of a PS recognition mechanism in addition to a novel, as yet undefined
receptor mediated recognition mechanism utilised by the untreated MDMO. In
addition, GC treatment was demonstrated to result in key changes to cytoskeletal
regulation which resulted in altered adhesion, migration and phagocytosis. In terms
of phagocytosis, the observed increase in Rac-1 activity may be hypothesised to be
responsible for increased membrane extension required for an augmented engulfment
of apoptotic cells, although roles for other signalling proteins, e.g. Cdc42 and Rho,
remain to be investigated.
MDMO, matured in the presence of Dex, showed alterations in many of the key
stages involved in the phagocytosis process, and one interesting question stemming
from these studies is whether Dex-treatment augments all the processes described by
'switching on' a master switch, i.e. by altering expression of a protein or signalling
pathway(s) which regulate phagocytosis. Data presented in this thesis, demonstrated
that the phagocytic augmentation of apoptotic neutrophils only required the
transrepressor activity of Dex. Thus, by comparing signalling molecules or receptor
expression in MDMO treated with Dex (demonstrates transrepressor and
transactivator activity) or with a GC with only transrepressor activity, changes
critical to augmented phagocytosis could perhaps be identified.
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My studies have also highlighted the importance of careful phenotyping of the target
apoptotic cell used in a phagocytosis assay. Neutrophils induced to undergo
apoptosis using different methods, resulted in differential expression of PS and
potentially altered phagocytosis as a consequence. The percentage of necrotic cells
present within the target cell population is also an important consideration, since
phagocytosis of necrotic cells but not apoptotic cells has been reported to be
associated with pro-inflammatory effects (Fadok et al., 2001). The apoptotic and
necrotic neutrophils could potentially be internalised using different receptors, and
therefore trigger different signalling pathways, making interpretation of data
difficult.
I therefore sought to generate a homogeneous population of apoptotic cells as targets.
Induction of apoptosis by exposure of cells to ultraviolet light has been used in many
studies (Fadok et al., 1992b; Hoffmann et al., 2001; Ogden et al., 2001), but in my
experiments always induced a significant level of necrosis in neutrophil populations.
The initiation of apoptosis using TNF/gliotoxin resulted in a synchronous induction
of morphological-defined apoptosis in nearly 100% of the neutrophils. This was in
contrast to the overnight 'aging', where the neutrophils formed three populations;
non-apoptotic, apoptotic and necrotic cells, which were difficult to further purify. A
study by Ren and colleagues used plasma-Percoll discontinuous density gradient
centrifugation to purify Tate apoptotic' neutrophils (distinguished from 'early'
apoptotic neutrophils by the presence of nuclear degradation) from a mixed
population of'overnight' aged neutrophils (Ren et al., 2001). However, the 'early
apoptotic' neutrophils (annexin V positive, PI negative) were not able to be purified
from the viable neutrophils using this method. Following 'overnight aging',
apoptotic neutrophils have been positively sorted from viable neutrophils, using
annexin-V-biotin and streptavidin-conjugated paramagnetic beads, and cells
recovered in the absence of calcium (Brown et al., 2002). However, whilst this
method removes the viable neutrophils, the apoptotic and necrotic cells are still
mixed. Following 'overnight aging', I attempted to separate apoptotic neutrophils
from necrotic and viable neutrophils using flow cytometric cell sorting. Annexin V
and PI were used to distinguish between the three populations. Following the
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purification of the annexin V positive, PI negative neutrophils (a process that took
several hours in order to obtain numbers sufficient for subsequent phagocytosis
studies), the neutrophils were cultured for one hour at 37°C, 5% CO2, in order to
mimic culture conditions during a phagocytosis assay. The purified apoptotic
neutrophils were then analysed using annexin V and PI, but it was found that
approximately 60% of the apoptotic neutrophils had become necrotic, demonstrating
that this method was not suitable for purifying apoptotic neutrophils.
The TNF/gliotoxin method, unlike overnight 'aging', did not require the presence of
serum (data not shown) and could potentially be used to investigate roles for serum
components in phagocytosis. However, it is worth noting that if the TNF/gliotoxin
apoptotic neutrophils had been used as the apoptotic targets in the initial experiments
investigating Dex-augmentation of phagocytosis, no augmentation would have been
seen.
The observation that Dex-treated MDMO showed differential levels of phagocytosis
between two populations of apoptotic human neutrophils, potentially rules out the
suggestion that Dex-treated MDMO are simply better phagocytes of any particle.
The use of apoptotic neutrophils induced by reagents such as Fas (Matsumoto et al.,
1995) and cycloheximide (Whyte et al., 1997) may add insight by allowing the
comparison of multiple targets.
Interestingly, the Dex-treated MDMO showed no difference in their ability to bind
'overnight aged' and TNF/gliotoxin treated neutrophils (although viable neutrophils
were not bound as readily). The 'binding' step may be less discriminate than the
engulfment step, serving instead to tether cells, which additional receptors then
differentiate between. It would therefore be interesting to extend my studies, by
investigating the binding and internalisation of different apoptotic cells, for example
the phagocytosis of apoptotic thymocytes, lymphocytes and eosinophils. Cross-
linking of CD44 specifically augmented MDMO phagocytosis of apoptotic
neutrophils but not apoptotic lymphocytes (Hart et al., 1997). However, 24 hour
treatment of monocytes with the GCs, methylprednisolone or Dex, augmented
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phagocytosis of apoptotic Jurket cells (T cell line) and apoptotic eosinophils
respectively, in addition to apoptotic neutrophils (Liu et ah, 1999).
The attenuation of Dex-treated MDMO phagocytosis of TNF/gliotoxin treated
apoptotic neutrophils when compared with 'overnight aged' neutrophils, has
potential implications at the inflammatory site, where the presence of TNF-a during
induction of neutrophil apoptosis may result in a failure in GC-MDMO recognition
of these cells. The surface phenotype differences and phagocytic recognition between
TNF-a (Murray et ah, 1997) and 'overnight aged' neutrophils might therefore
warrant further interest.
The studies presented here examined the in vitro effects of GCs on MDMO function.
If the in vitro inhibition of GC-mediated phagocytosis by IFN-y was also to be seen
in a physiological setting, with IFN-y inhibiting GC augmented phagocytosis of
apoptotic cells, the potency of GC treatment may be reduced. Importantly, chronic
inflammatory diseases such as rheumatoid arthritis (Radstake et ah, 2004; Schulze-
Koops and Kalden, 2001) and lung diseases such as chronic obstructive pulmonary
disease (COPD) (Majori et ah, 1999) have a predominant Thl cytokine profde. Anti-
IFN-y therapy may therefore help restore the beneficial anti-inflammatory effects of
GCs in the treatment of these diseases. Furthermore, any studies examining the role
of GCs in the resolution of inflammation in vivo, for example in mouse, may fail to
show beneficial effects of GC administration if the model is carried on a Thl
dominant strain, such as C57B1/6 (Mills et ah, 2000).
The down-regulation of MDMO surface expression of aL, aM and p2 integrins
(which pair to form LFA-1 and MAC-1) following Dex treatment, may affect
MDMO interaction with the surrounding environment. LFA-1 and MAC-1 play
critical roles in cell-cell adhesion and in the inflammatory response (Springer, 1990)
and a down-regulation in their surface expression may result in a reduced interaction
with their ligands, including the ECM molecule fibrinogen(Trezzini et ah, 1988)and
ICAM-1 (Diamond et ah, 1990)and -2 (Damle et ah, 1992), which are expressed on
endothelium. This could potentially impact on migration and MDMO binding to
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ECM. The adhesion status and cytoskeletal changes following Dex treatment were
associated with an altered migratory ability. If Dex-treated MDMO fail to migrate
towards apoptotic cells in vivo, then an augmentation in phagocytic ability becomes
inconsequential. The chemotactic response of GC-treated MDMO will be of great
interest, and the interplay of the cytokine milieu on this critical process should also
be investigated.
Dex-induced changes to MDMO phagocytic ability are open to modulation by
exogenous factors, namely cytokines and serum components, suggesting that the in
vitro phenotype may well be modified in an in vivo setting. The requirement for
serum during differentiation suggests that there is an interplay between serum factors
and GCs during differentiation which will require further investigation to be fully
elucidated. Examination of in vivo generated macrophages, differentiated in the
presence of GC, failed to demonstrate an augmentation in phagocytic ability in vitro.
One possibility is that the overnight culture of the lavaged macrophages reduced any
GC effect, or that the GC-treated macrophages had cleared from the peritoneum
during the 4 day period between GC administration and lavage. The investigation of
an in vivo effect of GCs on macrophage phagocytosis of apoptotic cells may be
assessed in mice, by injecting labelled apoptotic cells into the site of inflammation 24
hours after GC treatment, followed by the examination of lavaged macrophages.
In conclusion, the studies presented in this thesis have demonstrated that Dex-
treatment of MDMO augments phagocytic ability by alteration of multiple steps of
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Scanned arrays following incubation with radioactively labelled control and
Dex-treated MDMO cDNA probes. The area surrounded by the boxes are
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Interferon y suppresses glucocorticoid
augmentation of macrophage clearance of
apoptotic cells
Sarah J. Heasman, Katherine M. Giles, Adriano G. Rossi, Judith E. Allen, Christopher
Haslett and Ian Dransfield
MRC Centre for Inflammation Research, University of Edinburgh Medical School, Edinburgh, GB
One of beneficial effects of glucocorticoids (GC) in inflammation may be the augmentation of
macrophages' capacity for phagocytosis of apoptotic cells, a process that has a central role
in resolution of inflammation. Here we define the phenotype of GC-treated monocyte-
derived macrophages, comparing to IFN-y-treated and IL-4-treated monocyte-derived mac¬
rophages and combinatorial treatment. Our data indicate that the cytokine microenviron-
ment at an inflammatory site will critically determine monocyte functional capacity following
treatment with GC. In particular, whilst GC exert dominant regulatory effects over IFN-y in
terms of cell surface receptor repertoire and morphology, the acquisition of a macrophage
capacity for clearance of apoptotic cells is prevented by combined treatment. In terms of
mechanism, GC augmentation of phagocytosis was reversed even when monocytes were
pre-incubated with GC for the first 24 h of culture, a period that is critical for induction of a
highly phagocytic macrophage phenotype. These findings have important implications for
the effectiveness of GC in promoting acquisition of a pro-phagocytic macrophage pheno¬
type in inflammatory diseases associated with high levels of IFN-y





Macrophages play a central role in the immune system,
initiating and co-ordinating both innate immunity and the
adaptive immune response [1, 2], Macrophage produc¬
tion of matrix, enzymes and the cytokines that regulate
fibroblast migration and proliferation modulates the res¬
olution phase of inflammation [3, 4], In addition, the effi¬
cient clearance of extravasated leukocytes that have
been induced to undergo apoptosis prevents further
injury through the release of toxic or immunostimulatory
intracellular contents [5]. Importantly, phagocytic clear-,
ance of apoptotic leukocytes by macrophages induces
release of anti-inflammatory cytokines that promote res¬
olution of inflammation [6] and triggers changes in mac¬
rophage behavior that promote tolerogenic responses.
However, in situations where prolonged or chronic
inflammatory responses occur, leukocytes may not be
efficiently cleared by macrophages and consequently
[DOI 10.1002/eji.200324698]
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Abbreviations: GC: Glucocorticoid IDMEM: Iscove's mod¬
ification of Dulbecco's modified Eagles medium MDM«P:
Monocyte-derived macrophage
undergo secondary necrosis, releasing cytotoxic granule
contents and further exacerbating the inflammatory
response, potentially leading to the development of auto¬
immunity [7]. For example, the defective phagocytosis of
apoptotic cells that is observed in C1q deficiency contrib¬
utes to the development of systemic lupus erythematosus
[8]. Thus, defining the mechanisms that regulate this
important clearance process is essential for understand¬
ing the pathogenesis of many inflammatory diseases.
A number of studies indicate that micro-environmental
cues, e.g. extracellular matrix components and the cyto¬
kine repertoire, have a critical role in determining macro¬
phage behavior [9]. It is well established that pro- and
anti-inflammatory cytokines differentially activate macro¬
phages. LPS or pro-inflammatory cytokines such as IFN-
y and TNF-a induce "classically activated" macro¬
phages, which can be defined by production of nitric
oxide and reactive oxygen species [10, 11]. These mac¬
rophages show increased potential for the engulfment
and destruction of pathogenic organisms which is
reflected in the repertoire of receptors expressed; these
receptors include Fc and complement receptors that
enable recognition and internalization of immuno¬
globulin- and complement-opsonized particles [12].
Conversely, in response to cytokines with anti-in-
© 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji.de
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flammatory potential such as IL-4 and IL-13, macro¬
phage release of pro-inflammatory cytokines is inhibited,
inducing an immunoregulatory phenotype. These macro¬
phages are characterized by increased expression of
specific pattern-recognition molecules, such as the
mannose receptor [13, 14] and enhanced capacity for
endocytosis and antigen presentation [15]. Arginase-1
expression is also enhanced and competes with NO syn¬
thases, increasing the metabolism of arginine to orni¬
thine and urea, resulting in a decreased capacity for the
production of reactive nitrogen species [16] and a
reduced ability for pathogen clearance.
We have recently demonstrated that exposure of periph¬
eral blood monocytes to glucocorticoids (GC), e.g. the
synthetic glucocorticoid dexamethasone, results in dif¬
ferentiation towards a macrophage phenotype that
exhibits a markedly increased phagocytic capacity for
apoptotic cells; exposure to mineralocorticoids or sex
steroids does not do this [17]. Prolonged exposure of
monocytes to GC induced a homogeneous monocyte-
derived macrophage (MDM<I>) phenotype consisting of
small "rounded" cells with profound changes in their
cytoskeletal organization and a loss of actin-containing
podosomes [18].
Inhibition of macrophage phagocytosis by IFN-y 1753
sone in combination with IL-4, strongly increased the
percentage of MDMO that phagocytosed apoptotic neu¬
trophils compared with phagocytosis by untreated
MDMO (Fig. 1). We did not observe a difference in the
percentage of MDMO that phagocytosed apoptotic cells
when comparing IFN-y-treated and control MDMO.
However, in the presence of IFN-y, dexamethasone
failed to augment this phagocytosis (Fig. 1).
We assessed the mean fluorescence of phagocytic
MDM4> populations to provide further information about
the effects of these treatments on the number of apop¬
totic cells phagocytosed per MDM<I> (expressed as
mean fluorescence of phagocytic cells after subtraction
of the mean fluorescence of non-phagocytic cells).
Dexamethasone-treated MDMO showed increased fluo¬
rescence when compared with untreated MDMO (the
mean±SE was 655±84 compared with 407±111). Phago¬
cytic MDMO from IL-4- or IFN-y-treated populations
also showed slightly higher mean fluorescences
(510±163 and 650±142, respectively). Interestingly,
phagocytic MDM<L> treated with dexamethasone plus IL-
4 or dexamethasone plus IFN-y had lower mean fluores¬
cences of 455±101 and 456±106, respectively.
We sought to define the cell surface phenotype and func¬
tional repertoires of human monocytes treated with GC
and the cytokines IL-4 and IFN-y. In this manuscript we
present evidence that MDMO that have differentiated in
the presence of dexamethasone exhibit distinct receptor
expression patterns and functional status from either
IFN-y- or IL-4-activated MDMO. GC exert a dominant
effect upon the morphology and adhesive status of
MDM<t> following combination treatment with IFN-y or IL-
4. However, we demonstrate that IFN-y profoundly inhib¬
its the GC-induced capacity to clear apoptotic cells.
Indeed, even after exposure of MDMO to GC for 24 h,
subsequent exposure to IFN-y inhibited the acquisition of
a phagocytic phenotype, indicating that GC-induced
alterations in MDMO function are reversible. Our data
suggest that the cytokine milieu at an inflammatory site
will critically determine whether GC induce an MDM<t>
phenotype with high capacity to clear apoptotic cells; a
phenotype that would favor the resolution of inflammation.
2 Results
2.1 Dexamethasone-augmented MDM<I>
phagocytosis of apoptotic cells is inhibited in
the presence of IFN-y
We examined the effects of IFN-y or IL-4, in combination
with dexamethasone, on the phagocytosis of apoptotic
neutrophils by MDM4>. Dexamethasone, or dexametha-
I 1
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Fig. 7. Dexamethasone-induced phagocytosis of apoptotic
neutrophils is reduced in the presence of IFN-y. The phago¬
cytic ability of MDMO cultured in IDMEM containing 10%
autologous serum alone (control) or with combinations of
dexamethasone, IL-4 or IFN-y as described in Sect. 4.2 was
determined on day 5 by flow cytometric quantification of the
percentage of fluorescent MDM<I> following a 60-min incu¬
bation with CMFDA-labeled apoptotic neutrophils. Dexa¬
methasone treatment results in a highly phagocytic popula¬
tion of macrophages when compared with untreated macro¬
phages. MDMO treated with IFN-y plus dexamethasone
have a phagocytic ability similar to MDMO treated with IFN-
y alone, demonstrating that IFN-y is dominant in determining
phagocytic capacity. The results shown here represent the
mean±S.E of five separate experiments.
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2.2 Suppression of pro-inflammatory cytokine
release by dexamethasone
In view of the dominant effects of IFN-y on dexa-
methasone-induced augmentation of phagocytic func¬
tion, we next examined the release of pro-inflammatory
cytokines by treated MDMcjx As would be expected, IFN-
y-treated MDM<t> strongly up-regulated production of
TNF-a, IL-1 and IL-6 when compared with untreated
MDM<1> or IL-4-treated MDM<t (Fig. 2). Although produc¬
tion of most cytokines was effectively inhibited by dexa¬
methasone alone, co-culture of MDM<$ in the presence
of IL-4 and dexamethasone together produced further
inhibitory effects on the production of IL-6.
In contrast to the dominant effects of IFN-y on phagocy¬
tosis by dexamethasone-treated MDM®, reduced levels
of TNF-a, IL-6 and IL-1 production were found for
MDM<f> treated with dexamethasone in combination with
IFN-y, suggesting that dexamethasone remained able to
suppress the inflammatory cytokine production that was
induced by IFN-y.
Eur. J. Immunol. 2004. 34:1752-1761
2.3 MDM<I> cultured in dexamethasone exhibit
distinct surface receptor profiles
We next compared cell surface receptor profiles of
MDM4> cultured with dexamethasone, IFN-y or IL-4
alone, or with combinations of treatments. As would be
expected, the high affinity receptor for immunoglobulin,
CD64 (FcyRI), was strongly up-regulated by IFN-y-
treated MDM<J> when compared with untreated MDM<t>
(Fig. 3A) and was also augmented when MDM® were
exposed to IFN-y in combination with dexamethasone.
In contrast, CD64 was down-regulated by dexametha¬
sone when used alone (35% reduction in levels of
expression) and markedly down-regulated by IL-4 (70%
reduction in expression).
Dexamethasone-treated MDM<I> expressed slightly
reduced levels of FILA-DR when compared with
untreated cells; MDM<1> exposed to IL-4 or IFN-y showed
increased expression compared with untreated cells
(Fig. 3B). Interestingly, up-regulation of expression of
HLA-DR was not observed when MDM<t> were treated
with IFN-y or IL-4 in combination with dexamethasone,
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Fig. 2. Cytokine profiles of treated with dexametha¬
sone ± IL-4 and IFN-y for 5 days. Adherent monocytes were
cultured for 5 days either in 10% autologous serum alone or
with combinations of dexamethasone, IL-4 and IFN-y .
MDM4> supernatants were collected after 5 days and ana¬
lyzed using an inflammation cytokine bead array kit (Becton
Dickinson). Cytokine levels were determined by extrapola¬
tion from standard curves using cytokine bead array analysis
software. Results shown are the cytokine levels (mean±S.E)
from three separate experiments using MDM<t> from three
different, normal donors.
Fig. 3. Effects of dexamethasone, IL-4 and IFN-y on macro¬
phage cell surface receptor expression. Adherent mono¬
cytes were cultured for 5 days either in 10% autologous
serum or with combinations of dexamethasone, IL-4 and
IFN-y. The surface phenotype was assessed by indirect
immunofluorescence and flow cytometry using control lgG1
mAb, CD64 mAb (A), HLA-DR rnAb (B), CD86 mAb (C),
CD14 mAb (D), CD163 mAb (E) and ICAM-1 mAb (F).
Results, corrected for the mean fluorescence intensity
recorded for the lgG1 control, are expressed as the average
mean fluorescence (±S.E.) recorded for each antibody from
a minimum of three separate donors.
© 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji.de
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(Fig. 3B). IL-4-treated MDM4> expressed approximately
3-times the levels of CD86 when compared with IFN-y-
treated or dexamethasone-treated MDM<t> (Fig. 3C).
Expression of the adhesion molecule ICAM-1 on MDM4>
was increased following IFN-y treatment, consistent with
published data [19]. In contrast, both IL-4 and dexa-
methasone reduced ICAM-1 expression and IFN-y-
induced up-regulation of ICAM-1 was suppressed fol¬
lowing combined IFN-y and dexamethasone treatment
(Fig. 3F).
MDM<t> expression of CD14 was not affected by dexa¬
methasone treatment alone. In contrast, IL-4-treated
macrophages exhibit markedly reduced CD14 expres¬
sion, consistent with the induction of an immature
"dendritic-like" cell phenotype (Fig. 3D). Reduced
expression of CD14 expression was also seen following
treatment with IL-4 and dexamethasone in combination,
suggesting that the effects of IL-4 predominate (Fig. 3D).
The divergent effects of IL-4 and dexamethasone were
also found when expression of the mannose receptor
was examined. Dexamethasone and IFN-y both down-
regulated expression of the mannose receptor, whereas
IL-4 up-regulated expression (mean fluorescence inten¬
sities: control=58.7, IL-4=85.8, dexamethasone=18.4,
IFN-y=4.7) (n=2). Expression of the GC-responsive
hemoglobin scavenger receptor CD163 [20] was down-
regulated following culture in the presence of IL-4 or IFN-
y alone, but increased in dexamethasone-treated
MDM4> (Fig. 3E). Increased CD163 expression levels
were also observed following combined treatment with
dexamethasone and IFN-y, again suggesting a dominant
effect of dexamethasone.
2.4 Effects of dexamethasone and cytokines on
MDM<I> morphology
Our analysis suggests that suppression of dexa-
methasone-augmented phagocytosis by IFN-y is not
reflected by surface phenotype alterations, with dexa¬
methasone exerting a dominant effect. Morphological
examination demonstrated that a homogeneous popula¬
tion of smaller, less-well-spread MDM4> was induced by
GC when compared with the heterogeneous untreated
MDMO population (Fig. 4). When cultured in the pres¬
ence of IL-4 alone, MDM4> exhibited a highly spread,
polarized morphology with pronounced cellular pro¬
cesses and evidence of the formation of homotypic cell
aggregates (Fig. 4). A heterogeneous MDM<f> population
comprising multinucleated "giant" cells together with
smaller macrophages was observed in the presence of
IFN-y (Fig. 4). Culture of MDM<f> in the presence of IFN-y
plus dexamethasone, or IL-4 plus dexamethasone,
yielded a population of smaller "rounded" cells similar to
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Fig. 4. Dexamethasone is dominant over IFN-y and IL-4
cytokines in inducing cellular morphology. Adherent mono¬
cytes were cultured for 5 days on glass coverslips either in
10% autologous serum or with combinations of dexametha¬
sone, IL-4 and IFN-y. Representative photomicrographs
depict cellular morphology using phase-contrast micros¬
copy with a x63 objective. Control MDM4> represent a het¬
erogeneous population of cells containing giant, multinucle¬
ated cells as well as smaller mononuclear cells.
Dexamethasone-differentiated MDM<f> form a homoge¬
neous population of small, rounded cells. Combined treat¬
ment with either IL-4 or IFN-y plus dexamethasone also
yields a homogeneous population of small rounded cells,
similar to the dexamethasone-treated population, implying
that dexamethasone is dominant over both cytokines in
inducing cellular morphological changes.
those seen with dexamethasone alone. Together these
data suggest that dexamethasone exerts dominant
effects upon MDM<j> morphology.
2.5 Dexamethasone treatment alters adhesion
structures in MDM4>
We next examined the characteristic "podosome-like"
adhesion signaling complexes consisting of a punctate
actin foci surrounded by a ring of paxillin, vinculin and
other cytoskeletal proteins [21] that are present in
MDM<t>. Untreated or IFN-y-treated MDM<t> contain
abundant podosomes, whereas these structures were
absent from dexamethasone-treated MDM4> (Fig. 5).
IFN-y-treatment appears to drive differentiation towards
www.eji.de











Fig. 5. Dexamethasone is dominant over IFN-y and IL-4
cytokines in determining the adhesion status of the macro¬
phages. Adherent monocytes were cultured for 5 days on
glass coverslips either in 10% autologous serum or with
combinations of dexamethasone, IL-4 and IFN-y. Fixed and
permeabilized cells were stained for F-actin using rhoda-
mine phalloidan and paxillin (paxillin mAb and FITC-
conjugated anti-mouse-IgG), to visualize cytoskeletal orga¬
nization. In the representative photomicrographs shown,
podosomes are characterized by a foci of actin (red) which is
surrounded by a ring of paxillin (green). Untreated control
MDMO contain abundant podosomes (A). Podosomes are
also present in IFN-y-treated MDM4> (B). By contrast,
MDM<1> differentiated in the presence of dexamethasone
alone or dexamethasone plus IFN-y (C and D, respectively)
do not contain podosomes. These data demonstrate the
dominance of dexamethasone over IFN-y in determining the
adherence status of the macrophages.
a multinucleated phenotype and the podosomes in these
"giant" cells were particularly striking, where a cortical
ring of podosomes were formed, similar to the resorption
zone described for osteoclasts (Fig. 5B) [22]. Interest¬
ingly, IL-4 induces a polarized morphology with podoso¬
mes localized at the leading edge of the cell (data not
shown). Podosomes were absent from MDM4> cultured
in the presence of dexamethasone (Fig. 5C) or IFN-y plus
dexamethasone (Fig. 5D), in keeping with morphological
observations. Podosomes were also absent from MDM<1>
treated with IL-4 plus dexamethasone (data not shown).
These data confirm the dominant effect of dexametha¬
sone in terms of both morphology and cytoskeletal orga¬
nization in MDM<t>.
2.6 The mechanism of IFN-y suppression of
phagocytosis
In view of the finding that the first 24 h of culture was crit¬
ical for GC-mediated augmentation of MDM<t> phagocy¬
tosis [18], we sought to investigate whether IFN-y could
over-ride the effects of dexamethasone after this initial
24-h culture period. MDM<f> were exposed to either
dexamethasone or IFN-y for the first 24 h of culture, fol¬
lowed by culture for 4 days in medium alone, dexameth¬
asone or IFN-y. MDM4> phagocytosis of apoptotic cells
was augmented when monocytes were cultured in
medium for 24 h followed by the addition of dexametha¬
sone although less than when dexamethasone was pre¬
sent during the first 24 h (Fig. 6A). Addition of IFN-y
alone failed to alter the phagocytic capacity of MDM<f>
when compared to untreated control MDM4>. However, if
monocytes were incubated with IFN-y for 24 h prior to
the addition of dexamethasone, augmentation of MDM4>
phagocytosis of apoptotic cells was not observed. Sur¬
prisingly, if monocytes were incubated with dexametha¬
sone for the first 24 h of culture followed by addition of
IFN-y, the phagocytic capacity was also not augmented.
In view of the "switch off" of phagocytosis following IFN-
y treatment 24 h after dexamethasone treatment of
monocytes, we next sought to test whether engagement
of IFN-y signaling in GC-treated MDM4> would also
inhibit phagocytosis. MDM<t were treated with dexa¬
methasone at day 0 and then IFN-y was added on day 1,
day 3 or day 6 (on day 6, it was added either 1 h or 3 h
prior to the phagocytosis assay) (Fig. 6B). The results
show that treatment with IFN-y for a few hours prior to
phagocytosis did not inhibit phagocytic ability when
compared with MDM<1> treated with dexamethasone
alone. Indeed, the suppressive effect of IFN-y upon GC-
augmented phagocytosis was less pronounced the lon¬
ger the macrophages were exposed to dexamethasone
before IFN-y was added. These results demonstrate that
the IFN-y-mediated suppression of augmented phago¬
cytosis most likely induces changes in MDM<f> pheno¬
type rather than being a direct consequence of engage¬
ment of IFN-y-mediated signaling pathways.
3 Discussion
One of the most important observations in our study is
that IFN-y strongly suppressed the dexamethasone-
induced augmentation of apoptotic ceil phagocytosis by
macrophages (Fig. 1, 6A and 6B). Indeed, IFN-y retained
the ability to inhibit GC-augmented phagocytosis even
when monocytes had been pre-treated with dexametha¬
sone for 24 h. Exposure of MDM<I> to IFN-y at later time
points following dexamethasone treatment failed to
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F/g. 6. IFN-y reverses and blocks dexamethasone augmen¬
tation of MDM<1> phagocytosis of apoptotic cells. (A) Adher¬
ent monocytes were cultured for the first 24 h in IDMEM
containing 10% autologous serum alone, dexamethasone or
IFN-y. Cells were washed and then treated for the remaining
4 days in IDMEM containing 10% autologous serum, dexa¬
methasone or IFN-y to give a checkerboard of combination
treatments (24 h / 4 days). The phagocytic ability of the
MDM<t> populations was then determined by flow cytometry
as described in Sect. 4.5. Results are shown as the mean
percentage of macrophage phagocytosis ± S.E. from at
least three separate experiments. Augmentation of MDMO
phagocytic ability was observed following exposure to
dexamethasone for the first 24 h only, or for the final 4 days
of culture when compared with untreated MDMO. In con¬
trast, exposure to dexamethasone followed by IFN-y, or to
IFN-y prior to dexamethasone, resulted in a significant
down-regulation in MDM<1> phagocytic ability, demonstrat¬
ing that IFN-y can both reverse and block the
dexamethasone-augmented phagocytosis of apoptotic
neutrophils. (B) Adherent monocytes were cultured in
IDMEM containing 10% autologous serum and dexametha¬
sone, with the subsequent addition of IFN-y on day 1, or
day 3, or 1 h or 3 h prior to the phagocytosis assay on day 6.
The phagocytic ability of the MDMO populations was then
determined by flow cytometry. Results are shown as mean
percentage of macrophage phagocytosis ± S.E. from at
least three separate experiments. MDMO that were cultured
in dexamethasone and exposed to IFN-y on day 1 showed a
suppression in phagocytic ability compared with MDMO
treated only with dexamethasone. The addition of IFN-y on
day 3 led to only a slight reduction in phagocytic ability and
MDMO exposed to IFN-y for 1 h or 3 h only showed no inhi¬
bition in phagocytic ability.
reverse the augmentation of phagocytosis, suggesting
that the inhibition was not due to a direct effect of IFN-y-
mediated signaling. Previous studies have also sug¬
gested that the cytokine environment may regulate mac¬
rophage phagocytosis of apoptotic cells. When human
MDMcj) were given a 4-h exposure of IFN-y after 4 days
of culture, they displayed augmented phagocytosis of
apoptotic cells [23]. In contrast, phagocytosis of apop¬
totic cells by rat bone-marrow-derived macrophages
was inhibited by treatment for 48 h with IFN-y [24], Our
data suggest that although IFN-y-treated MDMO show
some augmentation of phagocytosis of apoptotic cells,
acquisition of a pro-phagocytic macrophage phenotype
in response to GC is lost in the presence of this cytokine.
One important implication of this work is that GC may fail
to stimulate macrophage phagocytosis in a Th1 environ¬
ment. Thus, one of the potential beneficial effects of GC-
treatment, i.e. facilitation of apoptotic cell clearance,
may be inhibited by IFN-y. Interestingly, a Th1 cytokine
environment has been suggested to contribute to corti¬
costeroid resistance in diseases like rheumatoid arthritis
[25]. This may also impact on the use of IFN-y to boost
host defense against infection via macrophage activa¬
tion following severe injury. Many trials of IFN-y therapy
have failed to show a clear improvement in patient out¬
come [26]. Whether IFN-y inhibits the ability of endoge¬
nous GC to regulate macrophage phagocytosis is not
known. Interestingly, expression of 11 [3 hydroxysterone
dehydrogenase is rapidly induced during monocyte dif¬
ferentiation [27] concomitantly with acquisition of capac¬
ity for phagocytosis of apoptotic cells [28].
We have previously suggested that the altered adhesion
observed in dexamethasone-treated MDM<t> may be
linked to augmentation of phagocytic capacity. On the
basis of morphological appearance, we would have
predicted that co-incubation with either dexamethasone
plus IFN-y or dexamethasone plus IL-4 would give rise to
a highly phagocytic phenotype. Fiowever, our data pro¬
vide the first evidence for dissociation between morphol¬
ogy/adhesion status and phagocytic capacity. Thus,
although cells treated with IFN-y plus dexamethasone
exhibit a small and rounded cell morphology without dis¬
tinct podosome adhesion structures, the augmented
phagocytic capacity of dexamethasone-treated macro¬
phages is not shared by MDM<1> treated with IFN-y plus
dexamethasone.
For other characteristics of MDMO that we examined,
dexamethasone exerted dominant effects over IFN-y,
inhibiting IFN-y-driven pro-inflammatory cytokine pro¬
duction and morphological appearance. Expression of
CD163 was up-regulated by dexamethasone even in the
presence of IFN-y and the IFN-y-dependent up-
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regulation of ICAM-1 and HLA-DR was attenuated by
dexamethasone. Our phenotype analysis also revealed
that the expression levels of the mannose receptor and
CD14, both previously implicated as phagocytic recep¬
tors [29, 30], show no correlation with the increased
phagocytic ability of dexamethasone-treated MDM<1>.
The mannose receptor was down-regulated following
GC treatment and CD14 showed no change in expres¬
sion when compared with untreated MDM<t>, potentially
excluding the involvement of these receptors in the aug¬
mented phagocytosis seen following GC treatment of
MDM<I>.
Our data support the suggestion that monocytes treated
with the GC differentiate to a phenotype distinct from the
classically activated IFN-y- treated MDM4> or an "alter¬
natively" activated IL-4-treated MDM<t>. We found that
the mannose receptor, a well-defined marker of alterna¬
tive activation [13], was expressed at higher levels on IL-
4-treated MDM<t>, but was reduced on MDM<t> cultured in
dexamethasone. Several other receptors exhibit differ¬
ential expression on IL-4- and GC-treated MDM<1>,
including HLA-DR, CD86 and CD163. MDM<T> that have
differentiated in GC or IL-4 exhibit distinct phenotypes,
the latter inducing a polarized appearance with many
cellular processes that is very different from the
"rounded" appearance of dexamethasone-treated cells.
Most importantly in terms of capacity for clearance of
apoptotic cells, IL-4 fails to induce a MDM<t> phenotype
that is capable of efficient phagocytosis of apoptotic
cells. IL-4-treated monocytes would have the potential
for antigen presentation and immunomodulation (high
HLA-DR and CD86), whereas dexamethasone-treated
MDM<I> exhibit "anti-inflammatory" characteristics with
reduced capacity for immunostimulation because of
down-regulation of HLA-DR and CD86.
Although both IL-4 and GC may be involved in counter¬
ing pro-inflammatory factors, their impact on macro¬
phage function would have distinct consequences in the
outcome of an inflammatory response. For example, dis¬
cordant regulation of the capacity of macrophages for
antigen presentation and apoptotic cell clearance may
be critical for "safe" disposal of apoptotic and necrotic
cells without the potential for "cross-presentation" of
autoantigen and the induction of an autoimmune
response. Together, these data suggest that the func¬
tional repertoire of IL-4- or dexamethasone-treated
MDMcj> is distinct. GC promote a "tolerogenic" pheno¬
type similar to that reported to be induced by IL-10 [31,
32], Interestingly, like GC, IL-10 up-regulates expression
of CD163, although the mechanism appears to be dis¬
tinct [33], Preliminary experiments indicate that treat¬
ment of monocytes with anti-IL-10 antibodies fails to
block the development of the phenotype we observe fol¬
lowing treatment with GC (S. J. Heasman, unpublished
observations). However, IL-10-cultured MDM<t> show
some augmentation of phagocytic capacity for apoptotic
cells (data not shown), suggesting that there may be par¬
allels in the mechanism of action of GC and IL-10.
In summary, the role that particular cytokines, steroids
and lipid mediators play individually, and in concert, will
critically determine the balance between pathogen clear¬
ance, resolution of inflammation, tolerance induction and
wound healing. In particular, data presented here sug¬
gest that defining the interplay between GC and IFN-y in
the regulation of macrophage function may unveil novel
therapeutic targets for treatment of inflammatory dis¬
ease.
4 Materials and methods
4.1 Antibodies and other reagents
All chemicals were from Sigma (Poole, Dorset, GB) unless
otherwise stated. Antibodies were used at saturating con¬
centrations as determined by titration in indirect immunoas¬
says and flow cytometry as follows: HL4-DR (clone WR18,
lgG2a, used at 1/100, Serotec, Oxford, GB), CD14 (clone
UCHM1, lgG2a, provided by Dr. Peter Beverley, Edward
Jenner Institute for Vaccine Research, Compton, GB), C54
(clone 15.2, provided by Dr. Nancy Hogg, Cancer Research
UK, London, GB), CD64 (clone 10.1, lgG1, used at 1/100,
provided by Dr.Nancy Hogg), CD86 (clone BU63, lgG1, used
at 1/50, Caltag, B-D Biosciences, GB), CD163 (clone Ber-
mac, lgG1, used at 1/35, Dako, Oxford, GB), mannose
receptor (clone 19.2, lgG1, Serotec), and lgG1 control
(MOPC, mouse lgG1 plasmacytoma, obtained from ECACC,
GB).
4.2 Cell isolation and culture
Mononuclear cells (MNC) and polymorphonuclear cells were
isolated from human blood by dextran sedimentation and
centrifugation over discontinuous Percoll™ (Amersham
Pharmacia Biotech, Buckingham, GB) gradients as previ¬
ously described [34]. The MNC (typically 15-20% mono¬
cytes by morphological analysis of cytocentrifuge prepara¬
tions or flow cytometric determination on the basis of laser
scatter properties and CD14 reactivity) were resuspended at
4x106 /ml in Iscove's modification of Dulbecco's modified
Eagles medium (IDMEM; Life Technologies, Paisley, GB) and
enriched for monocytes by selective adherence to 48-well
(0.5 ml/well) or 6-well (4.0 ml/well) tissue culture plates for
1 h at 37°C in 5% C02. Adherent monocytes were washed
three times and then allowed to differentiate for 5 days in
IDMEM containing penicillin/streptomycin and 10% autolo¬
gous serum prepared by recalcification of platelet-rich
plasma. Washed adherent MDM4> consisted of >90%
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CD14-positive cells at day 5 as assessed by flow cytometry.
In our hands GC did not induce monocyte apoptosis as
reported by Schmidt et al. [35]. Our unpublished data sug¬
gest that autologous serum over-rides the pro-apoptotic
effects of GC on monocytes. As detailed in the text, dexa-
methasone was added to a final concentration of up to
1 nm, whereas recombinant IL-4 and recombinant human
IFN-y (both obtained from R&D Systems, Minneapolis, USA)
were used at 10 ng/ml.
Isolated polymorphonuclear cells (typically 95-98% neutro¬
phils by morphological examination of cytocentrifuge prepa¬
rations) were resuspended at 20x106 cells/ml cells in IDMEM
and labeled with the fluorescent cell tracker dye carboxy-
methylfluorescein diacetate (CMFDA; Molecular Probes,
Leiden, The Netherlands), 2 (ig/ml for 15 min at 37°C in 5%
C02. Cells were then washed and cultured in 75 mm tissue
culture flasks (Nunc, Fisher Scientific, Leicestershire, GB) for
18-24 h at 4x106/ml in IDMEM containing 10% autologous
serum to induce spontaneous apoptosis. Microscopic
examination of nuclear morphology of cytocentrifuge prepa¬
rations of cultured cells was used to assess levels of apop¬
tosis and neutrophils were typically 50-60% apoptotic with
15-20% necrotic cells present, as determined by dual
annexin V / propidium iodide staining and flow cytometry.
4.3 Flow cytometric determination of cytokine release
Supernatants from MDM<t> that had been cultured for 5 days
were analyzed for the presence of IL-8, IL-6, IL-1fS, IL-10,
TNF-a and IL-12p70 using the Fluman Inflammation BD
Cytometric Bead Assay (Becton Dickinson, Oxford, GB) as
described by the manufacturer's assay protocol. Briefly,
50 |.il samples of cell supernatant were incubated with cap¬
ture beads to the six cytokines and a PE cytokine detection
reagent for 3 h at room temperature. Samples were then
washed once and 6000 events were acquired using a FACS-
Calibur flow cytometer (Becton Dickinson). Analysis of the
median FL-2 fluorescence associated with bead populations
defined by FL-3 labeling was made using Cellquest software
(Becton Dickinson).
4.4 Flow cytometric analysis of surface receptor
expression
MDM<t> obtained after 5 days of culture were washed in
Flanks' balanced salt solution (FIBSS) and incubated with
5 mM EDTA in Ca2+/Mg2+-free PBS on ice for 15 min to
detach the cells from the wells. The detached MDMO were
centrifuged at 220xg and washed in Ca27Mg2+-free PBS
containing 0.2% BSA and 0.1% sodium azide (flow buffer).
The pelleted cells were then incubated on ice for 30 min with
saturating concentrations of monoclonal antibodies to cell
surface determinants. The cells were then washed twice in
flow buffer and incubated for a further 30 min on ice with
FITC-labeled F(ab')2 fragments of goat anti-mouse-
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immunoglobulin (Dako; used at 1/50). Following two further
washes in flow buffer, the labeled cells were analyzed using
either an EPICS XL (Beckman Coulter, High Wycombe, GB)
or FACSCalibur flow cytometer (Becton Dickinson) after
acquiring 5000-8000 events per sample. Post-acquisition
analysis was performed either using Cellquest (Becton Dick¬
inson) or EXP032 (Beckman Coulter).
4.5 Quantitation of phagocytosis of apoptotic cells
Monocytes were cultured for 5 days in 48-well plates as
described above either in the presence of 10% autologous
serum alone (control), or in the presence of dexamethasone,
IL-4 or IFN-y, or combinatorial treatments at the concentra¬
tions detailed in the text. MDM4> were gently washed in
Ca27Mg2+-free FIBSS and phagocytosis of apoptotic neutro¬
phils was then performed as described previously [36].
Briefly, MDM4> were co-incubated with 0.5 ml of CMFDA-
labeled apoptotic neutrophils at 4x106/ml for 1 h at 37°C in
5% C02 after which the neutrophils were gently aspirated
and 0.25 ml of trypsin/EDTA added. Following incubation at
37°C in 5% C02 for 15 min and then at 4°C for 15 min,
MDM<t> were detached by vigorous pipetting. Flow cytome¬
try was then used to determine the proportion of phagocytic
macrophages (gated on the basis of forward- and side-
scatter properties) and the percentage of FL-1-labeled
MDM<t> was determined.
4.6 Indirect immunofluorescence analysis of
macrophage cytoskeleton
Monocytes were plated on sterile coverslips in 24-well
plates at 4x106/ml. After 5 days of differentiation, adherent
MDM<J> were fixed in 2 ml of 3% (w/v) para-formaldehyde at
room temperature for 20 min. Coverslips were then washed
three times in Ca27Mg2+-free PBS and free aldehyde groups
were then quenched with 50 mM NFi4CI/PBS at room tem¬
perature for 15 min. After three further washes in PBS, cells
were permeabilized using 0.1% Triton X-100 for 4 min. Fol¬
lowing a further three washes in PBS the coverslips were
incubated for 10 min in heat-inactivated AB serum (1/10) to
block non-specific antibody binding to Fc receptors. To
visualize podosomes within MDM<f>, cells were then incu¬
bated on ice for 30 min with mAb specific for paxillin (BD
Transduction Labs, Belgium). The cells were washed and
then labeled by incubating for 30 min with an Alexa-488
goat anti-mouse-immunoglobulin antibody (1/400 in PBS;
Molecular Probes). After a further three washes cells were
incubated with rhodamine phalloidin (1/800 in PBS; Molecu¬
lar Probes). The coverslips were then mounted onto slides
using an antifadent mounting medium (Molecular Probes)
and examined under oil immersion microscopy using a x63
objective using an Axiovert S100 immunofluorescence
microscope with Coolsnap LCD camera and Openlab image
acquisition software.
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Abstract
Glucocorticoids represent one ofthe most effective clinical
treatments for a range of inflammatory conditions, includ¬
ing severe acute inflammation. Although glucocorticoids
are known to affect processes involved in the initiation of
inflammation, the influence of glucocorticoids on the
mechanisms by which acute inflammation normally
resolves have received less attention. Apoptosis of granu¬
locytes present at inflamed sites leads to their rapid
recognition and internalisation by macrophages, a process
which may be important for resolution of inflammation.
However, if clearance of either eosinophils or neutrophils
is impaired, these cells rapidly undergo secondary necrosis
leading to release of pro-inflammatory mediators from the
phagocyte, potentially prolonging inflammatory responses.
Physiologically relevant concentrations of glucocorticoids
accelerate eosinophil apoptosis whilst delaying neutrophil
apoptosis during in vitro culture. Here we discuss key
pathways regulating the granulocyte apoptotic programme
and summarise the effects of glucocorticoids on monocyte
differentiation and the consequent changes to apoptotic
cell clearance capacity. Definition of the mechanisms
underlying resolution of inflammatory responses following
glucocorticoid treatment may unveil new targets for
modulation of inflammatory disease, allowing co-ordinated
augmentation of granulocyte apoptosis together with
increased macrophage capacity for clearance of apoptotic
cells.
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Introduction
Whilst the effects of glucocorticoids oil the events associ¬
ated with the initiation of inflammation have been studied
extensively (Pitzalis ct al. 2002. Webster et at. 2002), the
influence of glucocorticoids on the mechanisms by which
acute inflammation normally resolves have received less
attention. Over the past few years, we have been studying
the process of resolution of inflammation, hypothesising
that definition of the underlying mechanisms may allow
development of new therapeutic approaches aimed at
promoting the safe resolution of inflammatory responses
which underlie a heavy burden of disease in the lung and
other organs (Haslett et al. 1994) (see Fig. 1). It is now
clear that neutrophil granulocytes undergo constitutive
apoptosis (Savill ct al. 1989a) at inflamed sites, a process
associated with the 'disabling' of their potentially injurious
secretion responses and other effector functions including
adhesion and phagocytosis (Whyte et al. 1993a). Surface
molecular alterations, including marked down-regulation
ofexpression of FcyRIII (Dransfield et al. 1994), L-selectin
and uncoupling of integrins of the (32 family (Dransfield
et al. 1995), contribute to attenuation of functional
responsiveness. In addition, apoptosis-associated cell
surface alterations, including phosphatidylserine exposure
(Homburg et al. 1995), are thought to provide cues that
lead to rapid recognition and internalisation of apoptotic
cells by macrophages (Savill et al. 1989b). Importantly,
phagocytic clearance of apoptotic granulocytes, in contrast
to other phagocytic pathways, fails to promote the release
of pro-inflammatory mediators from macrophages
(Meagher et al. 1.992), which may be important for
the 'normal' resolution process. In addition, our studies
have shown that macrophages (Savill et al. 1990, 1992)
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Figure 1 Schematic representation of cellular changes associated with either resolution of inflammation or development of fibrosis.
Microbial infection is accompanied by infiltration of alveoli with inflammatory ceils, predominantly neutrophils. Resolution of inflammation
is associated with removal of microbial infection and return of tissue architecture to normal. In contrast, failure to resolve inflammation
results in chronic recruitment, matrix deposition and fibroblast migration and proliferation, leading to loss of gas exchange capacity.
subsequently emigrate from the inflamed site to draining
lymph nodes (Bellingan et al. 1996), where they may have
the potential to influence activation of cells of the acquired
immune system. Similarly, eosinophil granulocytes, which
have been strongly implicated in tissue injury in allergic
acute inflammation, are also programmed to die by
constitutive apoptosis. Whilst the rate of constitutive
eosinophil apoptosis is slower than that of the neutrophil
granulocyte, apoptosis also leads to rapid, non¬
inflammatory phagocytic clearance by macrophages (Stern
et al. 1992). However, if clearance of either eosinophils
or neutrophils is impaired, these cells rapidly undergo
secondary necrosis. In addition to the release of poten¬
tially toxic intracellular contents associated with necrosis,
one important consequence is that macrophage phago¬
cytosis of post-apoptotic cells leads to the release of
pro-inflammatory mediators, potentially prolonging
inflammatory responses (Stern et al. 1996).
Granulocyte deletion by apoptosis has been shown to be
amenable to external regulation by lineage-specific
inflammatory signals (Haslett et al. 1991, Stem et al. 1992,
Lee et al. 1993, Whyte ct al. 1993b, Hannah et al. 1995,
Murray et al. 1997, Ward et al. 1997, Coxon et al. 1999,
Hofinan et al. 2000), providing an opportunity for targeted
therapeutic intervention. However, if triggering of apop¬
tosis is to be considered as a therapeutic target, failure to
match the apoptotic cell load to the tissue clearance
capacity at an inflamed site may have deleterious
consequences in terms of resolution of inflammation.
Macrophage capacity for phagocytosis of apoptotic granu¬
locytes can be rapidly regulated by exogenous factors e.g.
following ligation of extracellular matrix receptors such as
CD44 (Hart et al. 1997, McCutcheon et al. 1998) or
prostaglandin receptors (Rossi et al. 1998). Thus,
co-ordinated acceleration of granulocyte apoptosis at
inflamed sites together with augmentation of macrophage
capacity to clear apoptotic cells may be a realistic
therapeutic goal (Ward et al. 1999a).
Glucocorticoids (GCs) represent one of the most
effective clinical treatments for a range of inflammatory
conditions, including severe acute inflammation. GCs
have profound effects, both on granulocyte apoptotic
programmes (Cox 1995) and macrophage phagocytic
function (Liu et. al. 1999). In particular, physiologically-
relevant concentrations of GCs, acting via the GC recep¬
tor, were found to accelerate eosinophil apoptosis whilst
journal of Endocrinology (2003) 178, 29 36 www.endocrinology.org
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Potential for tissue damage
Figure 2 Neutrophils are poised on a 'knife edge' decision of life or death. A range of extracellular stimuli can promote apoptosis or
survival. For those stimuli that drive survival, NFkB activation acts as a checkpoint that can result in engagement of cell death pathways,
leading to functional downregulation and preservation of membrane integrity. Apoptotic cells can then be swiftly cleared by phagocytes.
IFNy, interferon y. LTB-4, ieukotriene B4.
delaying neutrophil apoptosis during in vitro culture
(Meagher et ai. 1996). In this article, we will discuss key
pathways regulating the granulocyte apoptotic programme
following treatment with GCs, and describe recent data
relating to the effects of GC on monocyte differentiation
and the consequent changes to apoptotic cell clearance
capacity.
Granulocytes are poised on a knife edge of nuclear
factor kappaB (NFlcB)-mediated survival
It is now well established that at an inflammatory site there
are many cytokines and growth factors present that provide
survival signals for granulocytes with the potential to
over-ride granulocyte apoptotic pathways (see Fig. 2). We
have demonstrated important apoptosis-inhibiting effects
of inflammatory stimuli that increase cyclic AMP levels in
neutrophils (Rossi et al. 1995). The dramatic delay of the
caspase-dependent apoptosis in neutrophils by dibutyryl
cAMP (dbcAMP) was found to occur via a novel protein
kinase A (PKA)-independent signalling pathway involving
maintenance of mitochondrial potential (Martin et al.
2001). The survival effects of dbcAMP were independent
of phosphatidylinositol-3 kinase (PI3K) and MAP kinase
(MAPK) activation and our data point to a novel, revers¬
ible, transcriptionally independent mechanism of action of
dbcAMP that may provide opportunities to shift the
balance of pro-apoptotie and anti-apoptotic proteins
and hence accelerate clearance of granulocytes from
inflamed sites.
One of the most potent agents known to modulate
granulocyte apoptosis is bacterial lipopolysaccharide (LPS)
(Lee et al. 1993). Most inflammatory cells sense LPS using
a complex system that involves the interaction of LBP/
CD14/MD-2 and Toll-like receptor 4 (TLR4) (O'Neill
& Dinarello 2000, Triantafilou & Triantafilou 2002)
receptors which, when engaged, trigger inter-related
signal transduction pathways, including the MAPK
(ERK1/2, JNK and p38), PI3K and NFkB pathways to
orchestrate innate immune responses. Detailed investi¬
gation of the role of NFkB in control of granulocyte
survival has revealed that inflammatory mediators such as
LPS and granulocyte macrophage colony stimulating factor
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(GM-CSF) downregulate susceptibility of neutrophils to
Fas-directed death (L Murray, S O'Dea, D Harrison, C
Haslett & A G Rossi, unpublished data) implying that
specific pro-apoptotic regulatory pathways are overridden
by NFkB signalling pathways (Fig. 2). Although both
tumour necrosis factor-a (TNF-a) and LPS act to trigger
NFkB activation in neutrophils. TNFra-rnediated
activation of NFkB delays apoptosis in the majority of
neutrophils not induced into early apoptosis (Murray et al.
1997, Ward et al. 1999/)). The pronounced effects of
protein synthesis inhibitors upon granulocyte survival
supports the suggestion that NFicB-directed gene tran¬
scription and protein synthesis ofanti-apoptotic factors and
powerful cytokines delays apoptosis in 'inflammatory'
granulocytes.
We have demonstrated that the rate of constitutive
apoptosis in both neutrophils and eosinophils was greatly
accelerated by the NFkB inhibitor and fungal metabolite
gliotoxin. This effect was reproduced using other NFkB
inhibitors and suggests TNF-a-induced activation of
NFkB and production of survival proteins limits pro-
apoptotic effects and may delay apoptosis at later time
points. Similarly, for human eosinophils exposed to
TNF-a. cytoplasmic levels of iKBa, the inhibitory subunit
ofNFkB are rapidly reduced and NFkB is mobilised from
the cytoplasm to the nucleus (Fujihara et al. 2002),
Inhibition of TNF-a-mediated IkBcx degradation and
NFkB activation by gliotoxin treatment of eosinophils
reveals caspase-dependent pro-apoptotic properties of
TNF-a. Selective inhibition of eosinophil NFkB acti¬
vation may therefore represent an alternative target
for inducing specific deletion of eosinophils in diseases
including asthma and allergic rhinitis.
NFKB-dependent genes may7 also have a key regulatory
role in the pathways responsible for the metabolism of
prostaglandins (PGs) in granulocytes. Although many
natural prostaglandins (e.g. PGE2, PGA2. PGA,. PGF2u)
act either to delay apoptosis or have no effect, PGD2 and
its metabolite PGJ2 selectively induced eosinophil apop¬
tosis (Ward et al. 2002). In contrast, the sequential PGD2
metabolites A12PGJ2 and 15 dPGJ2 were found to induce
caspase-dependent apoptosis in both eosinophils and neu¬
trophils. Despite A1~'PGj2 and 15 dPGJ2 being known
activators of peroxisome proliferator-activated receptor
(PPAR)-y, apoptosis was not mimicked by synthetic
PPAR-y and PPAR-a ligands nor blocked by an
irreversible PPAR-y antagonist, suggesting a PPAR-y-
independent mechanism (Ward et al. 2002). We found
that A1~PGJ2 and 15 dPGJ, inhibited LPS-induced Ix*Ba
degradation and NFkB activation, thereby7 triggering
apoptosis. The powerful pro-apoptotic effects of A,-PGJ2
and 15 dPGJ2 in both eosinophils and neutrophils implies
that differences in the ability ofeosinophils and neutrophils
to process and degrade prostaglandins may be responsible
for the differential effects of PGD2 upon granulocyte
survival.
One potential limitation to the effectiveness of GCs in
treatment of inflammatory diseases is that they undesirably
prolong neutrophil survival (Cox 1995), increasing
the potential for secretion of pro-inflammatory granule
contents during inflammatory episodes. We believe that
definition of mechanisms by which glucocorticoid-
directed survival of neutrophils may be 'disengaged' may
improve the efficacy of GCs in neutrophilic inflam¬
matory diseases. Our preliminary data indicate that
glucocorticoid-mediated delay of neutrophil apoptosis is
reversed by7 inhibition of protein synthesis and inhibited
by blockade ofNFkB (C Ward & A G Rossi, unpublished
data). We suggest that GCs engage NFKB-directed
synthesis of 'survival proteins' that may be targeted to
make neutrophils respond to GCs in the same way that
eosinophils do.
Macrophages can be enabled for phagocytosis of
apoptotic granulocytes
Apoptotic cells have potentially toxic cellular contents and
autoantigens may be revealed or generated within apop¬
totic cells. Thus, defects in clearance of apoptotic cells
would be predicted to be associated with spontaneous
and/or persistent inflammatory responses and evidence of
autoimmunity to intracellular antigens (Lorenz et al.
2000, Beutler 2001, Botto 2001, Greidinger 2001, Stuart
& Hughes 2002). In support of this suggestion,
spontaneous/persistent tissue inflammation and auto¬
immunity is observed in mutant mice with proven and
probable defects in clearance of dying cells (Botto et al.
1998). Indeed, some patients with systemic lupus ery¬
thematosus exhibit (as y7et uncharacterised) defects in
macrophage phagocytosis ofapoptotic cells (Baumann et al.
2002). As discussed above, we would predict that upregu-
lation of macrophage capacity for 'safe' phagocytosis of
apoptotic granulocytes will represent an important aspect
of therapeutic strategies aimed at promoting the resolution
of inflammation.
We and others have shown that macrophage phagocy¬
tosis may be rapidly modulated in response to extracellular
environmental signals (Fig. 3). For example, elevation of
intracellular cAMP in human monocyte-derived macro¬
phages using the cell permeable cAMP analogue, db~
cAMP, specifically reduced the phagocytosis of apoptotic
neutrophils without affecting FcR-mediated phagocytosis
(Rossi et al. 1998). Treatment of macrophages with PGE2
resulted in rapid, transient increases in levels of intracel¬
lular cAMP and induced PKA-dependent morphological
alterations indicative of changes in the adhesive status of
the macrophage, including cell rounding and disassembly
of 'podosome' adhesion structures containing actin,
vinculin and talin that represent points of contact with
extracellular matrix (Rossi et al. 1,998). Consistent with
the suggestion that adhesive interactions may influence
tournal of Endocrinology (2003) 178, 29 36 vvvvw.endocrinology.org









Figure 3 Schematic representation of mechanisms that regulate macrophage phagocytosis. Cross linking of CD44/matrix receptors or
engagement of lipoxin receptors leads to rapid augmentation of phagocytic activity. In contrast, binding of prostaglandins to specific
receptors causes cytoskeletal changes that inhibit phagocytic function. Alternatively, glucocorticoids act via glucocorticoid receptors to
alter the pattern of gene expression (via either specific transactivation or transrepression) to alter cytoskeletal regulation within
macrophages.
macrophage phagocytic capacity, we demonstrated that
ligation of the matrix receptor CD44 rapidly and specifi¬
cally increases apoptotic neutrophil internalisatioii (Hart
et al. 1997). We now have very clear evidence that CD44
cross-linking is associated with the generation of intra¬
cellular signals that specifically augment clearance of
apoptotic neutrophils. First, binding of Fab' fragments of
CD44 antibodies does not promote phagocytosis, indicat¬
ing that these reagents do not mask sites that are normally
involved in negatively regulating cellular interactions in a
manner analogous to the sialomucin, CD43. Furthermore,
there does not appear to be 'capping' of CD44 within the
membrane e.g. within uropod-like structures following
cross-linking. Detailed temporal analysis of the CD44
cross-linking effects provides evidence that CD44 acts as
an 'enabler' of macrophage phagocytosis, recruiting other¬
wise non-responsive cells. Recent data from studies of
lung injury in CD44-deficient mice adds further weight to
a role for CD44 in the regulation of macrophage clearance
of apoptotic neutrophils in the resolution of inflammation
(Teder et al. 2002). Our preliminary evidence indicates
that engagement of specific signal transduction events
following CD44 cross-linking leads to rapid changes in
cytoskeletal regulation. We are currently investigating
whether CD44 initiates signals that influence cytoskeletal
regulatory molecules e.g. membrane recruitment of Rac
GTPase via guanine nucleotide exchange factors (GEFs)
such as Tiaml which have been shown to associate with
CD44 (Bourguignon et al. 2000).
Glucocorticoids facilitate clearance of apoptotic
cells, favouring resolution of inflammation
In contrast to the rapid effects of CD44 ligation, [cAMP],
elevation, or lipoxins (Godson et al. 2000), we found that
exposure of macrophages to GCs for 24 hours specifically
enhanced the uptake of apoptotic leukocytes by both
human and murine macrophage populations (Liu et al.
1999). These observations establish the capacity of GCs to
promote phagocytosis of cells undergoing apoptosis, raising
the possibility that anti-inflammatory effects of GCs may
involve pro-phagocytic effects. Iniportandy, glucocorticoid-
mediated enhancement of macrophage phagocytosis of
apoptotic cells was not achieved by costly loss of the
teleogically appropriate lack ofpro-inflammatory response,
failing to stimulate monocyte chemoattractant protein-1
(MCP-1) production and down-regulating interleukin
(IL)-8 release by the phagocyte (Liu et al. 1999).
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extracellular matrix
migration
Figure 4 A centra! role for pi 30°" in adhesion signalling. Schematic representation of events occurring downstream of integrin adhesion
receptor ligation. p130Cos links integrin-mediated src family kinase activation to Rho family GTPases and cytoskeletal assembly necessary
for adhesion, migration and phagocytosis. MLCK, myosin light chain kinase.
More recently, we have found that exposure of
peripheral blood monocytes to GCs during the first
24 hours of the 5-day culture period induced a highly
phagocytic monocyte-derived macrophage (MDMtp)
phenotype. This GC-MDMtp phenotype was character¬
ised by a marked morphological appearance, consisting of
smaller, more 'rounded' cells with more homogeneous
laser scatter properties in flow cytometric analysis (Giles
et ell. 2001). Functional and morphological homogeneity
was matched by cell surface phenotype, including specific
induction of expression of the haemoglobin scavenger
receptor, CD 163 following GC treatment. Our data
indicate that GCs acting via GC receptors have the
potential to re-programme monocyte differentiation to¬
wards an 'anti-inflammatory' phenotype. In light of recent
studies of apoptotic cell clearance in Caenorhabditis clcgans
(Ellis et al. 1991, Liu & Hengartner 1998, Wu & Horvitz.
19984,6, Chung ci al. 2000, Reddien & Horvitz 2000,
Gumienny et al 2001, May 2001), we next examined
key intracellular components that regulate cytoskeletal
coupling following adhesion. Alterations in the mor¬
phology of GC-MDMtp were mirrored by changes in
lournal of Endocrinology (2003) 178, 29 .36 www.endocrinology.org
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cytoskeletal organisation, with a loss of paxillin and acdn
containing podosome structures. Tyrosine phosphoryl¬
ation of paxillin and pyk2, proteins that are recruited to
adhesion contacts, were not phosphorylated in GC-
MDMtp. A particularly striking change was that GC-
MDMtp showed decreased expression of pi30 'as (Giles
et al. 2001), an adaptor protein that links integrin receptors
to Rho family GTPases and the MAPK pathway (see Fig.
4). Reduced expression of pi 30 'as would be predicted to
disrupt Crk/DOC,K180/ELMO complexes, which to¬
gether with reduced phosphorylation of paxillin and pyk2
may have implications for control of the turnover of
adhesion structures in macrophages.
Specific recruitment ofpl30Cas to focal contacts follow¬
ing adhesion to matrix may mimic loss ofpl30Cas observed
in dexamethasone-treated cells and thus influence the
availability of other components to drive cytoskeletal
re-organisation necessary for phagocytosis. We propose
that the repertoire of adhesion receptors that are engaged
on the macrophage surface might therefore control phago¬
cytic potential indirecdy by releasing or sequestering key
regulatory molecules like pl30Cas from focal adhesion
complexes. Time-lapse video microscopy analysis revealed
that despite the small rounded appearance of GC-MDMip
these cells are able to rapidly extend and retract cellular
processes. Thus, although recruitment of proteins such as
paxillin to podosome adhesion signalling complexes does
not occur in the absence of pi30 "as, Rac may still drive
the extension and retraction of processes required for
phagocytosis. One possibility is that other pi30 "ls -like
adapters such as I1EF1 and Efts/Sin, present in macro¬
phages may allow the recruitment of Rac/Crk/
DOCK 180 specifically to membranes in a manner that
facilitates phagocytosis of apoptotic cells and possibly other
particles. Importantly, these data raise the possibility that
expression or phosphorylation of pl30t as may have a
negative regulatory role upon macrophage phagocytic
potential. Our recent studies examining the effect of the
cytokine environment on GC-mediated monocyte differ¬
entiation have shown that the Thl cytokine interferon-y
reverses the augmentation of phagocytosis seen in the
GC-MDMtp (KM Giles, SJ Heasman & I Dransfield,
unpublished data). The reduction in phagocytic ability is
not accompanied by morphological changes, indicating
that adhesion status and the capacity for phagocytosis can
be dissociated. Further understanding of the interplay
between cytokine environment and GCs in inflammation
may allow the tailoring of therapies that facilitate the
resolution of inflammatory disease.
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